Official Symbol: TP53provided by HGNC
Official Full Name: tumor protein p53provided by HGNC
Primary Source: HGNC:11998
See related: Ensembl:ENSG00000141510; HPRD:01859; MIM:191170
Gene type: protein coding
RefSeq status: REVIEWED
Organism: Homo sapiens
Lineage: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo
Also known as: p53; LFS1; TRP53; FLJ92943; TP53
Summary: This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]

[Top][Help]Genomic regions, transcripts, and products

(minus strand) Go to reference sequence details Try our new Sequence Viewer

[Top][Help]Bibliography

GeneRIFs: Gene References Into Function What's a GeneRIF?

	1.	There are two polymorphic points in the 7th intron of human p53 gene, which could be associated with genetic susceptibility of oral neoplasms.
	2.	ZBTB2 is a potential proto-oncogenic master control gene of the p53 pathway and, in particular, is a potent transcription repressor of the cell cycle arrest gene p21 by inhibiting p53 and Sp1
	3.	Alemtuzumab is effective irrespective of genetic high-risk subgroups with TP53 mutations.
	4.	P53 expression seems to be related to some histopathological features of basal cell carcinomas
	5.	The arginine variant of rs1042522 within p53 is associated with increased risk of primary open-angle glaucoma.
	6.	analysis of the transcriptional axis mutant p53, E2F1 and ID4 which promotes tumor neo-angiogenesis
	7.	p53 staining was highest in Bowen's disease followed by actinic keratosis, squamous cell carcinoma, Paget's disease, keratoacanthoma, basal cell carcinoma and normal skin
	8.	There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.
	9.	Studied Neuroblastoma tumors from patients for miR-34a expression levels, 1p status, mutations in the TP53 coding region and mutations of the TP53 binding site. No mutations were identified in the coding region of TP53, or in the TP53 binding site.
	10.	A family with LFS harbors a germline TP53 mutation (R248W) located in the functional domain of the protein that binds to the minor groove of the DNA.
	11.	The increased levels of p53 in post-selection human mammary epithelial cells are due to the presence of an Mdm2 fragment that binds p53 but does not result in its degradation.
	12.	Results suggest that ribavirin enhances activities of mTOR and p53, which may account for its antiviral and antitumor effects.
	13.	Results suggest that alteration of the substrate specificity via binding to Mdmx may contribute to efficient ubiquitination and inactivation of p53 by Mdm2.
	14.	Data show that neither the status of p53 (wild-type vs. mutated, or inhibited by pifithrin-alpha) nor the expression of O(6)-methylguanine-DNA methyltransferase significantly affected the cell response to temozolomide.
	15.	Both Forkhead Transcription Factor 3a and Tumor Suppressor Protein p53 gene expression change under various stresses, leading to diverse physiological functions.
	16.	The higher frequency of the Pro/Pro phenotype of p53 in African American patients with colorectal adenocarcinoma is associated with an increased incidence of p53 mutations, with advanced tumor stage, and with short survival.
	17.	Data show that absolute alcohol as a fixative produced the best immunohistochemical staining of p53.
	18.	Presence of S100A6 coincides with more efficient nuclear accumulation of p53 under stress conditions.
	19.	Data show that Cav-1 expression in tumor tissues was correlated with both the Ki-67 and p53 expression.
	20.	TP53 deletion and chromosome 17 aneusomy is a common event in gastric adenocarcinoma and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis process of diffuse and intestinal types.
	21.	Data show that DADS induces G(2)/M arrest in colon cancer SW480 cells, probably through the downregulation of PCNA, p53 and cyclin B1 and upregulation of p21(WAF1).
	22.	Results suggest that an increased transcription of pro-apoptotic genes (p53 and Bcl-x(S)) in eutopic endometrium is significantly associated with endometriosis, which indicates dysregulation of apoptotic gene transcription associated with disease.
	23.	Data show that wt-p53 can suppress excessive replication of centrosomes that may contribute to the upregulation of Gadd45a and BubR1 protein expression as well as the downregulation of Aurora A protein expression.
	24.	the molecular mechanisms of different oxidizing molecules in inducing survival or the apoptotic response by activating Nrf2 or p53 in adenocarcinoma cells
	25.	The structure of the wild-type p53 protein and the structural & functional data that provide the molecular basis for understanding the effects of common cancer mutations are presesnted. Review.
	26.	depletion of Sestrin2 or Dram failed to affect autophagy in p53-deficient cells
	27.	Sirt1 inhibition resulted in an increase in senescence in PC3-p53 cells whereas it resulted in an increase in apoptosis in PC3 cells
	28.	Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
	29.	A genetic predisposition such as the p53 mutation should be investigated in bilateral choroid plexus papillomas in particular
	30.	The median survival time was shorter in patients with tumor TF mRNA levels above median values and when TP53 was mutated.
	31.	significant interrelationships of the investigated molecular alterations and clinicopathological characteristics in diffuse gliomas, which support a promising role of molecular markers (MGMT, p53, Ki-67)in the diagnostic assessment of these neoplasms
	32.	Higher levels of ATP5a1 expression are associated with certain Single Nucleotide Polymorphisms and with TP53 mutation.
	33.	p53 overexpression, NF-kappaB positivity, and beta-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.
	34.	Gambogic acid induced human breast cancer cells MCF-7 apoptosis by reducing bcl-2 expression via p53.
	35.	p53-mediated repression of miR-17-92 expression likely has an important function in hypoxia-induced apoptosis
	36.	The present study shows that the serum level of p53 is lower in the patients with type 2 diabetes than in controls or in subjects with IGT.
	37.	p53(+)bcl-2(-) phenotype is significantly correlated with the basal cell-like subtype and may be associated with the biologic aggressiveness of this cohort of molecular breast cancer.
	38.	there is an an association between HCV core and HAX-1, which promotes 5-FU mediated p53-dependent caspase-7 activation and hepatocyte growth inhibition
	39.	Our data show the first valid clinical evidence of the deregulation of HIC1-SIRT1-p53 loop in lung tumorigenesis and prognosis
	40.	we provided evidence for a crucial role for direct inhibition of p53 by MDM2 and suppression of the p19(ARF)/p53 axis in neuroblastoma tumorigenesis
	41.	NF-kappaB promotes oridonin-induced apoptotic and autophagic cell death through regulating p53 activation in HT1080 cells.
	42.	status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14(ARF) is likely to be the more critical determinant of clinical outcome in esophageal squamous cell carcinoma.
	43.	Results correlate with altered p53 phosphorylation and target gene expression in untreated human tumor samples and show that HIF2alpha likely contributes to tumor cell survival including during radiation therapy.
	44.	disruption of ERalpha-p53 interaction in vivo resulting in restoration of functional p53 is a cellular response to radiation
	45.	The clearer definition of the transcriptional behavior of p53 interaction with its RE will provide better insight toward the understanding of its fundamental role in cellular networks.
	46.	analysis of the interaction between the transactivation domain of p53 and PC4
	47.	Findings suggest that p53beta might play an important role in the formation of renal cell carcinoma and it might be used as a new predictor and therapeutic target for RCC.
	48.	The results of particular polymorphisms analyses were not highly significant after correction for multiple comparisons, present data suggest that variation at the p53 and p73 gene may have a role in Alzheimer's disease occurrence.
	49.	TP53 polymorphism has an age-dependent role n PAI-1 regulation
	50.	Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
	51.	TP53 codon 72 polymorphisms may be a risk factor for Nasopharyngeal carcinoma (NPC). Homozygote Pro/Pro genotype could significantly increase susceptibility to NPC, whereas Arg allele markedly decreases NPC risk.
	52.	In a high-risk Venezuela population, Arg carriers had a 4.6-fold higher risk of gastric cancer. The Arg/Arg genotype was more frequent in poorly differentiated gastric adenocarcinomas & the Arg/Pro genotype in well/moderately differentiated cases.
	53.	inhibition of glycolysis may only be beneficial for radiation therapy of cancer expressing wild-type p53.
	54.	Results demonstrated that the inhibition of spontaneous B cell apoptosis by CpG DNA was correlated to up-regulation of Bcl-xL, IAP and down-regulation of p53 and caspase 3 mediated through PI3K/AKT signaling.
	55.	The slow oligomerization of free p53, competing with spontaneous denaturation, has implications for the possible regulation of p53 by binding proteins and DNA that affect tetramerization kinetics as well as equilibria.
	56.	Forodesine induces apoptosis of CLL cells bypassing the DNA-damage/ATM/p53 pathway.
	57.	SIK1 links LKB1 to p53-dependent anoikis and suppresses metastasis.
	58.	The acetylation of Lys-120 does not appear to regulate the ability of p53 to interact with the pro-apoptotic proteins BCL-XL and BAK. However, displacement of the inhibitory MCL-1 protein from BAK is compromised when Lys-120 acetylation is blocked.
	59.	Data show that kidney bean husk extract exhibited antitumor effects accompanied by the increase in p-AMPK and p-Acc as well as antitumor proteins p53 and p21.
	60.	Data show that phloretin inhibits cell proliferation via the induction of apoptosis through the activation of p53, JNK and p38 mitogen-activated protein kinase signaling.
	61.	Data show that the inhibition of cell proliferation with L.lac CF was associated with an increase in p53 and p21 expression, the reduction of cyclin D1 expression, and retinoblastoma protein phosphorylation.
	62.	Results suggest that the electrophilic carbon center located in the alpha,beta-unsaturated carbonyl moiety of the cyclopentenone ring might be critical for the control of DNA-binding activity as well as cellular levels of p53 by 15d-PGJ(2).
	63.	Results suggest that lack of correlations between TGF-beta1 and p53 proteins could indicate mutations at the TGF-beta1-dependent apoptotic pathway.
	64.	Results show that no striking relationship was found in expression patterns of p53, Bcl-2, caspase-3, and Fas.
	65.	miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53.
	66.	Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.
	67.	Consistent with in vitro findings, a strong correlation between beta(4) overexpression and HIPK2 inactivation by cytoplasmic relocalization was observed in wtp53-expressing breast carcinomas.
	68.	Cabin1 inhibits p53 function on chromatin in the quiescent state; the presence of inactive p53 on some promoters might allow a prompt response upon DNA damage.
	69.	Mutations in the p53 gene impair its tumor suppressor function. Several of these tumor-derived p53 mutants can confer further aggressive oncogenic properties when overexpressed in p53-null cells.
	70.	Polymorphisms in p53 codon 72 and MDM2 SNP309 may be implicated in breast cancer of young women.
	71.	Data show that it can function in an autoregulatory loop consisting of RAP80, HDM2, and the p53 master regulatory network, implpying an important role for this loop in genome stability and oncogenesis.
	72.	The human p53 isoforms Delta133p53 and p53beta function in an endogenous regulatory mechanism for p53-mediated replicative senescence.
	73.	Axin is a critical determinant in p53-dependent tumour suppression in which Pirh2 and Tip60 have different roles in triggering cell-cycle arrest or apoptosis depending on the severity of genotoxic stress.
	74.	Findings confirmed the relationship of p53, MDM2, and COX-2 with the biological process of pancreatic cancer.
	75.	review of literature analysing influence of radon exposure on mutations TP53 in lung cancer patients; results are not consistent in order to support existence of a radon hotspot in TP53 gene [review]
	76.	The functional relationship of the the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) and the interactional role of p53 in vitro, was studied.
	77.	Pirh2 ubiquitin ligase has two novel isoforms that negatively regulate p53 independent of RING finger domains
	78.	ATM and ATR kinases, but not DNA-PK, which participate in DNA damage-activated checkpoints, regulate the phosphorylation of p53 at serine 15 in response to MNNG cell treatment
	79.	Analysis of pair wise genotype combinations revealed increase in risk for specific p73-MDM2 and p73-p53 genotype combinations.
	80.	A method developed to predict the effects of mutations in the p53 cancer suppressor gene, a protein that is involved in over 50% of all human cancers.
	81.	RREB-1 participates in modulating p53 transcription in response to DNA damage
	82.	Findings suggest that the influence of NAT2 genotype, alone or in combination with p53 genotype, may confer increased susceptibility to lung cancer.
	83.	functional inactivation of p53 by COX-2 can be one of the mechanisms by which COX-2 promotes tumorigenesis
	84.	hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation.
	85.	study found no link between polymorphisms in APOE, p53, and p21 genes and primary open-angle glaucoma in Turkish patients,although a larger sample is required to elucidate the role of these polymorphisms in the pathogenesis and course of glaucoma
	86.	Testing for p53 polymorphisms may allow identification of gastric cancer patients who will benefit from oxaliplatin-based adjuvant chemotherapy
	87.	Results show correlation between induction of p53, reactive oxygen species and phospho-p38, whereas p38(MAPK) inhibition rescued cell growth markedly.
	88.	Data demonstrate a novel function of the evolutionarily conserved chromatin remodeling subunit BRG1, which cooperates with CBP to constrain p53 activity and permit cancer cell proliferation.
	89.	p53 was an essential factor for Sp1 overexpression-induced apoptotic cell death in transforming cells.
	90.	This retrospective study evaluated 15 cases of inflammatory myofibroblastic tumours (IMTs) to determine histological atypicality, clinicopathological features, outcomes, and expression of anaplastic lymphoma kinase-1 (ALK1) and p53.
	91.	Epigenetic inactivation of MGMT plays an important role in the survival of glioblastoma patients and this inactivated gene is involved in p53 mutation.
	92.	an interaction between MDM2 SNP 309 and p53 with respect to tumor behaviors (including disease onset, tumor differentiation, LNECS and disease-free survival) was observed in sporadic Taiwanese OSCCs.
	93.	Studies discovered a novel molecular network between p53, KLF4 and ERalpha.
	94.	findings suggest that Stat3 and p53 are cooperatively involved in the development of renal cell carcinoma (RCC) but assessment of their mRNA expression may not be useful for predicting the prognosis of patients with RCC
	95.	Observational study of gene-disease association and DATA ERROR. (HuGE Navigator)
	96.	p53 mRNA expression of chronic benzene poisoning workers or benzene-exposure workers was significantly lower than that of nonexposure workers
	97.	XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway.
	98.	GPR87 knockdown sensitized cancer cells to DNA damage-induced growth suppression via enhanced p53 stabilization and activation.
	99.	cAMP levels may influence p53 function in malignant cells that retain wt p53, potentially affecting p53 both as a tumor suppressor during cancer initiation and maintenance, and as an effector of the apoptotic response to DNA-damaging agents
	100.	PAS may represent a novel class of drug that induces apoptosis in CLL cells independently of p53 status by a mechanism involving Noxa up-regulation.
	101.	No association was found between cervical cancer and TP53 codon 72 polymorphism
	102.	Expression of p53, BCL-2 and Ki-67 was upregulated in clinically localized prostate cancer compared with benign prostate tissue, with no alteration in E-cadherin expression.
	103.	Plk1 modulates Topors activity in suppressing p53 function
	104.	Positive expression of p16, Ki-67, and ProEx C and negative expression of p53 seem to be related to HPV-16 infection
	105.	results indicate that LOH of the PTEN gene and of D12S1051 is the molecular pathogenesis of the gastric adenocarcinoma, and the mutation of the TP53 gene is an additional hit for the oncogenesis of choriocarcinoma arising from gastric adenocarcinoma
	106.	incidence of TP53 mutations in pleomorphic xanthoastrocytoma may be underestimated and that molecular approaches should be used for greater diagnostic precision
	107.	When the p53 and MDM2 polymorphisms were combined, no multiplicative joint effect between the MDM2 GG and p53 Pro/Pro genotypes exists in the risk of developing AML
	108.	study investigated whether TP53 codon 72 polymorphism is associated with somatic mutations in breast cancer tumors
	109.	we determined the methylation statuso f the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2 mutation carriers with or without breast cancer. hypermethylation was detected only in the BRCA1 promotor
	110.	it is proposed that the loss of a second allele of Tp53 leading to the loss of p21 expression, and subsequent cell proliferation, compose a sequence of events that lead to morphological transformation & instigation of ovarian epithelial tumor development
	111.	p53 induces cell apoptosis and inhibits cell migration in part by downregulating TFF2 expression through an AP-1-like site, suggesting that TFF2 may be an important downstream target of p53.
	112.	There were no significant differences in the genotype (P = 0.0927) or allele frequencies (P = 0.1430) for p53 Arg72Pro polymorphism in patients with endometriosis.
	113.	The TP53 expression values obtained by amplicon densitometry and qRT-PCR were significantly and consistently better after automated homogenization (p<0.005) for both uvula and tumor samples.
	114.	The pathway is accelerated in the absence of p53, indicating that p53 normally holds the p16(Ink4a) response.
	115.	A panel of tests for p53 codon 72 Pro/Pro, PAI-1 4G/4G and VEGF -1154A/A may be useful to identify women at risk for implantation failure after IVF-ET.
	116.	Immunohistochemistry detected inhibin-alpha, -betaA and -betaB, Ki67, p53 and glycodelin A in invasive trophoblastic mole.
	117.	Depletion of the outer kinetochore protein hBub1 upon activation of SAC primarily triggers early cell death mediated by p53.
	118.	p53 affects the speed of oocyte development and may influence the oocyte selection through apoptosis during meiotic prophase I
	119.	The frequency of TP53 mutations in low-grade and high-grade carcinoma groups were found in 20% and 70.6%, respectively.
	120.	DN-R175H mutant p53 exerts a gain of oncogenic function by promoting disruption of E-cadherin intercellular contacts and activation of proliferation signals.
	121.	regulation of p53 multimerization that requires the concerted action of JNK and Ubc13 on polysome-bound p53.
	122.	in p53-deficient settings, suppression of ATM sensitizes tumors to DNA-damaging chemotherapy, whereas, in the presence of functional p53, suppression of ATM or its downstream target Chk2 actually protects tumors from being killed by genotoxic agents
	123.	P53 physically interacts with hBub1 at kinetochores in response to mitotic spindle damage suggesting a direct role for hBub1 in the suppression of p53 mediated cell death.
	124.	p53 plays a critical role in synergistic growth inhibition by erlotinib & EGCG via inhibiting nuclear factor-kappaB signaling pathway.
	125.	median pancreatic cancer survival in p53 positive group was 10.0+/-2.2 months and in p53 negative group was 6.0+/-2.5 months
	126.	TRAIL-induced apoptosis by Notch1 signaling is dependent upon p53 up-regulation
	127.	HER-2/neu, and p53 do not seem to play a significant role in the process of high grade transformation of AciCC
	128.	Both p53 and VEGF expression were associated with Microvessel count in gastric carconoma
	129.	cases of resistance to chemotherapy in CLL with TP53 mutation in the absence of the deletion of 17p [review]
	130.	down regulation of miR-34a, miR-29 and miR-17-5p in aggressive CLL with TP53 abnormalities
	131.	Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
	132.	No apparent correlation was found between p12(DOC-1) and p53 expressions in gastric carcinoma.
	133.	Binding to a consensus DNA sequence enhances p53 stability and prevents the formation of the misfolded conformation.
	134.	advanced DSB repair analysis may serve as a novel assay for the functional classification of p53 mutations.
	135.	Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer.
	136.	Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.
	137.	Co-depletion of Cdc6 and p53 in normal cells restored Cdk2 activation and Rb phosphorylation, permitting them to enter S phase with a reduced rate of replication.
	138.	p53 mutation present in nonneoplastic mucosa of inflammatory bowel disease patients
	139.	results demonstrate that the TP53-R337H mutation can significantly increase the risk of breast cancer in carriers, which likely depends on additional cooperating genetic factors
	140.	p53 codon 72 polymorphism may serve as a susceptible factor affecting the chances of Recurrent pregnancy loss and Recurrent implantation failure
	141.	Novel germline p53 mutation is associated with glioblastoma and colon cancer.
	142.	These observations suggest that the interaction of HBV and p53 at the levels of protein-protein and DNA-protein, which resulted in inactivation of p53 transactivation.
	143.	Covalent modification of mutant p53 per se is sufficient to induce apoptosis in tumor cells
	144.	Control of p53's transcriptional activity is crucial for determining which p53 response is activated (Review)
	145.	Study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients.
	146.	Data indicate that MKRN1 is a novel modulator of p53 and p21, preferentially leading cells to p53-dependent apoptosis by suppressing p21.
	147.	p53 nuclear expression is associated with disease progression from intramedullary to extramedullary sites in multiple myeloma.
	148.	Epstein-Barr virus nuclear antigen 3C, one of the EBV latent antigens essential for the B-cell immortalization in vitro, interacts directly with p53
	149.	a central tumour suppressor, p53, enhances the post-transcriptional maturation of several miRNAs with growth-suppressive function, including miR-16-1, miR-143 and miR-145, in response to DNA damage
	150.	epigenetic silencing of the TP53 promoter is not a frequent cause of the disorder in families suggestive of Li-Fraumeni syndrome but with no germline mutations in the coding part of the gene
	151.	The data suggest that dephosphorylation of serine 376 on constitutive nuclear p53 is a sensitive and early signaling event in the response of cells to DNA damage induced by ionizing radiation.
	152.	p53 may play a role in influencing tumor metastasis through Lasp1 in hepatocellular caarcinoma.
	153.	Results indicate that 249(Ser) mutation is a HCC important factor of carcinogenesis in Brazil and it is associated to large and poorly differentiated tumors.
	154.	p53 dysfunction in HCC can cause an upregulation of the HBx protein level through the stabilizing of HBx protein in HCC.
	155.	Data show that with MAK3 knockdown, p53 is stabilized and phosphorylated and there is a significant transcriptional activation of proapoptotic genes downstream of p53, and that localization of Arl8b is altered, suggesting that Arl8b is a Mak3 substrate.
	156.	Results describe the expression pattern of p53, BCL-2 and epidermal growth factor receptor proteins in the hydatidiform moles.
	157.	p53 and ATF-2 partly mediate the overexpression of COX-2 in H(2)O (2)-induced premature senescence of human fibroblasts.
	158.	Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression.
	159.	Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK and p53 activation, and induces senescence.
	160.	GATA-1 and p53 interact in erythroid cells, and activation of p53-responsive promoters in an erythroid cell line can be inhibited by the overexpression of GATA-1.
	161.	p53 hot spots, proximal and distal colon tumors were more similar to each other than distal colon and rectal tumors
	162.	UVA-induced apoptosis is caused by extensive oxidative damage leading to p53-regulated mitochondrial release, whereas UVB induces DNA damage and apoptosis signaling upstream of lysosomal membrane permeabilization
	163.	analysis of functional TP53 in nasopharyngeal carcinoma
	164.	gain-of-function p53 mutant acquires the de novo ability to stimulate Gal-3 expression and to increase chemoresistance in anaplastic thyroid carcinomas
	165.	TP53 Arg72Pro associated with the increased risk of sporadic papillary thyroid carcinoma.
	166.	The majority of the cases of Adenosquamous carcinoma of the pancreas had strong nuclear p53 positivity
	167.	Gastric cancer patients who had low FBXW7 expression levels and p53 mutation had a distinctively poor prognosis in comparison with other subgroups.
	168.	describes a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response
	169.	JFK promotes p53 turnover through assembly of an SCF (Skp1-Cul1-F-box) complex, revealing a pathway for the control of p53 degradation and providing a link between the SCF complex and p53 regulation.
	170.	results also provide a plausible explanation for the evolutionary positive selection of some alleles in the p53 pathway and demonstrate the alleles in the p53 pathway as a good example of antagonistic pleiotropy
	171.	Results suggest that prevalent haplotypes within the TP53 gene may modulate CRC risks in the population.
	172.	None of the inverted papillomas exhibited mutations in TP53
	173.	Suggest a synergistic effect between smoking and TP53 genetic polymorphisms on lung cancer risk compared with each risk factor alone.
	174.	p53 regulates angiogenesis in low-grade astrocytomas
	175.	Increased risk of head and neck cancer among individuals with combined p73 exon 2 G4A and p53 intron 3 variant alleles and a protective effect for those carrying the p53 exon 4-p53 intron 6 diplotype combination.
	176.	Results indicate that wtp53 and p53 mutants may differentially control cancer invasion and metastasis through the p53-MDM2-Slug pathway.
	177.	both NOLC1 and tumor protein 53 work together synergistically to activate the MDM2 promoter in NPC cells.
	178.	the deregulated miR expression pattern, miR-34a, miR-29 and miR-17-5p, in CLL patients with deleted and/or mutated p53 gene are closely associated to the biological subtypes of CLL
	179.	difference in p53 expression between mild and severe levels of photoaging was not statistically significant
	180.	The effects of specific p53 phosphorylations on its interaction with the Taz2 domain of p300, are examined.
	181.	p53 alterations were more frequent in non-endometrioid adenocarcinomas and mixed endometrioid adenocarcinomas-non-endometrioid adenocarcinomas than in high-grade endometrioid adenocarcinomas or low-grade endometrioid adenocarcinomas.
	182.	In the context of mutant p53, PML enhances its cancer-promoting activities.
	183.	MDM2 acts as an ubiquitin E3 ligase, downstream of p53, to regulate the degradation of mammalian FOXO factors.
	184.	NORE1A activates p21(CIP1) via promoting p53 nuclear localization.
	185.	simultaneous phosphorylation of S15 and S20 is causally associated with apoptosis, resulting in increased expression of specific p53-responsive pro-apoptotic genes.
	186.	Data show that FAT10 and mutant p53 levels in gastric cancer tissue were significantly correlated with lymph node metastasis and tumor, nodes, metastasis staging.
	187.	Results suggest that adenovirus-mediated transduction of p53 and p21-specific microRNAs may be useful for gene therapy of human cancers.
	188.	ASPP2 primarily binds to the core domain of p53, whereas iASPP predominantly interacts with a linker region adjacent to the core domain.
	189.	Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers.
	190.	Genetic changes in TP53 can be detected also in non-neoplastic lesions linked to chronic hepatitis C virus infection.
	191.	WTH3 played an important role in MDR development and revealed one of its transcription regulatory mechanisms, DNA methylation, which antagonized p53's positive impact on WTH3 expression
	192.	The frequency of GST-P polymorphism was not associated with p53 protein accumulation in esophagus epithelium
	193.	Increased metallothionein and p53 expression is associated with oral squamous cell carcinoma.
	194.	A poorer survival was observed among carriers of the variant allele of p53 intron 6 if compared with those carrying both wild-type alleles
	195.	Results identify PLA2R (phospholipase A2 receptor) as a potential new tumour suppressor gene crucial in the induction of cellular senescence through the activation of the p53 pathway.
	196.	acetylation at Lys-120 of p53 negatively regulates a signaling pathway leading to NFAT activation
	197.	ARNTL, RBCK1 and TNIP1 regulate p53 function.
	198.	Crystal structures of two complexes, a p53-like mutant peptide with the N-terminal domains of Mdm2 and Mdmx, respectively, are presented.
	199.	p53 mutations are frequent in tumor-surrounding histologically normal tissue, and some of them might be involved in lung carcinogenesis
	200.	Tubulin acetylation stimulates the binding and the signaling function of transcription factor p53.
	201.	p53 inactivation may promote malignant transformation of a subpopulation of melanocytes with the ability to survive BRAF(V600E)-induced senescence
	202.	11 TP53 SNPs were evaluated in women with CIN3+, 380 with HPV persistance. 3 were associated with increased risk: rs12951053, rs1042522, rs1642785.
	203.	p53-mediated tumor suppression can be attributed at least in part to the biological functions of PKR induced by p53 in genotoxic conditions
	204.	current understanding on p53 ubiquitination by Mdm2 with a particular focus on how the balance between protein levels and other post-translational modifications will direct the p53 response (Review)
	205.	Results indicate that Wip1 up-regulation is important in the pathogenesis of p53(+) and ER(+) breast cancer through the inactivation of p53 by dephosphorylation and the amplification of subsequent estrogenic effects through the E(2)-ERalpha-Wip1 pathway.
	206.	p53 gene mutations apparently precede the morphological changes in affected endometrial cells.
	207.	Artemis and DNA-PKcs participate in a new, signaling pathway to modulate p53 function in response to oxidative stress produced by mitochondrial respiration.
	208.	Data indicate that the level of HCCR-1 in breast cancer tissues is correlated with the HER2 overexpression, p53 mutation, and ER/PR status, and determination of HCCR-1 levels as options for HER2 testing is promising although it needs further evaluation.
	209.	HCC containing R249S can occur in the absence of significant recent exposure to aflatoxins. Short oligonucleotide mass analysis in low ongoing aflatoxin exposure may allow the detection of R249S in plasma several months ahead of clinical diagnosis.
	210.	p53 Arg72Pro Pro/Pro was associated with esophageal cancers.
	211.	Lung adenocarcinoma occurring in young patients tends to have a poorer prognosis, and angiogenesis of lung adenocarcinoma in young patients is more closely correlated with p53 expression than in elderly patients.
	212.	single nucleotide polymorphisms in TP53 gene is associated with lower response rate to the combination chemotherapy in advanced gastric cancer.
	213.	The presence of deleterious TP53 mutations in most, if not all, BRCA1-related breast cancers suggests that p53 loss of function is essential for BRCA1-associated tumorigenesis.
	214.	Study concludes p53 polymorphisms are not associated with primary open angle glaucoma (POAG) in the Japanese population.
	215.	A smaller-sized Sfp53 orthologue shows highly conserved native structure with DNA-binding, N-terminus and C-terminus domains, and has analogous p53 transcriptional activity.
	216.	The N-terminal region of GSK3 beta binds p53, this association promotes the acetylation of p53, and subsequently acetylated p53 dissociates from GSK3.
	217.	model that describes the influence that DNA damage has on the implementation of both the G2/M phase cell cycle arrest and the intrinsic apoptosis induction via its activation of the p53 synthesis process
	218.	Data show that p53 regulates ER expression through transcriptional control of the ER promoter, accounting for their concordant expression in human breast cancer.
	219.	ALK signaling leads to the functional inactivation and/or degradation of p53 in JNK and MDM2 dependent manners.
	220.	In the absence of telomerase, transgenic p53 mice aged with the same kinetics and pathological spectrum as p53 wild type mice.
	221.	There was no clear evidence of case heterogeneity by P53 overexpression except for suggestive differences in the risk association of non-cardia gastric adenocarcinoma in relation to smoking and BMI.
	222.	functional link between Cyr61 and p53 in cancers
	223.	Change of mitochondrial DNA is a common event in colorectal cancer with p53 mutation.
	224.	p53 acetylation liberates BAX from Ku70
	225.	p53 is primarily protective against ultraviolet rays-induced apoptosis in primary human fibroblasts and this activity of p53 does not require DDB2.
	226.	IFI16 and NM23/NDPK are simultaneously bound in vivo to the promoters of the oncogene cMYC and of P53
	227.	a novel mechanism by which mutant p53 acquires its gain of function via transactivating the GRO1 gene in cancer cells.
	228.	An approximately 32-fold increase in caspase-1 expression was observed in the p53-knockin cell line after dengue virus infection.
	229.	Stabilization and activation of p53 by spindle disruption requires the spindle checkpoint kinase TTK/hMps1.
	230.	No relationship was found between p53 mutations and the occurrence of second primary head and neck carcinomas
	231.	Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
	232.	Cutaneous hidradenocarcinoma has a relatively low frequency of TP53 mutations despite a high rate of p53 protein expression at the immunohistochemical level.
	233.	findings revealed Apak to be a negative regulator of p53-mediated apoptosis
	234.	p53 normally suppresses the generation of tetraploid cells, presumably by activating the intrinsic pathway of apoptosis.
	235.	Data show that FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53.
	236.	In leukoblasts from 82 patients with acute myeloid leukemia, various extent and frequency of differential allelic expression in the CDA, DCK, NT5C2, NT5C3, and TP53 genes was observed.
	237.	Results suggest that a physiological level of TopBP1 is essential for normal G(1)/S transition, but a pathological level of TopBP1 in cancer may perturb p53 function and contribute to an aggressive tumor behavior.
	238.	Among the 112 patients with urothelial carcinoma of the upper urinary tract 32 (28.6%) had altered expression of p53
	239.	study examined the associations between p53 mutations, p53 functional status, and mRNA and protein levels in hematopoietic cell lines
	240.	Hepatitis C virus genotype IV and p53 protein levels may have a role in the development of hepatocellular carcinoma among Egyptian patients
	241.	a higher frequency of p53 genetic mutations and increased AgNOR values exist in squamous cell carcinoma compared with basal cell carcinoma and squamous cell papilloma
	242.	We suggest that TP53 Pro47Ser and Arg72Pro polymorphisms and DNA hypermethylation are involved in susceptibility for developing extra-axial brain tumors.
	243.	We concluded that the p53 codon 72 Arg/Pro polymorphism is not associated with Primary open angle glaucoma in Brazilian patients.
	244.	Variants in the TP53 gene may modify the risk of late skin toxicity after radiotherapy.
	245.	Results highlight the role of SMAR1 in masking the active phosphorylation site of p53, enabling the deacetylation of p53 by HDAC1-MDM2 complex, thereby regulating the p53 transcriptional response during stress rescue.
	246.	Data show that upregulation of the p53 tumor suppressor during the restricted period of embryonic development significantly contributes to the Bst phenotype in Rpl24-deficient mice.
	247.	Results establish a new role for H2AX in the p53/p21 pathway and indicate that H2AX is required for p21-induced cell cycle arrest after replication stalling.
	248.	Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
	249.	Study provides evidence that p53, binding with Snail, is exported from a K-Ras-mutated cell through a vesicle transport-like mechanism, independently using a p53-nuclear-exporting mechanism.
	250.	This is the first description of p53 signatures adjacent to carcinoma, suggesting a role for this entity in the genesis of serous malignancy
	251.	Internalization of a peptide fragment derived from p53 tumor suppressor protein in human SJSA-1 cancer cells is shown to occur via adsorption-mediated, energy-dependent pathways, resulting in accumulation of the material in endocytic vesicles.
	252.	Data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation.
	253.	p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular mechanism of DNA-damage-induced apoptosis in hESC
	254.	The Pro allele at codon 72 of p53 was a risk factor for developing lung cancer.
	255.	The binding interactions between the N-terminal transactivation domain (TAD) of p53, the TAZ1, TAZ2, KIX, and nuclear receptor coactivator binding domains of CBP, and the p53-binding domain of HDM2, are examined.
	256.	first report showing p53 overexpression and its genetic background in malignant mixed Mullerian tumors of the peritoneum
	257.	The studies unravel a molecular mechanism underlying sumoylation-regulated p53 function and further uncover a new role of acetylation in antagonizing the inhibitory effect of sumoylation on p53 binding to DNA.
	258.	P53 gene mutations are significantly correlated with p53 protein over-expression in adenocarcinoma of gastric cancer patients from India.
	259.	Over-expression of the Tp53, CCND1, and C-myc genes appears to play a role in development of human cancer by regulating the expression of mRNA.
	260.	p53-dependent apoptosis upregulated by the I143T/G384A mutant PS1 gene may be associated, at least in part, with intracellular Abeta and proteasome impairment
	261.	p53 Pro72 variant is associated with an increased risk for colorectal cancer in the Korean population.
	262.	Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways.
	263.	The authors conclude that CinS and ExpR act to increase PlyB levels, thereby influencing the bacterial surface.
	264.	Human papillomavirus-infected esophageal squamous papillomas show low expression of cell-cycle markers (p16, p53).
	265.	Transcriptome profiling and TP53 sequencing of concurrent small cell and prostatic adenocarcinoma to determine the relationship between these entities.
	266.	Report role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
	267.	A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
	268.	TP53 genotyping may be of clinical interest in selecting patients who may benefit from cetuximab-based chemotherapy in metastatic colorectal cancer.
	269.	JNK activation essential for the autophagic cell death resulted in upregulation of Beclin-1 expression, Bcl-2 phosphorylation, and p53 phosphorylation, suggesting that these pro-autophagic signaling pathways are involved in the autophagic cell death.
	270.	cDNA microarray analysis does not indicate any specific target or treatment effects of head and neck squamous cell carcinoma with mutant P53 and over-expressed EGFR.
	271.	The efficient degradation of RNA containing AU-rich sequences (ARE) correlates with the efficient binding of p53 to ARE RNA in cytoplasm
	272.	Zalypsis provoked DNA double-strand breaks (DSBs), evidenced by an increase in phospho-histone-H2AX and phospho-CHK2, followed by a striking overexpression of p53 in p53 wild-type cell lines
	273.	increased level of p53 in astrogliomas is increasing as the tumor grade is increasing
	274.	This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.
	275.	Results show that p53 abrogation rescues both the small size phenotype and restitutes the functionality of epidermal stem cells of telomerase-deficient mice with dysfunctional telomeres.
	276.	Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells.
	277.	Results reveal a novel and direct role for p14ARF in the p53-independent maintenance of genomic stability.
	278.	p53 deletion without multiple aberrations is an independent negative prognostic factor for disease-free survival, relapse risk, and overall survival
	279.	The integration of PTEN and p53 into a common pathway for the induction of another tumor suppressor, Maspin, constitutes a tumor suppressor network of PTEN/p53/Mapsin that is operational under limited oxygen conditions.
	280.	p53 is not involved in the HDAC4 repression of p21(WAF1/Cip1) expression in cancer cells.
	281.	p53 plays an important role in proliferation in our studied population, since it is overexpressed in 92% of T-cell lymphoma cases.
	282.	The specific knockdown of individual protein kinases (PKs) has enabled the identification of a number of new PKs that control the expression of PCNA and p53 in ovarian cells.
	283.	TBX2 is a cell type-dependent survival factor under a p53-negative background.
	284.	The results of our study do not support a relevant role of the p53 polymorphism in head and neck carcinogenesis, either taken alone or in association with the HPV status.
	285.	EBNA3C enhances the intrinsic ubiquitin ligase activity of Mdm2 toward p53, which in turn facilitated p53 ubiquitination and degradation
	286.	combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors.
	287.	p53 activation may downregulate the AKT/mTOR pathway through a mechanism involving AMP kinase in mantle cell lymphoma
	288.	glioblastoma patients with TP53 codon 72 Arg/Pro alleles showed significantly shorter survival than those with Arg/Arg alleles
	289.	The over-expression of P53 in Nasal NK/T-cell lymphoma is probably associated with high incidence of EBV infection and unlikely a regulatory protein for the expression of MRP and LRP
	290.	there was no association between CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 ) and p53 gene polymorphisms and gestational trophoblastic diseases
	291.	Relationship of immunohistochemistry scores of altered p53 protein expression in relation to patient's habits and histological grades and stages of squamous cell carcinoma.
	292.	Thermodynamic experiments revealed the importance of hydrophobic interactions in the complex of Taz2 with p53 phosphorylated at Ser(15) and Thr(18).
	293.	Repression of E6 and E7 oncogenes results in restoration of p53 suppressor pathways and induced apoptosis in HPV16-positive oropharyngeal squamous cell cancer cell lines.
	294.	p53 mutation is an early genetic event affecting a diversity of molecular pathways in pancreatic carcinogenesis
	295.	Mutations in TP53 is associated with Salivary Gland Neoplasms.
	296.	Her-2/neu (47.1%), p-53 (31.74%), and their combined expression (15.87%) were not related to grade or stage of tumor in osteosarcoma
	297.	Unlike other DNA damage response-inducing agents, RITA treatment of cells induced a p53-dependent increase in phosphorylation of the eif2 alpha, requiring PKR-like endoplasmic reticulum kinase activity, and led to the downregulation of HIF-1alpha
	298.	The genetic polymorphisms of the p53, genes were found to be significantly different (p<0.05) between the uremic and non-uremic diabetes group
	299.	The release of PCAF from hSirT1 repression favors the assembly of transcriptionally active PCAF/E2F1 complexes onto the P1p73 promoter and p53-independent apoptosis.
	300.	There is a tight association between cold winter temperature and p53 Arg72 and between low UV intensity and MDM2 SNP309 G/G in a cohort of 4029 individuals across Eastern Asia that suggests causative selection.
	301.	Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.
	302.	the pathways regulated by the NF1 and p53 tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation
	303.	The prevalence of COX2 and p53 risk-alleles contributes towards susceptibility to the disease.
	304.	miR-125b, a brain-enriched microRNA, is a bona fide negative regulator of p53 in both zebrafish and humans
	305.	CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development
	306.	p53 oligomerization precedes its acetylation by providing docking sites for acetyltransferases.
	307.	p53 is selectively stabilized because the unanchored polyubiquitin that accumulates after USP5 knockdown is able to compete with ubiquitinated p53 but not with Mdm2 for proteasomal recognition
	308.	p53 either alone or associated with Human papilloma virus was not associated with the presence of uterine cervix adenocarcinoma
	309.	Study shows that TGFbeta-dependent cell migration, invasion and metastasis are empowered by mutant-p53 and opposed by p63.
	310.	Data suggest that the activation of the p53 pathway is involved in suberoyl bis-hydroxamic acid-induced apoptosis in MCF-7 cells.
	311.	Results suggest that nm23-H1 may act as a cellular protector against oxidative stress, possibly triggering increased expression of GPX1 and the p53-related antioxidative pathway.
	312.	CARF may act as a novel key regulator of the p53 pathway at multiple checkpoints
	313.	These findings deciphered the structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
	314.	These results suggest that multiple TP53 mutations in glioblastomas are due to deficient repair of DNA double-strand breaks caused by mutational inactivation of the NBS1 gene.
	315.	p53 stabilisation and caspase-3 activation concur to determine the apoptotic response mediated by Apollon knockdown in breast cancer cells.
	316.	Increased p53 expression in luminal cells was related to focal infiltration of polymorphonuclear leucocytes.
	317.	The balance of GLI1 and p53 functions, thus, determines cell numbers, and prevalence of p53 restricts GLI1-driven stem cell expansion and tumourigenesis.
	318.	The results of this study demonstrate that gankyrin overexpression downregulates p53 expression and promotes cell proliferation in a zebrafish model. Mdm2 expression was not affected by gankyrin.
	319.	The authors conclude that the E1B 55-kDa protein is not necessary to block activation of p53 in Ad5-infected cells.
	320.	Localization of N-myc downstream-regulated gene 1 and its significant correlation with p53 expression may play an important role in gastric cancer progression.
	321.	Increased PDF mRNA stability in response to hypoxia and cobalt chloride, but not doxorubicin, indicates that p53-dependent induction of PDF expression occurs via diverse mechanisms.
	322.	Results describe thet role of P53/P21 and RUNX 3 in the effects of 5-Aza-2'-deoxycytidine on human cancer cells.
	323.	For urine cytology, immunostaining method with epidermal growth factor receptor and p53 was useful for the differential diagnosis.
	324.	All cases expressed p53 proteins in basal and suprabasal layers. In the basal layer, the nuclei testing positive for p53 were stained intensely, while in the suprabasal layer, cells with slightly stained nuclei were predominant.
	325.	Chk1 affects Cdc25A via rapid phosphorylation and protein turnover, inhibition of Cdc25A transcription by p53-ATF3 is required for the maintenance of cell cycle arrest.
	326.	These results indicate a ROS-independent but p53/retinoblastoma protein-dependent senescence mechanism during hyperoxia.
	327.	miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network
	328.	ATM is a key regulatory protein to promote activation of p53 and Sp1 leading to PrP(C) elevation, which is required to reduce Cu(II) toxic effects and may play an important role in modulation of intracellular copper concentration.
	329.	the essential role of p53 in hyperpigmentation of the skin via the regulation of paracrine-cytokine signaling, both in keratinocytes and in melanocytes.
	330.	The switch from Mnt-Max to Myc-Max during bile duct ligation (cholestasis) and in hepatocytes treated with lithocholic acid is responsible for the induction in p53 and cyclin D1 expression and contributes to apoptosis.
	331.	the Sirt1-dependent proapoptotic effect of Salermide is p53-independent
	332.	epithelial tumor cells can suppress p53 induction in neighboring fibroblasts
	333.	Participation of p53 in the formation of breast fibroadenomas.
	334.	p53 immunocytochemistry detected 87% of the malignancies in specimens from biliary and pancreatic tree brushing in 24 patients with biliary strictures suspected for malignancy.
	335.	neither the TP53 Arg72Pro polymorphism nor the MDM2 SNP309 contributes significantly to either susceptibility or disease severity in systemic lupus erythematosus
	336.	p53 intron 7 ApaI polymorphism may be associated with human NSCLC.
	337.	study showed that p53 expression is directly correlated with undifferentiated endometrial carcinoma, lymph-node involvement and risk of death
	338.	The authors found that liberation of p53 through chemical antagonism of one of its major ubiquitin ligases, MDM2, using the small-molecule Nutlin-3 led to apoptosis of established LCLs and suppressed EBV-mediated transformation of primary B cells.
	339.	Genetic and pharmacologic perturbation of p53 directly influences SULF2 expression in tumor cell lines.
	340.	Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G(2)/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes.
	341.	SOX4, a new DNA damage sensor, is required for the activation of p53 tumor suppressor in response to DNA damage.
	342.	Data are the first demonstration that wild-type p53 protein binds to a response element within the EpCAM gene and negatively regulates EpCAM expression, and transcriptional repression of EpCAM contributes to p53 control of breast cancer invasion.
	343.	observations provide support for the idea that up-regulation of IFI16 expression by p53 and functional interactions between IFI16 protein and p53 contribute to cellular senescence.
	344.	The p53 codon 72 polymorphisms are associated with a higher risk of CRC and are associated with more advanced and undifferentiated tumours.
	345.	induction of p53 and apoptosis are reduced by green tea extract in UVB-irradiated human skin independent of transcriptional controls
	346.	MDM2 released from p53 by RITA promotes degradation of p21 and the p53 cofactor hnRNP K, required for p21 transcription
	347.	This study demonstrated that baicalin-induced apoptotic cell death in the breast cancer cells involves the up-regulation of proapoptotic p53 and bax, implying potential crucial roles of bax and p53 in the baicalin-induced apoptosis.
	348.	The combination of the MDM2 SNP309 and the three TP53 polymorphisms appear to be related to a higher grade of endometrial cancer.
	349.	The p53 codon 72 exon 4 BstUI polymorphism is only weakly associated with the risk of endometrial cancer and prognostic factors in Caucasian women.
	350.	Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	351.	Observational study of gene-disease association and genetic testing. (HuGE Navigator)
	352.	The experimental data suggest that the ANNEXIN A2 gene may relate to cellular apoptosis induced by p53 gene.
	353.	The P allele of the p53 R72P polymorphism has an increased risk for hepatocellular carcinoma in HbsAg-negative subjects, and exerts a synergistic influence on the risk for HCC when combined with HCC family history and the male gender.
	354.	Tp53 mutant human glioma cells are sensitive to UV-C-induced apoptosis due to impaired cyclobutane pyrimidine dimer removal.
	355.	RYBP decreases MDM2-mediated p53 ubiquitination by interacting with MDM2. RYBP induces cell-cycle arrest and is involved in the p53 response to DNA damage.
	356.	The R allele of the TP53 R72P polymorphism may contribute to the etiology of liver metastases, particularly among those with positive P53 expression tumors. Both TP53 C-8343G and C-1863T may be not associated with colorectal liver metastases risk.
	357.	Effect of ROS on angiogenesis in tumors expressing hot-spot p53 mutants was correlated with their ability to increase a content of HIF1 transcriptional factor responsible for up-regulation of VEGF-A mRNAs.
	358.	CARF plays a dual role in regulating p53-mediated senescence and apoptosis, the two major tumor suppressor mechanisms.
	359.	Data show that hTERT activity or inactivation of p53 can suppress the cell proliferation defects associated with lamin A mutants that are incorrectly processed.
	360.	Ins-72Pro haplotype in p53 with an increased cancer risk in BRCA2 mutation carriers has not been validated
	361.	p53 nucleolar association occurs in lung and bladder carcinomas.
	362.	nucleoplasmic relocation of nucleostemin during nucleolar disassembly safeguards the G2-M transit and survival of continuously dividing cells by MDM2 stabilization and p53 inhibition.
	363.	This selectivity of flavokawain A for inducing a G(2)-M arrest in p53-defective cells deserves further investigation as a new mechanism for the prevention and treatment of bladder cancer.
	364.	ING1 variants may modulate p53 activity and subsequently inhibit hepatoma cell growth by at least two possible mechanisms.
	365.	data suggest that the Mya arenaria p53 shares some functional similarity with human p53 as well as with other invertebrates, positioning the mollusk at a critical juncture in evolution of this gene family
	366.	These findings suggest that the histone methyltransferase SETD2 could selectively regulate the transcription of subset genes via cooperation with the transcription factor p53.
	367.	Results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.
	368.	p53 is as a cytotoxic bomb that can be triggered by granzyme K, leading to potentiating killing efficacy.
	369.	Up-regulation of p53 gene expression is associated with virus-mediated induction of type-I interferons.
	370.	Low rates of somatic p53 mutations in keratoacanthomas imply a minor role of p53 in the pathogenesis of keratoacanthoma.
	371.	p53 mutation is an initiating mutation in the majority of colitis-associated neoplasia, and K-RAS activation is an alternative gatekeeping mutation.
	372.	Overexpression of p53 oncoprotein is associated with gastric carcinoma.
	373.	the presence of the p53 codon 249 mutation from plasma DNA is significantly associated with hepatocellular carcinoma
	374.	P53 had neither diagnostic nor prognostic relevancein patients with bladder urothelial tumours
	375.	might be markers of depth of invasion or lymph node involvement in patients with gastric cancers
	376.	KLF6 and TP53 mutations are not frequent events in prostate cancer
	377.	Although p53 is mutated in trophoblast, it is functionally incompetent towards matrix metalloproteinases in these cells.
	378.	Study identifies PHLDA3 as a p53 target gene that encodes a PH domain-only protein and finds that PHLDA3 competes with the PH domain of Akt for binding of membrane lipids, inhibiting Akt translocation to the cellular membrane and activation.
	379.	findings of higher DNA concentrations with some p53 mutations in CFDNA from patients with NHL that match the previous reported p53 mutations from tumour DNA may hold promises that CFDNA may serve as a convenient source of tumour-derived DNA
	380.	p53-deficient neuroblastoma cells are largely resistant to nitric oxid (NO) killing and show much reduced maspin and PAI-1 mRNA and protein levels after NO treatment
	381.	A role for p53 in mediating altered trophoblast cell turnover in response to oxidative stress.
	382.	Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest.
	383.	The Snail-p53 binding as the new therapeutic target for K-Ras-mutated cancers including pancreatic, lung, and colon cancers.
	384.	p53-Mdm2 protein-protein and p53 mRNA-Mdm2 interactions affect Mdm2-mediated control of p53 expression using the Phe19Ala p53 mutant.
	385.	Spy1 fulfills a novel regulatory role in the intrinsic DNA damage response and maintains the balance between checkpoint activation, apoptosis, repair and cell cycle progression in response to exogenous or intrinsic damage.
	386.	p53 Mutations is associated with carcinoma of the esophagus and gastroesophageal junction
	387.	The p53-dependent transcriptional regulation of p21 in response to DNA damage by ultraviolet radiation and ionizing radiation compared.
	388.	The export of p53 from the nucleus is not sufficient to activate its cytoplasmic apoptotic function which may depend on the ability to deubiquitinate cytoplasmic p53.
	389.	Non-smoking and non-drinking patients with squamous cell carcinoma have the same risk for developing multiple tumors as their smoking and drinking counterparts without an increased expression of p53.
	390.	results support the hypothesis that p53 function is suppressed by aberrant HDM2 activity and suggest the possibility of targeting the p53-HDM2 regulatory axis as a therapeutic strategy in synovial sarcoma
	391.	53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling
	392.	TP53 mutation is highly recurrent in basal-like carcinoma independently of BRCA1 status, but not a common feature of BRCA1 luminal tumors.
	393.	combined alpha-methylacyl coenzyme A racemase/p53 analysis may represent a helpful tool to confirm dysplasia in inflammatory bowel disease.
	394.	the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.
	395.	Hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and regulates cellular proliferation and the expression of target genes by p53-independent mechanisms.
	396.	E6 F47R-induced cellular senescence is strongly dependent on p53 signaling pathway.
	397.	JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.
	398.	A TP53 single nucleotide polymorphism is critical for oncogenesis of glioblastoma in young patients.
	399.	Patients from Kashmir Valley, INdia with TP53 mutant esophageal squamous cell tumor had lower zinc levels than those with no mutation.
	400.	The aim of the study was to evaluate the correlation between clinical characteristics, histopatologic features and c-erbB-2 as well as p53 expression in cancer tissues.
	401.	The results show that p53 mutations characterize a small biologically aggressive subgroup of prostate cancers with a high risk of progression after prostatectomy.
	402.	analysis of p53 gene in prostate adenocarcinoma showed several mutations in high Gleason patients, according to tumor advanced stage; results showed localization of p53 & T antigen (TAg) into cytoplasm, but in TAg-negative tumors, p53 was nuclear
	403.	A homozygous p53 R248W gain-of-function mutation as the result of a CGG to TGG transition was identified in one of seven sebaceous gland carcinomas. It has been demonstrated previously that p53 R248W mutants inactivate ATM-directed HRR.
	404.	demonstrated no evidence for association of MDM2 SNP 309 or TP53 Arg72Pro allelic variants alone, or in combination, with overall survival (Figure 1A), progression free survival, relapse free survival or time to transformation
	405.	CPEB controls senescence and bioenergetics in human cells at least in part by modulating p53 mRNA polyadenylation-induced translation
	406.	p53 codon 72 polymorphism (Arg72Pro) frequencies with respect to the susceptibility and the clinical outcome of patients with Soft tissue sarcomas.
	407.	relation with p53 protein expression, p53 gene codon 72 polymorphism and infection with HPV DNA with pterygium
	408.	Results suggest that apoptosis inhibitory proteins are highly induced in squamous cell carcinoma/mutated p53 cells after heat treatment when compared to control cells.
	409.	These results provide a structural explanation for the dominant-negative effect of p53 and its lack of transcriptional activity.
	410.	Polygonatum cyrtonema lectin induces apoptosis and autophagy via a mitochondrial-mediated ROS-p38-p53 pathway
	411.	p53-dependent downregulation is consistent with an oncogenic function of RHAMM and the recently reported tumor-suppressive function of CD44 transcriptional repression by p53.
	412.	there was no association between the p53 antigen G72C polymorhphism and susceptibility or course of disease in patients with Wegeners granulomatosis
	413.	Only a small fraction of naturally occurring sequence variations of TP53 cause measurable perturbation of p53 function.
	414.	p53 may induce cell cycle arrest not only by well described mechanisms involving the induction of cyclin-dependent kinase inhibitors but also by the recruitment of pathways that reduce the availability of intracellular iron
	415.	Mdm2-mediated control of p53 synthesis and degradation has evolved in the p53 mRNA sequence and its encoded amino acids.
	416.	incidence and prognostic impact of TP53 mutations in a cohort of patients with adverse cytogenetics and those with losses on chromosome 17p
	417.	Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells
	418.	the identification and functional characterization of a novel TP53 germinal mutant allele (Cys275Phe c.824G > T p.C275F) in a large Italian Li-Fraumeni syndrome family
	419.	TP53 mutations in chronic lymphocytic leukemia were significantly associated with del (17p) and complex cytogenetic abnormalities
	420.	ANKRD11 has a role as a p53 coactivator and may be involved in a regulatory feedback loop with p53
	421.	additional inactivation of p53 in malignant primaries and benign recurrences contributes to myoepithelial neoplastic transformation and aggressive tumour growth.
	422.	the detection of a TP53 abnormality in early stage CLL is often associated with progressive disease,however, a subset of these cases with mutated IGHV genes may have stable disease for many years, never requiring therapy
	423.	Alterations in both the p53 and p16-Rb pathways are associated with squamous cell carcinoma arising in mature cystic teratoma.
	424.	Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
	425.	Report differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
	426.	Proton beam induces apoptosis of hypoxic tumor cells by the p53-dependent and p38/JNK MAPK signaling pathways.
	427.	wild type p53 suppressed the S100A6 promoter up to 12-fold in a dose-dependent manner
	428.	p38 kinase which was activated during p53-induced senescence was not observed in vitamin C-treated EJ cells
	429.	TsA markedly down-regulated the expression of cyclin D1 and CDK4, up-regulated the expression of p21WAF1 and p53 and induced cell cycle arrest at the G1 phase in MCF10A-ras cells
	430.	Meta-analysis of gene-disease association and gene-environment interaction. (HuGE Navigator)
	431.	REVIEW. p53 represses RHAMM and CD44 expression
	432.	These results highlight the prognostic value of CDK4 amplification and of simultaneous EGFR-p53 alterations in the clinical outcome of patients with primary GBM.
	433.	The inactivation of TP53 is similar in familial pancreatic adenocarcinomas as in sporadic pancreatic adenocarcinomas.
	434.	p53 in mitochondria may be a component of an error-repair pathway and serve as guardian of the mitochondrial genome.
	435.	c-Abl and p53 are important for execution of the cell death program initiated in A2E-laden RPE cells exposed to blue light, while JNK might play an anti-apoptotic role
	436.	direct interaction between NM23-H1 and macrophage migration inhibitory factor (MIF) is critical for alleviation of MIF-mediated suppression of p53 activity
	437.	Alterations in the p53 gene may be indicative of poorer prognosis and greater recurrence in patients with urothelial bladder tumor.
	438.	Strap regulation reflects the coordinated interplay between different DNA damage-activated protein kinases, ATM and Chk2 (Checkpoint kinase 2), where phosphorylation by each kinase provides a distinct functional consequence on the activity of Strap.
	439.	p53 expression seems to negatively influence survival in non-smoking non-alcoholic patients with squamous cell laryngeal carcinoma.
	440.	expression of miRNAs is downregulated in senescent cells and in breast cancers harboring wild-type p53. These miRNAs are repressed by p53 in an E2F1-mediated manner
	441.	The crystal structures of the p53 core domain incorporating the hot spot mutation R249S, the core domain incorporating R249S and a second-site suppressor mutation H168R and its sequence-specific complex with DNA and of the triple mutant, were determined.
	442.	Genotoxic stress promotes the p53-dependent up-regulation of the homologous miRNAs miR-192 and miR-215.
	443.	Results suggest that nonactivated p53 has limited binding activity, whereas upon activation it binds to essentially all its targets. Additional triggers are most likely required to activate the transcriptional program of p53.
	444.	TP53 methylation was probably not implicated in gastric carcinogenesis
	445.	p53 siRNA enhanced reprogramming efficiency of pluripotent stem cells generation induced from human adult fibroblasts
	446.	Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse
	447.	In this immunohistochemical study, 80% of all vulvar intra-epithelial neoplasia were negative for p53 tumor suppressor protein.
	448.	TP53 mutation but no CHEK2*1100DelC variant in familial gliomas.
	449.	GBP-2 is regulated by p53 and may have a role in esophageal squamous cell carcinomas
	450.	Completely inhibits Saccharomyces cerevisiae growth under minimal media conditions and down regulates thioredoxin expression.
	451.	epirubicin-cyclophosphamide treatment induces senescence-like features in TP53 wild-type tumor, while in TP53 mutated tumors, chemotherapy induces mitotic catastrophe and tumor death
	452.	Skin cells grown in culture showed a notable decrease in the UVB fingerprint mutation on the p53 tumor suppressor gene in fibroblasts during proliferation.
	453.	HER-2/neu, AR, and p53 are expressed in a subset of histologically and clinically benign pleomorphic adenomas. These markers cannot be used to reliably predict early carcinomatous transformation in pleomorphic adenoma.
	454.	Protein expression neither of p16(INK4a) nor of p53 correlated with high-risk human papillomavirus status
	455.	TP53 levels were not helpful in identifying patients who would benefit from neoadjuvant treatment of rectal cancer.
	456.	Polymorphism Arg72Pro in tumor suppressor gene TP53 increases the risk of lung cancer, especially for small cell lung cancer and heavy smokers.
	457.	analysis of the coordinated immediate responses by p16INK4A and p53 pathways in UVB-irradiated human skin cells
	458.	analysis of the expression of fatty acid synthase, Ki-67 and p53 in squamous cell carcinomas of the larynx
	459.	TP53 mutations may have a role in progression of breast cancer
	460.	p53 and GLI1 may have a role in tumor cell survival
	461.	Report genetic alterations of TP53 in Korean colorectal cancer patients.
	462.	A novel p53-dependent transcriptional mechanism regulates adaptor protein p66shc expression operative in the vascular endothelium and may be important in impairing endothelium-dependent vascular relaxation.
	463.	data suggests that TP53 mutations are associated with poor outcome in diffuse large B-cell lymphoma of germinal center subtype patients
	464.	PPARgamma and TP53 genes may be candidates for molecular markers in pediatric MDS, and that these potentially recurrent deletions could contribute to the identification of therapeutic approaches in primary pediatric MDS
	465.	p53 directly affects hPar1 expression and function, thus providing evidence for direct binding between p53 and hPar1 chromatin.
	466.	S100A6 is induced by tumor necrosis factor-alpha via an NF-kappaB-dependent mechanism, serving a role in homeostasis to limit tumor necrosis factor-alpha-induced apoptosis by regulating p53 phosphorylation
	467.	This review concludes that a selective gain of pro-survival functions of wild-type p53 in cancer cells will confer a survival advantage that counteracts tumor therapy.
	468.	Inhibition of MT2A expression by siRNA in the HIPK2 knockdown cells restored p53 transcription activity.
	469.	Ets-1 binds cooperatively to the EBS palindrome of the hp53 promoter.
	470.	with aging there is an increase of mutant like conformation state of p53 in peripheral blood cells, which is more pronounced in Alzheimer Disease patients
	471.	incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in >or=5%TP53-deleted cases
	472.	The authors show that Pirh2-p53 interaction is dependent on the C-terminal zinc binding module of Pirh2, which binds to the tetramerization domain of p53.
	473.	Different from ERbeta, p53 interacts with HDAC1 and CtBP1 and forms an inhibiting transcriptional complex that could compete for binding to Sp1 sites with ERalpha transcriptional complex and inhibit BRCA2 transcription more significantly
	474.	15d-PGJ(2) induces vascular endothelial cell apoptosis through the signaling of JNK and p38 MAPK-mediated p53 activation both in vitro and in vivo
	475.	Resveratrol displays converse dose-related effects on fluorouracil-evoked colon cancer cell apoptosis: the role of p53 is reported.
	476.	The role of p53 in the sustained phosphorylation of c-Jun-N-terminal kinase mediating melanoma apoptosis induced by 2-acetyl furanonaphthaquinone is reported.
	477.	4-HNE is involved in p53-mediated signaling in in vitro cell cultures as well as in vivo that can be regulated by glutathione transferase
	478.	STX6 can be induced by DNA damage and Mdm2 inhibitor Nutlin-3 in a p53-dependent manner.
	479.	Epistatic analysis that p53 inhibition results in a maximum level of autophagy.
	480.	the kinetic stabilization of microtubules enhances the microtubule-mediated transport of p53 into the nucleus
	481.	Methylation on arginine residues is an underlying mechanism of control during the p53 response.
	482.	These data indicate that elevated Skp2 expression may overcome p53-dependent cell cycle checkpoints in melanoma cells and highlight Skp2 actions that are independent of p27(Kip1) degradation.
	483.	Results describe the possible involvement of p53 in the osteocyte apoptosis observed in Idiopathic osteonecrosis of the femoral head.
	484.	Principal component analysis was performed on the atomic contact maps of an experimentally restrained ensemble of the human p53 transcriptional activator domain.
	485.	p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
	486.	maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation
	487.	PML disruption by EBNA1 requires binding to the cellular ubiquitin specific protease, USP7 or HAUSP, but is independent of p53.
	488.	the cytoplasmic localization of p53 as the most important feature for p53-mediated autophagy inhibition.
	489.	p53 phosphorylation and localization status is associated with expression of ADP ribosylation factor like 2.
	490.	oxidative modification of p53 could be involved in the neuronal loss observed in neurodegenerative conditions
	491.	TP53 mutations are associated with chemoresistance in breast cancer, defined as progressive disease on therapy for mutations affecting p53 loop domains L2/L3).
	492.	Aberrant DNA methylation was not associated with p53 mutations in ovarian carcinoma.
	493.	knockdown of endogenous MBP-1 is involved in cellular senescence of HFF through p53-p21 pathway.
	494.	Ubiquitin over-expression promotes the destabilization of the ubiquitin protein ligase E6AP, by a mechanism involving self-ubiquitination, and the stabilization of p53.
	495.	Two conserved CPEs in the p53 3'UTR regulate stability and translation of a reporter mRNA in non-irradiated as well as irradiated cells.
	496.	G > A polymorphism at intron 6 of p53 may contribute to the level of DNA damage in occupational exposure to vinyl chloride.
	497.	Data show that nitric oxide derived from S-nitrosoglutathione activates ASK1 in THP-1 human myeloid macrophages, induces accumulation of HIF-1alpha protein, and induces accumulation of p53 in normal but not HIF-1alpha knockdown THP-1 cells.
	498.	TP53 gene expression was significantly higher in colorectal cancer patients than in healthy volunteers.
	499.	three different COX-2 mutations and five different P53 mutations are associated with non-small-cell lung carcinoma
	500.	Strong p53 nuclear staining was detected in smokeless tobacco keratosis, squamous cell carcinoma and alveolar ridge keratoses.
	501.	Influence of tetramerization on site-specific post-translational modifications of p53 are reported.
	502.	Results suggest that the Arg/Arg genotype polymorphism of p53 may represent a potential risk factor for the development of lung cancer independent of the human papillomavirus infection.
	503.	Tat contributes to neuronal degeneration through activation of a pathway involving p53 and p73.
	504.	the TP53 polymorphism, at the 347 residue, is not associated with any clinicopathological findings of patients with breast cancer.
	505.	Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China.
	506.	The data showed that hepatocellular carcinoma patients had a significantly higher mean anti-p53 antibody values (p=0.0001), than both liver cirrhosis patients and healthy control groups.
	507.	These observations suggest that most endopolyploid tumour cells are not reproductively inert and that Aurora-B may contribute to the establishment of resistant tumours post-irradiation.
	508.	functional inactivity and mutations of p53 differentially affect TS, potentially influencing response to TS inhibitor-based treatment
	509.	Expressed in most dysmorphic neurons in focal cortical dysplasia type II.
	510.	crystal structure of N-terminal domain of Mdmx bound to 15-residue p53 peptide was determined; structure reveals that although principle features of Mdm2-p53 interaction are preserved, the Mdmx hydrophobic cleft on which the p53 peptide binds is altered
	511.	Describe TP53 expression in developing pituitary gland.
	512.	findings suggest that the combined variants of p53 and p73 significantly increase the risk of HPV16-associated oral cancer, especially among never-smokers
	513.	overexpression of p-ATF2, p-STAT3 and possibly p53, but not p63 or p73, may contribute to the tumorigenesis of cutaneous vascular tumors.
	514.	Proteasome inhibition-mediated premature cell senescence can only be initiated and maintained in the presence of functional p53.
	515.	direct interaction of p53 with mitochondrial antiapoptotic proteins including Bcl-2 is the major route for apoptosis induction in CLL cells
	516.	Report relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder.
	517.	The presence and absence of a dominant negative p53 mutation may thus provide a predictor of early recurrence in oral SCC patients.
	518.	interaction of PI3K/Akt/mTOR and p53 pathways after their simultaneous blockade using the dual PI3K/mTOR inhibitor PI-103 and the Mdm2 inhibitor Nutlin-3.
	519.	p53 mutations are not always associated with malignant transformation in epithelioid angiomyolipoma.
	520.	p53 codon 72 SNP ws not associated with susceptibility to or age at onset of OSCC or OSF. p53 codon 72 SNP Arg/Arg polymorphism was associated with progression of OSCC, OS and DSF in irradiated patients.
	521.	An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
	522.	polymorphism at codon 72 modulates the risk of lung cancer in Brazilian patients with African ethnical background
	523.	The p53 codon 72 and 16-bp duplication polymorphisms were not associated with the increased risk of gastric cancer and did not seem to contribute to gastric cancer susceptibility among Koreans.
	524.	expression of p53 and Ki-67 antigen is helpful to predict tumor recurrence and prognosis in skull base chordomas.
	525.	TP53 inactivation may have a role in progression of chronic lymphocytic leukemia
	526.	Germline p53 mutation is associated with adrenocortical carcinoma and subsequent osteosarcoma
	527.	integrin beta4 is implicated in and associated with p53 in autophagy of lung cancer cells
	528.	Results investigate eight polymorphisms in the region encompassing exon 2 to 4 of TP53 and examine their association with cervical cancer risk.
	529.	Mdm2 regulates p53 levels also by targeting ribosomal protein L26 for polyubiquitylation and proteasomal degradation.
	530.	Myc as an important target for cooperative actions of p53 and Pten in the regulation of normal and malignant stem/progenitor cell differentiation, self-renewal and tumorigenic potential
	531.	Influence of prothymosin alpha and its mutants on activity of the p53 tumor suppressor
	532.	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
	533.	p53-independent events regulating expression of protein-coding genes and microRNAs within the network can define the cellular outcome of p53 activation.
	534.	TP53 mutation is associated with metastatic pulmonary adenocarcinomas.
	535.	CK1 has a role as the Ser20 site kinase for p53 in DNA virus-infected cells
	536.	Its loss of function is critical for the molecular pathogenesis of uterine papillary serous carcinoma.
	537.	senescence of primary NHP cells expressing progenitor cell markers CD44, alpha2beta1, p63, hTERT, and CK5/CK18, involves loss of telomerase expression, up-regulation of p16, and activation of p53.
	538.	A375 cells exposed to selenocystine showed an increase in levels of total p53 and phosphorylated p53
	539.	MAP1B light chain can interact with the tumor suppressor p53.
	540.	P53 has a role in malignancy and epithelioid differentiation in GISTs
	541.	these results imply a regulatory connection between the FA pathway and activation of TP53 for responding to DNA damage
	542.	This study provides evidence of a positive association between parameters reflective of angiogenesis, and p53 expression in HCCs
	543.	vascular endothelial growth factor, receptor KDR and p53 protein are expressed in transitional cell carcinoma of the bladder
	544.	IL-8 and p53 protein expression is regulated through inverse activation of the p38 MAPK and the JNK pathways and the NF-kappaB p65 expression
	545.	p53 over-expression predicted both transformation to diffuse large B-cell lymphoma and poorer overall and cause-specific survival of patients with follicular lymphoma.
	546.	Results describe the location and expression of human papillomavirus 18 E6 and p53 proteins.
	547.	sarcomatous transformation of diffuse-type tenosynovial giant cell tumors involves aberrations of cyclin A, P53, and chromosome arm 15q
	548.	analysis of the intramolecular interaction in FOXO3a and its binding with p53
	549.	Immunohistochemistry using antibodies to determine the protein expression of Fas, Fas-L, Bax, Bcl-2, p53 and c-Myc in skin of venous ulcer patients.
	550.	An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication.
	551.	Hsf1 is required for p53 nuclear importation and activation, which implies that heat shock factors play a role in the regulation of p53.
	552.	results demonstrate that in p53-deficient human gastric cancer cells, restoration of functional miR-34 inhibits cell growth and induces chemosensitization and apoptosis, indicating that miR-34 may restore p53 function
	553.	Alleles of three noncoding TP53 markers were associated with NTD risk.
	554.	Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers
	555.	Together these results identify ASPP2 as a bona fide DDA3 interacting protein, and suggest that the ASPP2/DDA3 interaction may inhibit ASPP2 in stimulating the apoptotic signaling of p53.
	556.	concomitant presence of somatic alteration in mtDNA and the DNA binding domain of the p53 gene facilitates cell survival and tumorigenesis
	557.	The protein structure prediction of CP2 family in order to elucidate the molecular mechanism of the CP2-directed regulation of gene expression.
	558.	Transcription from P2 is believed to be controlled by p53 and a single-nucleotide polymorphism (SNP309, T>G) in P2 is reported to be associated with increased risk for, and early development of, malignancies
	559.	These results suggest that p53 influences TLR3 expression and function and highlight a role of p53 in innate immune response in epithelial cells.
	560.	Data suggest that the R3IM motif of DSS1, in conjunction with the complexes of 19S RP and 20S core particle, regulates proteasome interaction through RPN3/S3 molecule, and utilizes a specific subset of poly-ubiquitinated p53 as a substrate.
	561.	sPDZD2 sensitized mutant p53-positive DU145 cells and wild-type p53-positive MCF-7 cells to apoptosis induction through genotoxic stress imposed by sub-lethal concentration of hydrogen peroxide
	562.	a TP53 mutation in follicular lymphoma may have a role in disease progression
	563.	Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.(
	564.	Damage of exon 5 of p53 gene by arsenic is associated with precarcinomas and carcinomas.
	565.	homozygous TP53 arginine genotype is not a potential risk factor for development of penile squamous cell carcinoma in subjects of African ethnicity.
	566.	Results suggest the involvement of the p53 codon 72 polymorphism in the skin tanning response and potential interaction with skin pigmentation on melanoma risk.
	567.	the deregulation of both the p53 and the p73 pathways plays an important role in inducing head and neck cancers
	568.	Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy.
	569.	Body mass index is not associated with a higher TP53 mutation frequency in bladder tumors
	570.	IGF-1R-dependent UVB-induced premature senescence required the phosphorylation of p53 serine 46.
	571.	Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)
	572.	Noncanonical DNA motifs as transactivation targets by wild type and mutant p53 are reported.
	573.	Patients with head and neck squamous cell carcinoma having a high portion of tumour cells expressing p53 had a shorter survival than the other groups
	574.	Monitoring for sequential change of serum p53-Abs before and after radiotherapy in patients with esophageal carcinoma is uuseful to evaluate the response to the treatment and prognosis of the patients.
	575.	ReportGene expression profiles modulated by the carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
	576.	L11 cooperates with L5, resulting in a robust inhibition of the E3 activity of MDM2, and a stabilization and activation of p53 approaching that achieved by p14(ARF).
	577.	PCAF regulates the balance between cell-cycle arrest and apoptosis in hypoxia by modulating the activity and protein stability of both p53 and HIF-1alpha.
	578.	the germinal center phenotype, P53 accumulation, and t(14;18) were independent factors for simian virus 40 association (P=0.029, 0.006, and 0.014, respectively) in diffuse large B-cell lymphomas
	579.	MGMT promoter methylation modulated by p53 status could partially promote p53 mutation occurrence in advanced lung tumors
	580.	TP53 Pro47Ser and Arg72Pro SNPs are not associated with risk and prognosis of human gliomas
	581.	Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations in colonic and pancreatic neoplasms
	582.	Ki-67- and p53-immunostained cells were mainly located in the suprabasal layers. p63-positive cells were found throughout the lining cystic epithelium.
	583.	p53 overexpression strongly downregulates the transcriptional efficiency driven by an H ferritin promoter construct containing only the NF-Y recognition sequence.
	584.	The role of p53, followed by Ki-67, as predictive factors
	585.	findings provide a molecular rationale for the role of human Spot 14 protein in the p53-dependent transcriptional activation of specific genes via diverse pathways in cells
	586.	There is a molecular association of the p53 codon 72 arginine allele with tumor aggressiveness and treatment resistance in advanced breast cancer.
	587.	These results indicate that the E1B protein fulfills an early function that correlates efficient entry into the late phase with the localization of E1B and p53 in the nucleus of Ad5-infected normal human cells.
	588.	p53 expression in liver tissue was higher in the hepatitis C virus-associated hepatocellular carcinoma (HCC) patients compared to normal controls & correlated well with the HCC grade; p53 is implicated in the poor prognosis of HCV-HCC
	589.	p53 mutations are present in a subset of pituitary carcinomas and are usually associated with a high percentage of tumor cells overexpressing the p53 protein.
	590.	MMR-dependent intrinsic apoptosis is p53-independent, but stimulated by hMLH1/c-Abl/p73alpha/GADD45alpha retrograde signaling
	591.	Several members of a Malaysian family had a duplication of a GGCGTG motif starting at nucleotide 17579 in exon 10, resulting in an in-frame insertion of two amino acids between residues 334 & 336 in the tetramerization domain of the p53 protein.
	592.	Results further strengthen the association between germline TP53 mutations and childhood choroid plexus carcinomas, even when occurring in the absence of familial tumour susceptibility.
	593.	p53 mutation was observed in 87% of esophageal squamous cell carcinoma, in 80% of esophageal dysplasia, in 0% of normal mucosa.
	594.	Transcription regulation assays with MCL-1 promoter deletion mutants showed that most of the p53 inhibitory effect was mediated by the -41 to +16 bp promoter binding sites only for TATA-binding protein and other basal transcription factors.
	595.	Andrographolide inhibits human colorectal cancer Lovo cell growth by G1-S phase arrest and inducing the expression of p53, p21 and p16.
	596.	TAF6delta has a pivotal node in a signaling pathway that controls gene expression programs and apoptosis in the absence of p53
	597.	data link EWS-FLI1 to the NOTCH and p53 pathways and provide a plausible basis both for NOTCH tumor suppressor effects and oncogenesis of cancers that retain wild-type p53
	598.	wild-type TP53 in CRC cells favours the progression of tumours expressing markers for hypoxia in their stroma, rather than in the epithelial compartment
	599.	p53 represses the PDGFRB promoter, facilitating the p53-induced apoptosis, whereas tumor cells with p53 mutation or a high level of DeltaNp73 or Myc could become refractory to the regulation.
	600.	Zac1 might be involved in regulating the p21(WAF1/Cip1) gene and protein expression through its protein-protein interaction with p53 and HDAC1 in HeLa cells.
	601.	These observations suggest that the relative cytoplasmic abundance of PTB protein, under DNA-damaging conditions, might contribute to regulating the coordinated expression of the p53 isoforms.
	602.	KAI-1 and p53 show inverse expression in uterine and endometrial carcinomas and sarcomas. The reduced KAI-1 expression may be the result of dysregulated p53 function and could be a step in endometrial carcinogenesis.
	603.	differences in cellular responses to stress between the TP53 codon 72 genotypes contribute to the differences in cancer incidence and longevity observed earlier for these genotypes
	604.	Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease are reported.
	605.	These results represent a definitive argument demonstrating that Li-Fraumeni syndrome results from TP53 haplodeficiency.
	606.	neither the Ins16bp or Arg72Pro polymorphisms of p53 considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
	607.	confirmed a high incidence of TP53 mutations in AML with a complex aberrant karyotype and demonstrated that TP53 mutations are very rare in AML without a complex aberrant karyotype
	608.	BAK oligomerization by p53 utilizes conserved residues of the p53 DNA binding domain
	609.	Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
	610.	observations confirm a new role for p53 as a uPA mRNA binding protein that down-regulates uPA mRNA stability and decreases cellular uPA expression
	611.	Prognosis of patients with p53-overexpressing ovarian cancer is affected by the MHC class I status of tumour cells and ovarian cancer patients can generate immune responses to the p53 tumour antigen.
	612.	the human glutathione S-transferase P1 gene is a novel transcriptional target of the p53 tumor suppressor gene
	613.	p53 status and efficacy of primary anthracycines/alkylating agent-based regimen according to breast cancer molecular classes are reported.
	614.	tumor cell incubation with pioglitazone results in increased levels of p53 and p27 and decreased levels of cyclin D1
	615.	structural analysis of the tumor suppressor p53 [review]
	616.	Data show that germ cell single base substitution mutation frequencies are very similar to somatic tissue TP53 mutation frequencies.
	617.	an interactive effect was detected such that MDM2 TT TP53 Arg/Arg double homozygotes, and individuals carrying both a MDM2 G allele and a TP53 Pro allele, were at increased risk of t-AML
	618.	These results indicate that acidic domain of MDM2 provides essential information for acetyltransferase p300 and deacetylase HDAC1 and is indispensable for MDM2 to negatively regulate the acetylation of p53.
	619.	results suggested that beta1,4GalT II might serve as a target gene of p53 transcription factor during adriamycin-induced HeLa cell apoptosis, which elucidated a new mechanism of p53-mediated cell apoptosis
	620.	MIF physically associates with p53 and negatively regulates p53 function.
	621.	identify OKL38 as a novel p53 target gene that is regulated by Peptidylarginine deiminase 4 and plays a role in apoptosis
	622.	Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis
	623.	mutations in different exons of p53 are related to different phenotypes
	624.	c-Abl and Cdk5 cooperatively regulate maximal activation of p53, resulting in neuronal death in response to oxidative stress by hydrogen peroxide.
	625.	crystallographic anlaysis of molecules that bind to p53 from a drug screening assay
	626.	PEDF induces human umbilical vein endothelial cells apoptosis through the sequential induction of PPARgamma and p53 overexpression.
	627.	Report p53 expression in abberant crypt foci and colorectal neoplasms.
	628.	p53 levels were significantly higher in lung parenchyma in subjects with emphysema
	629.	These results establish a link between the p53 tumor suppressor and RNA processing via hnRNPA2/B1 and RNA Helicase A.
	630.	a novel role for p53 as an mRNA-binding protein that regulates increased PAI-1 expression and stabilization of PAI-1 mRNA in human lung epithelial and carcinoma cells
	631.	investigation of the involvement of the CDKN2A, CDKN2B and p53 genes in actinic keratosis (AK) and in the progression of AK to squamous cell carcinoma
	632.	confirmed 27 TP53 mutations in 68 primary breast cancers analyzed by high-resolution melting curve scanning and direct sequencing. Using scanning and automatic calling, there was high specificity (>95%) across all DNA preparation methods
	633.	Pim-1 induces the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma
	634.	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.
	635.	ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo
	636.	Point mutation at exon 5 of the p53 gene was present in colonic and stomach neoplasms, they could be considered to be of the same origin originated from a common epithelial stem cells.
	637.	inflammatory levels of NO inhibit epithelial cell migration, because of suppression of ERK1/2 signaling, and activation of HIF-1alpha and p53, with potential consequences for epithelial repair and remodeling during airway inflammation
	638.	Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.
	639.	the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3beta (GSK3beta), which was inactivated by protein kinase C (PKC).
	640.	analysis of 31 bilateral breast cancer (biBC) pairs (12 synchronous & 19 metachronous cases); TP53 sequence alterations were detected in 7 patients; 2 had mutations in both neoplasms & in 5 biBC pairs the TP53 gene was affected in only 1 of the tumors
	641.	a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.
	642.	study examined the presence of mutations in TP53 at codon 249 (Ser-249, considered as a hallmark of mutagenesis by aflatoxin) and in CTNNB1 in circulating free DNA of patients with hepatocellular carcinoma or chronic liver disease from Alexandria, Egypt
	643.	Extra-nuclear p53-dependent apoptosis may constitute a fail-safe mechanism against dominant inhibition.
	644.	The existence of a functional binding site for the tumor suppressor p53 near the proximal CCAAT box and the fact that the basal expression of annexin A1 in human colon adenocarcinoma cells is driven by p53 at the transcriptional level, is shown.
	645.	analysis of solar light-induced p53 mutagenesis in SKH-1 mouse skin
	646.	Hibiscus syriacus extract exhibits a cytotoxic effect on lung cancer cells by activation p53 and AIF.
	647.	No significant difference in the distribution of p53 codon 72 genotypes was observed between endometriosis patients and controls.
	648.	AEN is an important downstream mediator of p53 in apoptosis induction in cancer.
	649.	Results could not indicate significance of P53 mutations for evaluation of residual clone malignancy.
	650.	polymorphisms and haplotypes in the TP53 gene, including Arg72Pro, were not significantly associated with lung cancer in a Korean population
	651.	These results suggest a role of PAD4 in the regulation of p53 target gene expression.
	652.	Study shows that mitochondrial p53 is highly efficient in inducing the release of soluble and insoluble apoptogenic factors by severely disrupting outer and inner mitochondrial membrane integrity.
	653.	stabilization of p53 mRNA in hepatocellular carcinoma cells is involved in TIP30 control of cellular oxidative stress and apoptosis induction
	654.	TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors are reported.
	655.	5-Aza-2'-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis.
	656.	The association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.
	657.	p53 regulated transcripts including Puma/BBC in tetraploid but not diploid tumor cells is modulated by Chk1 inhibition
	658.	review of kinase-independent interaction of FAK with p53with focus on FAK and p53 signaling, which link signal transduction pathways
	659.	Study of conformational mutant p53 as a new putative marker to discriminate Alzheimer disease(AD) from non-AD patients.
	660.	No association was detected between the TGFB1, IL10, TP53, and HMOX1 genes and DGF. The G allele of the TNF polymorphism rs3093662 was associated with DGF in an adjusted analysis.
	661.	Impaired p53 function in tumour stroma might be related to genomic instability and could enable stromal cell survival in the destabilising tumour microenvironment.
	662.	A feedforward loop involving c-Myc and eIF4F that serves to link transcription and translation and that could contribute to the effects of c-Myc on cell proliferation and neoplastic growth.
	663.	ATM is a key mediator of the MT-hTer-47A dysfunctional telomere response, even in cells lacking wild-type p53.
	664.	Nuclear TP53 accumulation may be relevant in patient's prognosis in neuroblastic tumors.
	665.	Expression of p53, in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix
	666.	ATM or TP53 deletion is associated with high expression level of CD38 and TP53 deletion as a possible prognostic factor in Chinese patients with chronic lymphocytic leukemia
	667.	conclude that the effect of p53 codon 72 genotype on breast cancer survival is dependent on p53 gene status, the P/P variant is strongly associated with poor prognosis among patients with a wild-type p53 tumor
	668.	Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.
	669.	acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter
	670.	nuclear extracts immunodepleted of p53 or nuclear extracts of p53-null cells were unable to excise UVC-induced DNA adducts, and introduction of p53 by transfection restored the excision activity
	671.	This study provides the first evidence that p53 is involved in the regulation of EBV lytic cycle initiation.
	672.	A significant association was found in Dukes' B stage colorectal cancer patients between the GSTM1 and p53 gene variants and survival.
	673.	Notch-1 upregulates EGFR expression and also demonstrate Notch-1 regulation of p53 in gliomas.
	674.	p53 single-nucleotide polymorphism is associated with the early development of hepatocellular carcinoma in Korean patients with chronic HBV infection.
	675.	A possible correlation between overexpression of p53, proliferating cell nuclear antigen (PCNA), and c-erbB-2, and the clinicopathologic features of laryngeal squamous cell carcinoma, was investigated.
	676.	A novel isochroman derivative inhibited apoptosis in vascular endothelial cells through depressing the levels of integrin beta4 and TP53.
	677.	K-ras and p53 genes are altered in Tamoxifen-associated endometrial carcinoma
	678.	In the absence of p53 function, the resulting derepressed CD44 expression is essential for the growth and tumor-initiating ability of highly tumorigenic mammary epithelial cells.
	679.	Oral verrucous carcinoma tumorigenesis may involve the inactivation of p53, which is associated with HPV infection.
	680.	was no difference in the expression of EGFR, p185(erbB-2) or Bcl-2, or in nuclear accumulation of p53 in these IDC from pre- vs. post-menopausal women.
	681.	Data identified TAF3 as an evolutionarily conserved negative regulator of p53 transcription activation function.
	682.	data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors.
	683.	All of the E6 genes from different HPV types displayed similar abilities to mediate the degradation of both p53 and MAGI-3
	684.	p53 has a role in preventing centrosome amplification, ERalpha phenotypic heterogeneity and metastasis in breast cancer
	685.	Neither germline variants in p53 nor MDM2 SNP309 play an underlying role in the development of very early onset CRC
	686.	PKC epsilon mediates TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression and downregulation of Bid in breast cancer cells
	687.	Inhibition of methylation in hnRNP K attenuated the recruitment of p53 to p21 promoter, and reduced p53 transcriptional activity.
	688.	the p53 gene does not appear to play a major role in pheochromocytoma tumorigenesis.
	689.	p53 of stromal fibroblasts affects the response of a tumour against chemotherapy by inducting senescence in the fibroblasts which results in the production of growth factors acting onto the cancer cells by paracrine mechanisms.
	690.	These results suggest that a p53-dependent cell cycle checkpoint monitors changes of cellular NS levels via the impediment of MDM2 function.
	691.	Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context.
	692.	DNA damage combined with hypoxia modulated both the intensity of the p53 response and the composition of downstream target genes.
	693.	frequency of TP53 mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than reported. We found that TP53 is not directly involved in development of drug resistance in high-grade ovarian serous carcinomas.
	694.	High zinc status in normal bronchial epithelial cells upregulates p53 expression which in turn elevates p21, inducing G2/M blockage.
	695.	Intrinsic radiosensitivity of 39 human tumor cell lines segregate into distinct genotype-dependent radiosensitivity groups that associate with mutATM, wtTP53, mutTP53, and an unidentified factor in some glioblastoma cells.
	696.	the functional role of the intrinsic activation of p53 during Mk differentiation is to control polyploidization and the transition to endomitosis by impeding cell cycling and promoting apoptosis.
	697.	disruption of the spindle-assembly checkpoint does not directly influence p53 activation, but the shortening of the mitotic arrest allows cyclin E-CDK2 to be activated before the accumulation of p21(CIP1/WAF1).
	698.	Thus, elevated levels of CCN3 protein regulated by p53 might influence cell adhesion.
	699.	Downregulation of caspase 2 levels by p53 may help to determine cell fate by preventing cell death when unnecessary.
	700.	Results correlate P53 status and mutation site/type with nuclear protein accumulation, clinicopathologic variables and data on K-ras mutations and high-level microsatellite instability.
	701.	TP53 may have a direct, allele specific, role in 5-FU mediated response.
	702.	Genetically programmed cell death is related to the p27, cathepsin and survivin pathways in Fuchs' dystrophy and to the p21 and p27 pathways in pseudophakic bullous keratopathy.
	703.	p53 promotes theaflavin-induced apoptosis in a transcription-dependent manner through mitochondrial death cascade.
	704.	autophagy is regulated by cytoplasmic p53
	705.	p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation
	706.	Data show that the elimination of the salt bridge and the inversion of the flexibility of L1 and L3 are directly or indirectly responsible for deactivating the tumor suppressor p53.
	707.	functional interaction of NEDL1 with p53 might contribute to the induction of apoptosis in cancerous cells bearing wild-type p53.
	708.	following DNA damage, PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, thereby protecting p53 from inhibition by Mdm2, leading to p53 activation.
	709.	The demonstration that p53 binds directly to the PIK3CA promoter and inhibits its activity identifies a novel mechanism whereby these two mediators regulate cellular functions.
	710.	These findings indicate that p53 is a transcriptional regulator of DUSP1 in stress responses.
	711.	Results suggest that genetic analysis of TP53 can select patients at high risk of bladder tumour progression that should be followed closely and may benefit from early radical surgical procedures.
	712.	data suggest that UVB-induced, stress-induced premature senescence in skin fibroblasts plays an important role in p53-related apoptosis resistance and tumor suppression activity
	713.	Results suggest that the parthenolide-induced apoptosis of A549 cells is due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling.
	714.	New triterpenoid from Panax ginseng exhibits cytotoxicity through p53 and the caspase signaling pathway in the HepG2 cell line.
	715.	stabilization of MDMX by Akt may be an alternative mechanism by which Akt up-regulates MDM2 protein levels and exerts its oncogenic effects on p53 in tumor cells
	716.	TP53 is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or ovarian cancer families of French Canadian descent
	717.	The Pro allele in the codon 72 of TP53 was observed in 5/9 glioma tumors.
	718.	TERT association with TP53 mutations indicates that TERT activity is downregulated by functional p53 protein in breast tumors.
	719.	TP53 Arg72Pro polymorphism, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma
	720.	Increased TP53 expression was associated with invasive adenocarcinoma of the prostate
	721.	Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
	722.	Induced the transition from cardiac hypertrophy to heart failure through the suppression of hypoxia inducible factor-1(HIF-1), which regulates angiogenesis in the hypertrophied heart and promotes apoptosis.
	723.	Overexpression of p53 is associated with several different clinicopathological features of ovarian carcinoma including parameters of stage, tumor grade and prognosis.
	724.	A signaling cascade for the regulation of p53 in response to ionizing radiation was proposed that involves activation of DNA-PK and Akt/PKB and inactivation of GSK-3 and Mdm2.
	725.	HIPK2 has a critical role in maintaining the transactivation activity of wtp53; low expression of HIPK2 may impair the p53 function in tumors harboring wtp53
	726.	although p53 mutation is relatively rare, the type and distribution of mutations in low-grade B-cell malignancy patients does not differ significantly from other forms of cancer
	727.	results support the notion that acetaldehyde plays a role in TP53 mutations in esophageal cancers
	728.	p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma.
	729.	p53Arg homozygosity is associated with the development of sporadic colorectal adenocarcinoma, in the Greek-Caucasian population studied
	730.	Data suggest that p53 pulses result from repeated initiation by ATM, which is reactivated by persistent DNA damage.
	731.	study investigated the correlation of p53 abnormalities in 15 patients with pulmonary large cell carcinomas; 5/15 expressed p53 and none had mutant p53 sequences; there was a negative survival correlation with positive p53 immunostaining (P = 0.05)
	732.	Tacrolimus ointment neither blocks ultraviolet B nor affects expression of thymine dimers and p53 in human skin.
	733.	p53/47 controls the folding, the oligomerisation and the post-translational modification of p53 complexes and that it diversifies p53 properties in a cell stress-dependent fashion.
	734.	CSN5 is a pivotal regulator for both p53 and MDM2
	735.	the ability to promote Lys(63)-mediated polyubiquitination of COMMD1 is a novel property of ARF independent of p53
	736.	Compared to PAI-1 protein levels, Chalkley counts and MIB-1, HER2+ and mutations of TP53 were the strongest independent markers of poor prognosis irrespective of nodal statusin breast cancer.
	737.	p53 was not associated with survival after radiotherapy in high-risk breast cancer, but BCL2 might be.
	738.	The clinical outcome for breast cancer patients is significantly different for different TP53 mutation types.
	739.	B7-H4 was expressed more often in pancreatic ductal carcinoma than was p53.
	740.	the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (proliferative, secretory, and atrophic, and endometrial glandular and stromal breakdown[beta-catenin]
	741.	the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (proliferative, secretory, and atrophic, and endometrial glandular and stromal breakdown
	742.	results support Killin as a missing link between p53 activation and S phase checkpoint control designed to eliminate replicating precancerous cells, should they escape G(1) blockade mediated by p21.
	743.	Lentiviral delivery of small hairpin RNA targeting Tthymidylate kinase in combination with a low dose of doxorubicin as a new approach to kill colon cancer cells regardless of p53 status.
	744.	p53-mediated mir34a, mir34b, and mir34c up-regulation and ING2 down-regulation may be involved in the senescence pathway.
	745.	Study identifies p53 acetylation as an indispensable event that destabilizes the p53-Mdm2 interaction and enables the p53-mediated stress response.
	746.	determined the average ensemble structure of the intrinsically disordered N-terminal transactivation domain in both the full-length tetrameric p53 protein and in its complex with a specific DNA response element
	747.	Conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas.
	748.	The results presented in this report emphasized flow cytometry as an important tool for the fast evaluation of p53 protein expression levels as bioindicator of individual exposure to acute ionizing radiation.
	749.	Describe a novel p53 rescue compound that induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
	750.	MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.
	751.	TP53 Pro47Ser and Arg72Pro SNPs are not involved either in susceptibility to developing gliomas or in patient survival
	752.	Combined increased p53 and reduced membranous beta-catenin protein expression indicated a very poor prognosis in patients with esophageal squamous cell carcinoma.
	753.	TGF-beta(1) production in carcinoma cells was associated with doxorubicine-mediated p53 expression in MCF-7 cells or high basal level of p53 in T47D cells.
	754.	DLBCL in pre-menopausal women of central European Caucasian ethnicity was not associated with SNP309 G. Neither SNP309 nor SNP72 seem to be correlated with age of onset, diagnosis, or survival of diffuse large B-cell non-Hodgin lymphoma patients.
	755.	Abrogation of G2 checkpoint by Geldanamycin may play a central role in sensitizing p53-negative tumor cells to DNA-damaging and decatenation-inhibiting agents.
	756.	mutated over wild-type P53 mRNA exists in glioblastoma cells with heterozygous mutations of this gene.
	757.	p53 family may play a role in the epithelial cell response to H pylori infection.
	758.	Tubal p53 signature merits serious consideration as an important early event in serous carcinogenesis in BRCA+ women.
	759.	in epithelial cells, some of the functions of p53 leading to cell-cycle arrest and apoptosis are restrained by HHV-6B infection, whereas other cellular defences, causing inhibition of virus transcription, are partially retained.
	760.	P53 mutations are associated with higher levels of Intratumoral T cells.
	761.	Flotillin 2 is a direct transcriptional target of the p53 family member genes in human cancer cells.
	762.	These results suggested that Annexin A2 may play roles in p53 induced apoptosis and it is also involved in regulation of cell proliferation.
	763.	UNC5H4 amplifies p53-dependent apoptotic response.
	764.	Microsatellite alterations, and p53 tumor mutations are associated with non-small cell lung cancer patients
	765.	The data show that immunostaining for p53 and HbF as well as karyotype analysis are useful for the differential diagnosis of myelodysplastic syndrome and aplastic anemia.
	766.	data indicate that in early and advanced gastric tumors, p53 and bcl-2 protein accumulation is more intense in gastric mucosa adjacent to advanced tumors and p53 immunoreactivity peaks in advanced carcinomas
	767.	an important role for the DNA damage response mediated by ATR-Chk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.
	768.	The DNA binding domains of p73 exhibited enhanced thermodynamic stability relative to the p53 DBD, and the p73 surface is less complementary for DNA binding, which may account for the differences in affinity and specificity for p53 REs.
	769.	CARF exerts a vital control on the p53-HDM2-p21WAF1 pathway that is frequently altered in cancer cells.
	770.	lymphocytes showed repeatedly an extensive proportion of TP53 mutated cells, harboring various TP53 mutations, mostly single-point, in individual cells. The mutation targeting exhibited characteristic traits of the somatic hypermutation process
	771.	cigarette smoking may influence breast cancer risk through interaction with p53.
	772.	Superior outcome of t(8;21) acute myeloid leukemia patients is partly due to an activated p53 pathway, and that loss of the p53 response pathway is associated with disease progression.
	773.	Can physically interact with the transcription elongation complex and influence transcription elongation.
	774.	In the group of patients < or =53 yrs and with TP53(-) tumors platinum-based therapy is possibly equally efficient.
	775.	that the recruitment of YB1, PURalpha, and H1.2 to the p53 target gene Bax is required for repression of p53-induced transcription.
	776.	The p53 target sequences possessing the inverted repeat symmetry were shown to form a cruciform structure in sufficiently negative supercoiled DNA.
	777.	Investigation of the mechanism underlying p53 reactivation in hepatitis B virus X-protein-expressing cells.
	778.	The p53 Pro72 homozygous non-small cell lung cancer patients often presented high-grade tumours and had significantly poorer survival rates than patients with R72 homozygotes or heterozygotes.
	779.	p53beta and Delta40p53 are expressed in melanoma and this may have important implications for understanding resistance of melanoma to DNA-damaging chemotherapy.
	780.	p53 and p16(INK4A) are promising candidates for the pulmonary molecular screening of heavy smokers healthy individuals.
	781.	Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis.
	782.	p53 is activated by stimulation of mismatch repair in response to the misincorporation of deoxynucleotides into newly synthesized DNA, long before the lack of pyrimidine nucleoside triphosphates causes the rate of DNA synthesis to slow appreciably.
	783.	p53 and p73 repress a number of growth-related genes and that in many instances this repression may be through the induction of p21.
	784.	Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma
	785.	Histone deacetylase inhibitors may overcome neuroblastoma drug resistance by restoring p53 tumour-repressor function via its hyper-acetylation and nuclear migration.
	786.	p53 positivity was significantly associated with higher risk of disease-specific and recurrence-free mortality in HPV-HR head and neck neoplasms.
	787.	the role of triptolide as a sensitizer to TRAIL-induced apoptosis in part by independent modulation of XIAP expression and p53 signaling.
	788.	E6-AP not only enhances the degradation of p53 but also regulates the neuronal cell growth.
	789.	Identification of anomalous, detectable conformational state of p53 from sporadic Alzheimer's disease (AD) patients allows differentiation of fibroblasts from those of age-matched non-AD subjects and suggests a role for conformationally altered p53 in AD.
	790.	patients with chronic lymphocytic leukemia (CLL) we have identified a novel p53 splicing variant, lacking the whole coding sequence of exon 6.
	791.	Aberrations could be considered markers responsible for the development of odontogenic lesions.
	792.	Results describe the interrelationship between H pylori and Epstein-Barr virus infection in gastric carcinogenesis, focusing on p53 mutation and c-Myc, Bcl-2 and Bax expression.
	793.	The distinction between various populations may be because of differences in racial composition and/or exposure to distinct environmental factors that have a different impact on systemic lupus erythematosus incidence along with the Argp53Pro genotype.
	794.	Overexpression of p53 was associated with poor survival in gallbladder carcinomas.
	795.	Stimulation of KLF6 expression by IGF-I in a p53-dependent manner may constitute a novel mechanism of action of IGF-I, with implications in normal cell cycle progression and cancer biology.
	796.	A novel cis-element in the 5' coding region of p53 mRNA and its interaction with heterogeneous nuclear ribonucleoprotein (hnRNP)C1/C2, is described.
	797.	Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
	798.	quercetin stabilized p53 at both the mRNA and protein levels to reactivate p53-dependent cell cycle arrest and apoptosis in HepG2 cells
	799.	p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 are expressed in human corneal endothelial cells despite donor ages.
	800.	p53 expression and certain apoptosis markers correlate with survival in thymic neuroendocrine tumors.
	801.	The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts
	802.	p53 mutations and microsatellite instability differ in patients with gallbladder carcinoma between two distinct high-incidence areas
	803.	significantly higher levels of HCV RNA replication and viral protein expression in Huh7 cells when their p53 expressions were knocked down; p53 found to directly interact with IRF9
	804.	Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription.
	805.	Upregulation of MDR1 by DeltaNp73alpha is mediated by interaction with p53 at the MDR1 promoter.
	806.	in endometrial carcinoma p53 overexpression was directly associated with unfavorable clinicopathologic factors: advanced stage, histologic subtype, advanced patient age and nodal metastasis
	807.	P53 expression in H1299 cells reduced the sub-G1 fraction. p53 enhanced the repair of UV-induced DNA damage. Human p53, unlike CHO-K1 p53, may play active roles in both UV-induced apoptosis & repair.
	808.	p53 codon 72 variant genotypes modify the risk of human papiloma virus 16-associated SCCOP and may be markers of genetic susceptibility to HPV16-associated squamous cell carcinoma of the mouth and pharynx.
	809.	Both germ line and somatic alterations of the TP53 pathway influence incidence and survival of ovarian carcinoma.
	810.	Required for the elimination of cells with aberrant CD43 expression.
	811.	The specific binding of the C-terminal acidic domain (AC-D) of the human TFIIEalpha subunit to the pleckstrin homology domain (PH-D) of the human TFIIH p62 subunit is demonstrated.
	812.	There is no any association of polymorphous marker C(-594)CC of TP53 gene with DPN in Russian patients with type 1 diabetes mellitus living in Moscow.
	813.	optimal binding of STAGA to p53 involves interactions of STAGA subunits TAF9, GCN5, and ADA2b, respectively
	814.	CARPs together with MDM2 enhance p53 degradation, thereby inhibiting p53-mediated cell death.
	815.	p53 mutation spectra and differences with histology in lung cancers.
	816.	The proper combination of IFNalpha and conventional chemotherapeutic agents may be a rational strategy for the treatment of human osteosarcoma with functional p53.
	817.	Together our results show that hDDA3 is a p53- and DNA-damage down-regulated target that exhibits oncogenic characteristics.
	818.	Smo mutants augment p53 binding to the E3 ubiquitin-protein ligase Mdm2 and promote p53 ubiquitination.
	819.	the Hes6-CBP complex in PML-NB may influence the proliferation of cells via p53-dependent and -independent pathways.
	820.	identified the binding site of the p53 and FAK interaction and demonstrated that mutating this site and targeting the site with peptides affects p53 functioning and viability in the cells.
	821.	This review emphasizes various mechanisms activated by p53 signalling that can confer protection to cells with damaged DNA in the context of p53's pro-apoptotic and pro-survival activities.
	822.	Patients with pathologically N0 disease and p53 gene mutation must be carefully monitored for local recurrence or distant metastasis.
	823.	enhanced phosphorylation of p38 and p53 (ser15) in ZS cells was normalized after suppression of Gadd45 by siRNA
	824.	PUMA exerts a negative feedback on p53 and p21, leading to p21-dependent growth suppressive and survival changes.
	825.	These findings indicate that R337H may be a low penetrance mutant which predisposes to multiple cancers
	826.	[Review] Besides its ability to promote apoptosis through transcription dependent mechanisms, p53 may also be able to activate apoptosis independent of transcriptional regulation.
	827.	cytosolic p53 may participate in the regulation of clathrin-mediated endocytosis to control the correct signaling from EGFR
	828.	Deletion of the 9p21 locus inhibits p53 protein; studies of the ARF-MDM2-P53 pathway link survival and chemoresistance in patients with abnormalities in 17p and 9p
	829.	PTEN acquires unexpected properties by enhancing gain-of-function mutant p53 (mut-p53) protein levels. PTEN restoration to cells harboring mut-p53 leads to induction of G(1)-S cell cycle progression and cell proliferation and to inhibition of cell death.
	830.	Data suggest that p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
	831.	Results suggest that the roles of p53 and nucleotide excision repair in the recovery from UV-induced replication are separable and DDB2-independent.
	832.	Results show that p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.
	833.	ERK and JNK MAPK/Elk-1/Egr-1 signal cascade is required for p53-independent transcriptional activation of p21(Waf1/Cip1) in response to curcumin in U-87MG human glioblastoma cells
	834.	Therefore, our results suggest that the interaction between Sirt2 and 14-3-3 beta/gamma is a novel mechanism for the negative regulation of p53 beside the well-characterized Mdm2-mediated repression.
	835.	The prevalence of MDM2 gene amplifications and single nucleotide polymorphism 309 in 284 colorectal tumors in relation to TP53 mutational status and genomic instability, is analyzed.
	836.	The morphology and cell cycle proteins immunoexpression of the novel probable preinvasive lesion - bronchiolar columnar cell dysplasia (BCCD), is decribed.
	837.	These findings suggest that inhibition of the class I PI3K signaling pathway is a potential strategy for managing gastric cancers.
	838.	A correlation of p53 expression with AI and PI was found in pilocytic astrocytoma but not in glioblastoma.
	839.	High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma
	840.	Suggest beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer.
	841.	the potential use of R-Roscovitine as a bitargeted anticancer drug that functions by simultaneously causing p53 activation and NF-kappaB suppression.
	842.	DEC1 is induced by the p53 family and DNA damage in a p53-dependent manner. p53 family proteins bind to, and activate, the promoter of the DEC1 gene.
	843.	the functions of p53 play substantial roles in many other pathologies as well as in the aging process [review]
	844.	p53-mediated apoptosis occurs by a PIDD- and caspase 2-dependent mechanism, and p53's full transcriptional regulatory functions may be required only for events that are downstream of cytochrome c release
	845.	results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors
	846.	p53 mutations at CpG dinucleotides provide further evidence for a molecular link between chronic inflammation and esophageal malignancy.
	847.	p53 codon-249 mutations are associated with X-ray repair cross complementing protein 1 polymorphism Arg399Gln among the Guangxi population of China.
	848.	among p53 Arg/Arg carriers, HPV infection, smoking, and drinking might further increase the risk of esophageal squamous cell carcinoma development
	849.	These data suggest a more complex role for TRIM22 during T lymphocyte activation than merely as an antiproliferative factor.
	850.	mutant p53 loses its ability to suppress DNMT1 expression, and thus enhances methylation levels of the p16 ( ink4A ) promoter and subsequently down-regulates p16(ink4A )protein.
	851.	compromise of either p53 or Rb pathways during melanocyte transformation leads to up-regulation of survivin expression in melanoma
	852.	p53 homolog, p63, may participate in governing global repair instead of p53 in keratinocytes
	853.	circulating anti-p53 antibodies (anti-p53Ab) in sera of cancer patients may have a role in disease progression
	854.	the presence of both HPV infection and TP53 mutations may define a particular group of tumors with a more aggressive phenotype in advanced oral squamous cell carcinoma
	855.	Changes in p53 expression seen in urothelial and sinonasal inverted papillomas suggest they may share common evolution.
	856.	p53 is required for the efficient removal of cross links in human cells; cytotoxic cross links persist in p53-deficient cells.
	857.	p53 function is not sufficient to suppress glucose uptake in cells and tumors that could theoretically support aerobic glycolysis.
	858.	The proliferative activity and p53 overexpression increased with the dedifferentiation of tranitional cell bladder carcinoma.
	859.	although HPV16 (human papiloma virus 16) and mutated p53 may coexist in a subset of squamous cell carcinomas of the head and neck, HPV16 and disruptive p53 mutations seem to be nonoverlapping events
	860.	SS18-SSX1 can negatively regulate p53 tumor-suppressive function by increasing the stability of its negative regulator HDM2.
	861.	These results indicate that in thyroid cancer cells, TAp73alpha is able to increase p53 protein level and function by interfering with Mdm2-mediated p53 degradation.
	862.	ability of p53 to down-modulate osteoprotegerin production by endothelial cells may be an additional important mechanism
	863.	homeodomain interacting protein kinase 4 phosphorylates p53 at serine 9 is important for p53 mediated transcriptional repression.
	864.	p63 exhibits several transcriptional and stress-response properties similar to those of p53
	865.	germ line and somatic alterations of the p53 pathway influence the incidence and survival of ovarian carcinoma
	866.	in a Portuguese population, the p53 R72P polymorphism is not associated with an increased susceptibility to squamous intraepithelial lesions or cervical cancer development
	867.	that Skp2 controls p300-p53 signaling pathways in cancer cells, making Skp2 a potential molecular target for cancer therapy.
	868.	defects in the p53 regulatory cascade do not appear operational in this leukemia
	869.	P53 immunohistochemical profile may be useful in detecting colorectal adenomas with a malignant potential.
	870.	During fludarabine treatment of Raji and MEC1 cells, proteolytic derivatives of p53 with MW of ~47 and ~40 kDa appeared. There were 8 phosphorylated forms. These could play crucial roles in apoptosis induction.
	871.	These findings suggest novel Cdk1/cyclin A phosphorylation sites, which appear to be associated with p53-independent cell death following etoposide treatment.
	872.	Study shows that p53 over expression in Crohn's Disease is associated with dysplasia that may progress to a higher grade of neoplasia over time.
	873.	p53 mutation was exhibited in pulmonary sclerosing haemangioma. The mutation rate in polygonal cells was higher than that in surface cuboidal cells
	874.	p53 is of limited value only, being largely overshadowed by the prognostic capability of FIGO stage and extent of residual disease.
	875.	A high proportion of familial microsatellite instability cases and a lower incidence of TP53 mutations were found in Saudi colorectal carcinoma.
	876.	The increase of cell membranous phosphatidylcholines containing unsaturated fatty acid residues induces phosphorylation of p53 through activation of ATR.
	877.	p53 codon 72 and intron 3 polymorphisms are associated with non-small cell lung cancer
	878.	These studies suggest that PARC-interacting peptides are promising candidates for the enhancement of p53-dependent apoptosis in tumors with wt cytoplasmic p53.
	879.	Our results indicate that nicotinamide treatment attenuates p21WAF1 expression through Sp1 downregulation, and suggest a possible involvement of nicotinamide metabolism in cellular gene expression.
	880.	a network involving signal coactivation of NF-kappaB and STAT3, differentially modified by p53 inactivation or mutation, promotes altered BAX/BCL-XL expression and cell survival in HNSCC.
	881.	Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens.
	882.	The data support that the frequencies and patterns of somatic mutation of the p53 genes in colorectal cancer are variable among populations.
	883.	P53 mediated regulation of metallothionein transcription in breast cancer cells is reported.
	884.	P53 Arg72Pro and MDM2 T309G polymorphisms contribute to the risk of developing stomach cancer.
	885.	Current study showed p53 was associated with induction of apoptosis and cell proliferation in early stage gastric cancers, but not in the subserosa of advanced gastric cancer.
	886.	An animo acid substituition is a risk factor for breast cancer.
	887.	Risk for head and neck squamous cell carcinoma may be assocated with single-nucleotide polymorphism in the promoter region.
	888.	Isoleucine 31-type p53 may be partly involved in familial gastric cancer because of its low transcriptional activity and low cell proliferation suppressing activity.
	889.	Some mutant forms can be reactivated by amifostine, mostly in the DNA-binding domain.
	890.	TP53 mutations reduce the prostate cancer (PCa)-free survival time in patients with needle biopsy of the prostate and primary benign diagnosis; Exon 6 mutations enhance the risk of being affected by PCa 32-fold
	891.	a combined expression of survivin and p53 was associated with an increased risk of tumor local progression.
	892.	Observational study and meta-analysis of gene-disease association. (HuGE Navigator)
	893.	Observational study of gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	894.	Observational study of genotype prevalence, gene-disease association, and gene-environment interaction. (HuGE Navigator)
	895.	Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)
	896.	Observational study of genetic testing. (HuGE Navigator)
	897.	Observational study of gene-environment interaction. (HuGE Navigator)
	898.	Observational study of genotype prevalence and gene-environment interaction. (HuGE Navigator)
	899.	Observational study of genotype prevalence and genetic testing. (HuGE Navigator)
	900.	Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	901.	Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	902.	Meta-analysis of gene-disease association. (HuGE Navigator)
	903.	Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	904.	Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	905.	Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
	906.	Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)
	907.	Observational study of genotype prevalence. (HuGE Navigator)
	908.	Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)
	909.	Observational study of gene-disease association. (HuGE Navigator)
	910.	Expression of p53 expression was weak or not detected in dental follicles with reduced and stratified squamous epithelium
	911.	p53 activity is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes
	912.	HHV-6B induces p53 Ser392 phosphorylation by an atypical pathway independent of casein kinase 2 protein and p38 kinases.
	913.	Examine interaction between TP53 and the C-terminal fragment of p53 (M protein).
	914.	Findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer. Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph node metastases.
	915.	These data provide evidence that there is a novel signaling pathway from Dishevelled to p53.
	916.	In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
	917.	Genetic alterations of the p53 tumor suppressor gene were seen in a mixed serous carcinoma of the endometrium.
	918.	initially p53-negative tumors and initially p63-positive tumors that retain this labeling pattern may follow less aggressive biological courses and present better prognoses
	919.	Pathways of signaling by S100A4, by its interaction with and sequestration of p53, and by Notch also seem differentially operational in the induction of apoptosis
	920.	Renal cell carcinoma frequently has p53 mutations, so therapy restoring p53 may markedly improve the response rate of immunochemical therapy combining IFN-alpha and 5-FU.
	921.	Data show that knockdown of either p53,but not p16(INK4a) or Rb, allows cells to bypass premature senescence that is induced by BS69 knockdown.
	922.	accumulation of VRK1 in tumours with mutant p53 could result in stimulation of other signalling pathways
	923.	TP53 DNA-binding mutations were the most significant predictor of poor OS; TRAILreceptor-2 (DR5) was the most differentially underexpressed gene in the TP53 mutated cases
	924.	Alterations in the expression of p53, survivn, and bcl-2 take place in a concerted fashion, implying that many of these cases may share common abnormalities.
	925.	In etoposide-treated LNCaP cells, p53 bound the AR promoter, which contains a potential p53 DNA-binding consensus sequence. loss of p53 function in prostate cancer cells contributes to increased expression of AR.
	926.	There is heterogeneity in the requirement for transactivation subdomains 1 and 2 of p53 without any subdomain-specific contribution to p53-induced gene expression.
	927.	Maspin expression is inversely correlated with mutant p53 expression in gastric cancer, which suggests that maspin expression is regulated by the p53 pathway.
	928.	this study failed to demonstrate correlation between maspin loss and p53 expression in malignant melanoma using both individual slides and tissue microarray of carcinomas.
	929.	Compar. proteome anal.to RNA expr. array showed modest correl. of RNA and protein level = relevance of post-trans. regul. in lymphomagenesis. Data bank search identified 13 out of 17 referenced proteins (76%) as members of a TP53-dependent network.
	930.	The expression of iNOS induces oxidative stress in nasopharyngeal carcinoma. p53 mutation was associated with iNOS overexpression. This suggests that the p53 gene is not the direct target of DNA damage by 8-OHdG accumulation.
	931.	A new G-to-A transition at position +1 at the invariant G at the exon 8 donor splice site leads to numerous aberrant splicing-products.
	932.	study showed higher frequency of p53 mutations in esophageal adenocarcinoma (EAC)than previously reported, but only as a late event in carcinogenesis; 72R allelic polymorphism was of potential significance in the development of Barrett esophagus &/or EAC
	933.	Immunohistochemistry localized elevated p53 to a mainly nuclear distribution in neurons and glia in sections from temporal lobe epilepsy hippocampus
	934.	R248W may predispose to composite tumors and to neuroblastoma in individuals with Li-Fraumeni syndrome.
	935.	The results indicate protective associations of p53 Arg72Pro heterozygous variant with postmenopausal and MDM-2 SNP309G along with p53 Arg72Pro heterozygous variant with premenopausal breast cancer risk.
	936.	results of the present study have indicated that p53 mutations occur at the ileovesical anastomosis in patients who have undergone clam ileocystoplasty
	937.	An important role for autophagy in tumor suppression via full-length ARF in both p53-dependent and p53-independent manners, depending on cellular context.
	938.	There is no association between radon exposure and p53 expression, indicating that maybe the effect of radon is not mediated through p53 alterations.
	939.	Results identify cross talk between the p53 and nonsense-mediated mRNA decay pathways that regulates the expression levels of H-ras splice variants.
	940.	CP-31398 induced mitochondrial translocation of p53, leading to changes in mitochondrial membrane permeability pore transition (MPT) and consequent cytochrome c release in these cells.
	941.	In 50 of the 66 primitive colorectal tumor cases at least one significant alteration was identified in Ki-Ras and/or TP53 and/or p16(INK4A) genes.
	942.	Eighteen mutations (12 missense, one nonsense, two deletions, three nucleotide substitutions at the level of the splice-junctions) and two polymorphisms were detected by FAMA in 17 patients with colorectal cancar.
	943.	The evaluation of a large number of actinic keratosis specimens have found a low gene mutation rate in low-graded AK lesions. p53 mutations rather than p16(INK4a) and/or Ha-ras mutations may be an early event in the development of AK to cutaneous SCC.
	944.	linear relationship and prognostic role of the p53/p21/PCNA pathway in gastrointestinal stromal tumors. Abnormalities of the p53/p21WAF1 pathway lead to increased proliferating states, thereby triggering the progression of GISTs.
	945.	P53 overexpression and changes in phenotypic expression could contribute to the malignant transformation of colorectal precursor lesions.
	946.	p53 codon 72 polymorphism in Italian women have a minor role in determining genetic susceptibility to endometriosis
	947.	A new signaling pathway, DHA-PPAR-gamma-p53, in mediating the apoptotic effect of DHA in Reh cells.
	948.	a family with Li-Fraumeni syndrome in which initially a novel germline TP53 intron 5 splice site mutation was found
	949.	The culture of cells in the Cl(-)-replaced medium significantly increased expressions of p21 mRNA and protein without any effects on p53.
	950.	The increased apoptosis of peripheral blood lymphocytes from adult-onset Still's disease patients may be associated with the effect of IL-18 through up-regulation of FasL and p53 transcripts.
	951.	NUMB enters in a tricomplex with p53 and the E3 ubiquitin ligase HDM2 (also known as MDM2), thereby preventing ubiquitination and degradation of p53
	952.	Over expression of H179Y-mutant p53 promoted G1 to S phase transition with enlarged cell size and increased cyclin A1 and Cdk4 expression in HELF cells.
	953.	the p53 protein encoded by the 770delT allele is as abundant as the wild-type protein, as removal of the C-terminal p53 domain leads to a stabilized mutant protein, whose abundance is markedly increased when NMD is inhibited.
	954.	Inactivation of p53 may be associated with the appearance of central consolidation within pure ground-glass opacity (GGO) on HRCT which reflects invasive features and may be useful as a molecular marker.
	955.	suggests the unique role of Chk1 in preventing abrogation of the G2 checkpoint in p53+/+ cells
	956.	interplay between TFIIEalpha and the tumor suppressor protein p53 in regulating transcriptional activation that may be modulated by the phosphorylation status of p53
	957.	direct interaction between HAUSP and p53 is not absolutely required for it to antagonize efficiently Mdm2-mediated ubiquitination of p53
	958.	reveal a novel p53 apoptotic pathway in which it initiates apoptosis by transcriptionally repressing ARC
	959.	p53 Arg72Pro heterozygous genotype was overall an independent prognostic factor...of lung cancer
	960.	By comparing the expression of p53, cyclin D1, p16, hTERT, and TSP-1 in spontaneously regressing keratoacanthoma and squamous cell carcinoma, the changes in the expression of these proteins to specific stages of skin carcinogenesis, is defined.
	961.	transcription mediated by p53 is impaired by mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic
	962.	a crucial role of p53 in determining p27 upmodulation following HER2 activation
	963.	Data suggest that Pin1 is required for efficient loading of p53 on target promoters upon stress, and that after phosphorylation of p53 triggered by cytotoxic stimuli, Pin1 mediates p53's dissociation from iASPP, promoting cell death.
	964.	levels of p53/p21waf1 mRNA in blood lymphocytes collected before chemotherapy may predict the chemoresponses of lung cancer patients.
	965.	germ-line p53 mutations and sex had significant effects on cancer risk in patients with Li-Fraumeni syndrome
	966.	the p53 codon 72 polymorphism may be associated with gastric cancer among Asians, and that difference in genotype distribution may be associated with the location, stage, and histological differentiation of gastric cancer (Review)
	967.	Here we report a significant trend toward lower frequency of TP53 mutations with increasing number of Pro72 alleles (P = 0.02). Overall, Pro72 allele carriers had significantly lower frequency of TP53 mutations compared with Arg72 homozygotes (P = 0.02).
	968.	TP53 mutations are frequent events in bladder cancer progression and gelsolin relates to TP53 status, tumor staging and clinical outcome.
	969.	p53 is a direct transcriptional target gene of hPitx1. This observation is concordant with the recent identification of hPitx1 as a tumor suppressor gene.
	970.	The acetylation of two lysine residues in p53 promotes recruitment of the TFIID subunit TAF1 to the p21 promoter through its bromodomains.
	971.	Combination of PTEN/p53/PCNA represent an independent prognostic factor for tumor recurrence and disease-specific survival in hepatocellular carcinoma after surgery.
	972.	tissue-specific epigenetic regulatory mechanisms might be involved in p53 instability in breast cancer.
	973.	Coxsackievirus B3 (CVB3) infection markedly reduced ATF3 expression at mRNA and protein levels in parallel with p53 degradation, and preservation of p53 expression rescued CVB3 infection-induced ATF3 downregulation.
	974.	insulin-like growth factor binding protein-5 plays a role in the regulation of cellular senescence via a p53-dependent pathway and in aging-associated vascular diseases
	975.	the ectopic expression of IKKalpha into cells silenced for USP11 restores p53 expression, demonstrating that USP11 functions as an upstream regulator of an IKKalpha-p53 signaling pathway.
	976.	Specific TP53 mutations in L3 domain alone (only in DFS) or in combination with specific Ki-ras mutations at codon 13 are associated with a worse prognosis in sporadic Colorectal cancer.
	977.	This meta-analysis produced evidence for interesting tumor site differences in the predictive value of TP53 mutation for survival benefit from 5FU chemotherapy.
	978.	Results suggest that the cross talk between lysine methylation and acetylation is critical for p53 activation in response to DNA damage and that Set7/9 may play an important role in tumor suppression.
	979.	p53 plays a role in regulation of replication timing of the human genome through the control of cell-cycle checkpoints.
	980.	Human head and neck squamous cell carcinoma cells transfected with mutant TP53 injected subcutaneously into hind legs of nude mice show reduced sensitivity due to repair of radiation-induced damage.
	981.	Extent of mutation predicts response to antineoplastic agents.
	982.	study describes the presence of different p53 gene mutations in astrocytic gliomas in direct correlation to histologic characteristics of dissected tumor areas
	983.	this large collaborative study did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer
	984.	Results show that p53 seemed to have a significant role in cellular glucose metabolism and G2/M checkpoint, according to beta-irradiation, and could cause a different therapeutic response of (18)F-FDG uptake in cancer cells.
	985.	p53 status should be taken into account when deciding which therapeutic drug to use in glioblastoma multiforme.
	986.	nuclear apoptosis repressor with caspase recruitment domain (ARC)is induced in cancer cells and negatively regulates p53
	987.	Splicing fidelity is p53 dependent.
	988.	Data suggest that cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
	989.	These data suggest that P1 promoter is the main driving force for transcribing the bcl-2 gene and P1 activity is modulated by M and P2 in a p53-dependent and -independent manner.
	990.	Immunohistochemical detection of TP53 expression is a biomarker of malignant progression in Barrett's oesophagus but sensitivity is too low to act as a criterion to inform endoscopic surveillance strategies.
	991.	dThdPase, but not mutant p53, plays an important role in tumor angiogenesis in ductal adenocarcinoma of the pancreas
	992.	Serum p53 antibodies are expressed in the early stages of colorectal cancer
	993.	Hsp27 may play a general role in regulation of cellular senescence by modulating the p53 pathway.
	994.	p53 dissociation from some promoters is due to DNA-mediated charge transport through the base-pair stack. Photo-oxidative dissociation, despite being triggered from distance, is sequence-selective. Disulfide bonds are formed.
	995.	Activation of p53 mediated pathways in the glia of HIV-associated dementia patients may contribute to neuroinflammatory processes that promote neurodegeneration by inhibiting glial proliferation and/or promoting glial cell dysfunction.
	996.	study to identify the common factors governing the DNA-binding loss of p53c upon substitution of Arg 273 to His or Cys,which are abundant in human tumour
	997.	The codon72 and IVS7+72C>T polymorphisms of the p53 gene are unlikely to contribute to the pathogenesis of idiopathic male infertility with spermatogenetic failure.
	998.	Nutlin-3 abrogates both pre-osteoclastic proliferation and differentiation through a p53-dependent pathway
	999.	Downregulation of caveolin-1 expression affects bleomycin-induced cell cycle arrest and subsequent cellular senescence that is driven by p53 and p21.
	1000.	K-cyclin/Cdk9 interaction greatly enhanced the kinase activity of Cdk9 toward p53.
	1001.	Based on these results, we conclude that HO activity is involved in the regulation of p53 expression in a ROS-independent mechanism.
	1002.	The Pro/Pro genotype of the TP53 codon72 polymorphism increases oral cancer risk in non-smokers and worsens their prognosis.
	1003.	Embryos have varying sensitivity to the stresses of production and culture in vitro, and this resulted in variable expressivity of TRP53.
	1004.	Active regulator of SIRT1 (AROS) is the first direct SIRT1 regulator to be identified that modulates p53-mediated growth regulation.
	1005.	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.
	1006.	p53 Arg/Arg genotype does not seem to represent a risk marker for the development of cervical lesions in the majority of the European countries analysed.
	1007.	Single nucleotide polymorphisms within p53 are associated with chronic lymphocytic leukemia.
	1008.	type of TP53 mutation, especially missense mutation, is a strong prognostic indicator for disease-free survival and disease-specific survival in node-negative breast cancer, particularly in combination with ERBB2 amplification
	1009.	There is positive role for PI3K in p53 activation by anticancer agents, and suggest that the efficacy of PI3K inhibitors in cancer therapy may be greatly affected by the tumor p53 status.
	1010.	It is recorded that borealin is a cell cycle regulator, down-regulated in response to p53/Rb-signaling, and up-regulated in many types of cancerous tissues.
	1011.	by NF-kappaB activation, Tax elevates the level of the cellular p53 in human T-cells
	1012.	reveal a direct regulatory connection between p53-responsive stress signaling and Hbo1-dependent chromatin pathways
	1013.	show an important link between ATM activity and the tumor-suppressive function of B56gamma-protein phosphatase 2A
	1014.	Mutation of the IP6-binding sites impair oligomerization, reduce interaction with Mdm2, and inhibit p53-dependent antiproliferative effects of beta-arr2
	1015.	Furthermore, results indicate that induction of apoptosis in HCT-116 p53(wt) cells after ibuprofen treatment is in part dependent on a signalling pathway including the neutrophin receptor p75(NTR), p53 and Bax.
	1016.	The ultimate activation status of p53 target genes can be defined at steps downstream of p53 binding to chromatin and p53iated recruitment of histoneifiying activities.
	1017.	This review discusses implications of recent studies of the capacity of p53 to control the expression of specific microRNAs which may subsequently become involved in cancer and other critical biological processes.
	1018.	p53 NLS-selective nuclear import pathway and that both soluble and insoluble proteins are involved in its function.
	1019.	We conclude that the free radical scavenger edaravone suppresses X-ray-induced apoptosis in MOLT-4 cells by inhibiting p53.
	1020.	our data support the view that patients with P53 overexpression are significantly associated with an unfavorable outcome, whereas
	1021.	p53 is an indispensable component of cellular signaling system which is regulated by caveolin-1 expression, involving Akt activation and increase in cyclin D1, thereby promoting proliferation of breast cancer cells.
	1022.	ChIP and expression studies for individual genes indicate that human endogenous retrovirus p53 sites are likely part of the p53 transcriptional program and direct regulation of p53 target genes
	1023.	p53 is predominantly nuclear and functional in neuroblastoma regardless of differentiation status.
	1024.	molecular dynamics simulations of wild-type p53 and the R337His mutant at several different pH and salt conditions
	1025.	In alternative lengthening of telomere cells, TRF2 inactivation/silencing triggers cellular senescence and substantial loss of telomeric DNA upon stable TRF2 knockdown.
	1026.	Disruptive TP53 mutations in tumor DNA are associated with reduced survival after surgical treatment of squamous-cell carcinoma of the head and neck.
	1027.	Stroma-specific loss of heterozygosity or allelic imbalance is associated with somatic TP53 mutations and regional lymph-node metastases in sporadic breast cancer but not in hereditary breast cancer.
	1028.	Paclitaxel has potential for use as a radiosensitizer in the treatment of patients with prostate cancer with either wild-type or mutant p53 genetic status.
	1029.	Cells expressing mutant forms of E6 that are unable to bind p300/CBP or bind p53 failed to block acetylation of p53 at lysine 382 and were sensitive to growth arrest by interferon.
	1030.	AG490 enhances UCN-01-induced cytotoxicity in p53 defective cell lines by suppression of BAD phosphorylation and induction of BAX and PARP cleavage
	1031.	These results indicate that mutations and consequent dysfunction of P53 gene may result in chronic inflammation and hyperplasia in RA (Rheumatoid Arthritis) patients.
	1032.	Genome-scale chromosomal copy number alteration profiles and mutational statuses of p53 and beta-catenin in 87 hepatocellular carcinoma tumors were clarified.
	1033.	human papillomavirus 18 E6 protein sensitizes HeLa cells to Herpes simplex virus-dependent apoptosis through hTERT and p53.
	1034.	NF-kappaB promotes expression of a novel NF-kappaB-related gene signature and cell survival in HNSCC that weakly express TP53, a subset previously associated with inactivated wild-type TP53, greater resistance to chemoradiotherapy, and worse prognosis
	1035.	rerview of NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma [review]
	1036.	MAGED2, a novel protein, is a p53-dissociator.
	1037.	p53 mutation and human papilloma virus mediated p53 inactivation possibly constitute two independent pathways of head and neck squamous cell carcinoma tumourigenesis
	1038.	These data implicate a role for p73 in squamous cell carcinoma of the oesophagus and suggest a complex interaction between p53, p73 and HPV in the aetiology of the disease.
	1039.	These findings provide evidence that activation of TP53 gene transcription by PKCdelta triggers TP53-dependent apoptosis in response to DNA damage.
	1040.	in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating (i) activation and nuclear translocation of STAT5 and p53 and (ii) an increased Bax/Bcl-2 ratio
	1041.	Tumor suppressor p53 Arg72Pro polymorphism leads to increased longevity, but not to decreased risk of cancer.
	1042.	data suggest that this tumor suppressor gene plays a critical role in the multistep carcinogenesis process for esophageal squamous cell cancer
	1043.	provide new insight into a potential role of p53 as a component involved in the dynamic regulation of the major pathway of cytotoxic T-lymphocyte-mediated cell death and may have therapeutic implications
	1044.	study reveals there are differences in the frequencies & types of K-ras & p53 mutations found in pancreatic adenocarcinomas of patients in high-pollution & low-pollution regions in Egypt & suggests that environmental factors may explain these differences
	1045.	The apoptogenic activity of BM-ANF1 was mediated through p53 tumor-suppressor gene expression followed by the expression of p21(Cip1) and p27(Kip1)linking it with cell cycle arrest at G1 phase in cancer cells.
	1046.	The targeted degradation of p53 by E6 may contribute to the invasive phenotype exhibited by cervical cells that contain high-risk HPV types.
	1047.	Mutant p53 attenuates TGF-beta1 signaling. This was exhibited by a reduction in SMAD2/3 phosphorylation and an inhibition of both the formation of SMAD2/SMAD4 complexes and the translocation of SMAD4 to the cell nucleus.
	1048.	Mutant and wild-type p53 proteins are ubiquitinated and degraded through overlapping but distinct pathways.
	1049.	ATP binding function of MDM2 can mediate its chaperone function toward the p53 tumor suppressor
	1050.	loss of IFI16 activates p53 checkpoint through NBS1-DNA-PKcs pathway
	1051.	p53 mutation is associated with non-small cell lung carcinoma
	1052.	High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.
	1053.	Loss of TP53-DNA interaction induced by p.C135R point mutation in lung cancer
	1054.	ZNF307 might suppress p53-p21 pathway through activating MDM2 and EP300 expression and inducing p53 degradation
	1055.	We observed that the Pro72/Pro72 genotype of p53 is much less represented in children with nonsyndromic mental retardation than in controls and suggest that subjects carrying the Pro allele are protected from this disease.
	1056.	Individuals with the Pro/Pro genotype have an increased risk of developing nasopharyngeal carcinoma in Tunisia.
	1057.	Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age
	1058.	variant codon 72 p53 genotypes and the absence of the glutathione S transferase 1 (GSTM1) detoxification pathway, act in multiple myeloma disease progression
	1059.	these preliminary data suggest that polymorphism at codon 72 of the p53 gene influences the clinical course of ulcerative colitis, with continuous disease associated with p53 Pro homozygosity
	1060.	p53 and Ki-67, but not bcl-2, cyclin D1 or HER-2 may have roles in the process of tumor genesis in non-small cell lung carcinoma
	1061.	findings suggest no association between oligodendroglial tumors and the SNP in codon 72 of TP53; also no correlation was found among the TP53 codon 72 polymorphism and prognosis, p53 expression, and chromosomes 1p and 19q status
	1062.	Study reports that p18(Hamlet) can also mediate the cell cycle arrest induced in response to gamma-irradiation, by participating in the p53-dependent upregulation of the cell cycle inhibitor p21(Cip1) (CDKN1A).
	1063.	HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway.
	1064.	HPV16/18 E6 is expressed in HPV DNA-positive lung tumors and is involved in p53 inactivation to contributing to HPV-mediated lung tumorigenesis
	1065.	Discuss how tissue specificity, polymorphisms of genes associated with the p53 pathway, other genetic alterations, or p53 mutant heterogeneity can have a profound impact on the spectrum of p53 mutations (review).
	1066.	Analysis of neuroblastoma cell lines indicated that in contrast to previous reports, wild-type p53 was fully functional in all neuroblastoma lines tested; inactivation of p53 in neuroblastoma cells resulted in establishment of a MDR phenotype.
	1067.	N33, STK11 (19p13) and TP53 might play a role in the development of metastasis in larynx and pharynx squamous cell carcinomas.
	1068.	p53 mutations in plasma DNA from healthy individuals suggest that p53 mutations in plasma DNA may be a marker of carcinogen exposure from tobacco smoke.
	1069.	Loss of heterozygosity (LOH) of the hDMP1 gene was detectable in approximately 35% of human lung carcinomas, which was found in mutually exclusive fashion with LOH of INK4a/ARF or that of P53. DMP1 is a pivotal tumor suppressor for human lung cancers.
	1070.	Wip1 acts as a gatekeeper in the Mdm2-p53 regulatory loop by stabilizing Mdm2 and promoting Mdm2-mediated proteolysis of p53.
	1071.	two p53 haplotypes harboring the intron 3 polymorphic (+16bp) allele are associated with a higher risk of breast cancer in the Turkish population
	1072.	Activation of AKT, possibly through the PI3K-AKT pathway, is an important component of ASCC tumorigenesis that contributes to MDM2 and TP53 accumulation in the nucleus.
	1073.	levels of c-myc expression were up-regulated and those of p53 expression were down-regulated by HCV F protein.
	1074.	PC4 interacts with the DNA binding and C-terminal domains of p53 through its DNA binding domain, which is essential for the stimulation of p53 DNA binding.
	1075.	pGSK-3beta-ser-9 may confer the cisplatin resistance of ovarian carcinomas through the stabilization of p53 expression
	1076.	Though not formally excluded, these results do not support models in which p53 binds specific RNA partners in vivo.
	1077.	p53 preferentially occupied the promoters of growth arrest genes p21 and GADD45 in senescent normal human diploid fibroblasts.
	1078.	a new role for YY1 as both an inducer of p53 instability in smooth muscle cells, and an indirect repressor of p21WAF1/Cip1 transcription, p21WAF1/Cip1-cdk4-cyclin D1 assembly and intimal thickening.
	1079.	The rapid shift from a shorter p53 protein form (delta) toward the full-length protein (alpha) underscores the complexity of p53 protein modulation in patients undergoing chemotherapy.
	1080.	The p53 level was higher than in normal larynxes, whereas laryngeal cancer presented the lowest levels.
	1081.	Azurin binds to the flexible L(1) and s(7)-s(8) loops of the p53 DBD and stabilizes them through protein-protein tight packing interactions.
	1082.	This is an overview/review of studies of the p53-protooncogene protein MDM2 module and associated pathways from a systems biology perspective.
	1083.	The combination of p53 and p21 expressions in biopsy findings can thus predict the histological effectiveness of hyperthermochemoradiotherapy.
	1084.	Findings may indicate p53 codon 72 polymorphism as a risk factor for HNSCC.
	1085.	HPV18 E6 oncoprotein contributes to tumor angiogenesis by inducing VEGF transcription from the promoter in a p53-independent manner.
	1086.	Results indicate that the differential p53-regulated expression of survivin at different stages of the cell cycle results in different cellular outputs under the same apoptosis-inducer.
	1087.	The p53-positive tumors had more lymph node metastasis, and p53-positive had the worst prognosis with gastric cancer.
	1088.	phosphorylation of Pirh2 may act as a fine-tuning to maintain the balance of p53-Pirh2 autoregulatory feedback loop, which facilitates the tight regulation of p53 stability and tumor suppression
	1089.	modulation of p53Pro72Pro-mediated susceptibility to cervical cancer by immunogenetic factors could possibly be mediated through cross talk between HPV16/18-induced immune evasion and cell transformation
	1090.	In light of current treatment regimens for AIDS-related primary effusion lymphoma, this review discusses the benefits of using reactivation of the p53 pathway as a novel principle for the treatment of this virally induced highly aggressive malignancy.
	1091.	The combined immunohistochemical and genetic data of carcinoma ex pleomorphic adenoma and intraductal carcinoma showed genetic or morphological evidence of dysfunctional p53, indicating that this is an early event in malignant transformation.
	1092.	Deletion or mutational inactivation of the p53 gene represents an important step in the tumorigenicity of pancreatic cancer.
	1093.	KLF6 and p53 mutations are involved in the development of nonpolypoid colorectal carcinoma, whereas K-ras and B-raf mutations are not
	1094.	We report the histological and genetic study of two glioblastomas, one case arising de novo and the other case arising 3 years after a previously diagnosed anaplastic astrocytoma, with concurrent EGFR amplification and TP-53 mutation
	1095.	A strong correlation was found between the expression of p53 and p130, which was apparent in Stages 1 and 3, but not in Stage 2. These results suggest a novel p53/p130 axis in bladder tumors.
	1096.	The phosphorylation of p53 was associated with its transcriptional activity and stability modulated by LMP1
	1097.	Overexpression of stathmin is an early protumorigenic event in human hepatocarcinogenesis, and its up-regulation can be mediated by gain-of-function mutations in p53.
	1098.	RbAp48-mediated transformation of HPV16 is probably because of the regulation by RbAp48 of tumor suppressors retinoblastoma and p53, apoptosis-related enzymes caspase-3 and caspase-8, E6, E7, cyclin D1 (CCND1), and c-MYC.
	1099.	Changes in the intrinsic thermodynamic stability of p53 reduce the level of folded and hence functional p53 substantially in E. coli.
	1100.	The data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers.
	1101.	by disrupting the DNA binding activity of E2F1, BTG3 participates in the regulation of E2F1 target gene expression. Therefore, our studies have revealed a previously unidentified pathway through which the activity of E2F1 may be guarded by activated p53.
	1102.	Alterations in p53 were more commonly observed in localized GISTs at higher risk of relapse, and suggesting that they are significant as an independent, poor prognostic factor.
	1103.	results indicate an important role of p53 in esophageal squamous cell carcinoma (ESCC) also in low-incidence regions; in combination with the p53 Arg72 variant HPV infection could contribute to risk of ESCC in these cases
	1104.	KRAS G34A mutation was relatively common to all classes of specimen, whereas TP53 gene C742T and G818C mutations were significantly more frequent in lichen sclerosus than normal genital skin.
	1105.	CHIP might be a direct chaperone of wild type p53 that helps p53 in maintaining wild type conformation under physiological condition as well as help resurrect p53 mutant phenotype into a folded native state under stress condition.
	1106.	In breast cancer, bone morphogenetic protein 7 (BMP7) is a novel target gene regulated by the p53 family and mediates the cell survival function of the basal physiologically relevant level of p53.
	1107.	TAp73 is a stress-response gene and a downstream effector in the p53 pathway
	1108.	The up-regulation of PTEN inhibited Akt and MDM2, which enhanced the level of p53, thereby inducing G(2)/M arrest and apoptosis.
	1109.	Data suggest that cylindrospermopsin induces stress responses that result in the activation of the p53 transcription factor.
	1110.	ANXA7 and p53 can distinctly regulate LOX transcription that is potentially relevant to the arachidonic acid -mediated cell growth control in tumor suppression.
	1111.	p53 induces monocytic differentiation and the G2-phase cell cycle arrest, but not apoptosis of BM2 monoblasts, implying independence of the p53-driven apoototic and differentiation/proliferation pathways.
	1112.	Bcl-x(L) interacts with the DNA binding site of p53, but Bak does not interact with this site
	1113.	HCMV uses a shift from p53 to HDM2 ubiquitination and destabilization to obtain protracted high levels of p53, while promoting cell cycle traverse
	1114.	study of EGFR, HER2, TP53& KRAS mutations of p14arf expression of non-small cell lung cancers in relation to smoking
	1115.	p53 mutation is associated with intraductal papillary mucinous neoplasms of the pancreas
	1116.	p14ARF signals through hAda3 to stimulate p53 acetylation and the induction of cell senescence
	1117.	The results suggest that p53 expression in gonads of human male fetuses significantly increases in the 20th week.
	1118.	Alterations in TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 genes of microsatellite instability are rare in urinary bladder carcinoma and they are not associated with microsatellite instability or the presence of p53 mutations.
	1119.	Radiation-induced somatic mutations were observed in TP53 indicating an early role of TP53 in the radio-sarcomagenesis indicating gene activation in sarcoma.
	1120.	The expression of p53 was significantly higher in esophogeal squamous cell neoplasm than in non-tumorous tissue.
	1121.	Lack of evidence that p53 Arg72pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
	1122.	Common variation in the TP53 gene could modify the risk of invasive breast cancer.
	1123.	study found that lymphomas harboring p53 missense mutation with/without nonsense mutation had a highly significantly larger nuclear gross area than lymphomas with silent p53 mutation or lacking mutation
	1124.	no mutation of p53 and RB2/p130 genes was identified in any of the blood samples from Malaysian nasopharyngeal carcinoma; there was an identical G-->4 C nucleotide change at codon 280 of p53 gene in all the NPC cell lines
	1125.	The researchers found that p53 (-) status was a solid predictor for FR in pre-radiation biopsy specimens.
	1126.	p53 like other binding partners of cdc25C, regulates entry into mitosis by binding to cdc25C
	1127.	These results suggest that the Val allele of CYP1A1 Ile462Val polymorphism and the Pro allele of TP53 Arg72Pro polymorphism contribute to an increased risk of gallbladder cancer among Japanese women and men, respectively.
	1128.	MEG3 non-coding RNA may function as a tumor suppressor, whose action is mediated by both p53-dependent and p53-independent pathways
	1129.	Tumors that contained wild-type p53 were significantly more likely to express WT1, and presence of WT1 in glioma support that WT1 expression is important in glioma biology.
	1130.	In C33-A cells, arsenic treatment leads to a transient increase in p53 followed by a drastic reduction in its nuclear levels and an increase in cell proliferation.
	1131.	the histone lysine-specific demethylase LSD1 interacts with p53 to repress p53-mediated transcriptional activation and to inhibit the role of p53 in promoting apoptosis
	1132.	Mutations in exons 5-9 of the p53 gene were screened for using the non-isotopic RNase cleavage assay (NIRCA) and confirmed by direct sequencing, followed by immunohistochemical analysis for p53 protein
	1133.	Results unravel a novel mechanism by which ERalpha opposes p53-mediated apoptosis in breast cancer cells.
	1134.	p53 can form a complex with dephosphorylated Bad thereby converting it to a pro-apoptotic player.
	1135.	in diffuse large B-cell lymphoma, molecular alterations in ice, bcl-2, c-myc and p53 are present in hematopoietic cells from bone marrow as well as in primitive hematopoietic progenitors
	1136.	it is concluded that mutation of p53 & deletion of p16 might play important roles in the tumorigenesis of gliomas and it was significantly associated with the grade of tumor differentiation; P53 protein accumulation can indirectly reflect p53 mutation
	1137.	study indicated only p53 & RNASEL genotypes had significant influence on age of onset of Lynch syndrome in an additive mode of inheritance & that effects of both variants are purely additive supporting the notion that p53 & RNaseL pathways do not interact
	1138.	In a proteomic screen for p53 interactors the cullin protein Cul7 efficiently associates with p53.
	1139.	TP53 mutations had low diagnostic accuracy for pancreatic neoplasms.
	1140.	Wild-type and mutant p53 are shown to differentially regulate MMP-13 expression in malignant peripheral nerve sheath tumors.
	1141.	The evolutionary perspective in this review indicates that p53 evolved so as to play a subtle but very important role during development, and suggests that p53 was primarily selected for its developmental role and not as a tumor suppressor gene.
	1142.	Wip1 overexpression abrogates the homeostatic balance maintained through the p38-p53-Wip1 pathway, and contributes to malignant progression by inactivating wild-type p53 and p38 MAPK as well as decreasing p16 protein levels in human breast tissues.
	1143.	This is the first report showing loss of heterozygosity at the intron 1 region of p53 gene in human brain tumors.
	1144.	transcription factors p53, NF-kappaB, and AP-1 may be important determinants of the heterogeneous pattern of gene expression, whereas STAT3 and EGR1 may broadly enhance gene expression in head and neck squamous cell carcinomas
	1145.	These findings support a novel p53 --> CDIP --> TNF-alpha apoptotic pathway that directs apoptosis after exposure of cells to genotoxic stress.
	1146.	Distribution of a single nucleotide polymorphism in the TP53 codon 72 (Arg/Pro) was studied in Southeast Asia and Oceania where information about this polymorphism was lacking.
	1147.	interphase Fish on samples from 30 MCL patients revealed p53 deletions in 13 cases
	1148.	In lung cancer patients, p53 accumulation could be due to a decrease in full-length MDM2 isoform together with an increase of the 57-kDa MDM2 isoform that was unable to stimulate p53 degradation.
	1149.	abrogation of p53 function in post-selection human mammary epithelial cells inactivates cell cycle checkpoints
	1150.	p53 expression may have a role in the carcinogenesis of squamous cell cervical carcinoma whereas Bcl-2 expression has no role. Ki-67 expression can not be used in determining the aggressiveness of CIN lesions
	1151.	No deletions were found in the p53 gene of these MD tumor cell lines, truncations in the p53 ORFs observed in this study might result from alternative splicing of the p53 gene.
	1152.	Risk of cancer is markedly increased in heavy smokers (>20 pack-years) with squamous-cell carcinoma carrying an amino acid substitution.
	1153.	S7 binds to MDM2, in vitro and in vivo, and the interaction between MDM2 and S7 leads to modulation of MDM2-p53 binding by forming a ternary complex among MDM2, p53 and S7.
	1154.	Photodynamic therapy resistant HT29 cell variants are differentially sensitized to UVA compared with UVC due, in part at least, through the altered expression levels of BNip3, Hsp27 and mutant p53.
	1155.	Non-small cell lung cancer cells with nonfunctional TP53 might be sensitized against radiation by genistein or estradiol.
	1156.	p53 mediates interstitial cystitis APF-induced growth inhibition of human urothelial cells.
	1157.	Patients with primary colorectal cancer with low TSP-1 expression, with or without detection of mp53 gene product, are more likely to harbor lymph node metastasis than patients with higher expression.
	1158.	transcription-based stress response involving replication protein A, ATR, and p53 has evolved as a DNA damage-sensing mechanism to safeguard cells against DNA damage-induced mutagenesis
	1159.	BAG-1 negativity in association with p53 and c-erbB2 positivity identified a subgroup of tongue cancer patients with an aggressive phenotype
	1160.	p53 genetic alterations found in gastric stump carcinomas & intestinal-type primary gastric carcinomas could originate from a similar pathway; no association found between p53 gene status & P-gp expression
	1161.	p53 protein expression in vivo does not correlate with the outcome of patients with primary in primary glioblastoma.
	1162.	TP53BP1 variants may have protective effects on head and neck cancer risk.
	1163.	Fluorouracil may show translational regulation and control p53 expression in a colon cancer cell line.
	1164.	mutations were found mainly in more advanced stages of urinary bladder cancer & at the CIS stage (carcinoma in situ); it cannot be excluded that the observed polymorphism at codon 213 may be a predisposing factor for urinary bladder carcinoma development
	1165.	impact of TP53 mutations and codon 72 genotype on survival of ovarian cancer patients
	1166.	p53 mutation was observed in 4 of 13 specimens of endometriosis coexisting with ovarian clear cell carcinoma, whereas no mutations were detected in solitary endometriosis or endometriosis coexisting with ovarian endometrioid carcinoma.
	1167.	Positivity for p53 was strong and diffuse in 5 uterine tumors and in 3 ovarian tumors. p53 expression in 6 of the uterine specimens and 7 of the ovarian specimens was present in fewer tumor cells, of weak intensity, or both.
	1168.	No correlation between Pidd expression and the p53 mutation status of oral squamous cell carcinoma, suggesting that Pidd expression may be regulated by p53-independent mechanisms.
	1169.	damage-activated switch in Hdm2 ubiquitin ligase preference from P53 to itself and Hdmx is central to P53 activation
	1170.	TP53 mutation status and gene-expression based groups are important survival markers of breast cancer.
	1171.	Bivariate analysis of p53/BAX proteins possibly may provide further prognostic evidence in colon cancer.
	1172.	ubiquitination-mediated repression of p53 by Mdm2 acts at least, in part, through inhibiting the sequence-specific DNA binding activity
	1173.	The present study showed elevated expression of topo-I, Ki-67, and mutant p53 in patients with uterine carcinosarcoma suggesting sensitivity to topo-I-targeted drug treatment.
	1174.	The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.
	1175.	Electron microscopy on the conformationally mobile, unbound p53 selected a minor compact conformation
	1176.	Comparative genomic hybridization and immunohistochemical assessment of EGFR, PTEN, p53, and MIB-1 expression in 13 oligodendrogliomas, one oligoastrocytoma and 23 high-grade astrocytomas is reported.
	1177.	This study identifies SET8 as a p53-modifying enzyme, monomethylating p53 at lysine 382(p53K382me1) and identifying (p53K382me1) as a regulatory posttranslational modification of p53.
	1178.	bcl-2 and p53 expression in neuroblastoma is related to DNA fragmentation
	1179.	NFBD1 plays an important role in the decision of cell survival and death after DNA damage through the regulation of p53
	1180.	p53 mutation spectrum shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the skin carcinogenesis of renal transplantation patients.
	1181.	Te strong nuclear expression of p53 in these and other pediatric GBMs could indicate that p53 dysregulation is important to tumorigenesis.
	1182.	analysis of the transactivation function of p53 alleles in cancer
	1183.	Aberrations of the p53, Rb and p27 pathways are associated with aggressive clinical behavior in DLBCL.
	1184.	These observations demonstrate a novel regulatory role for p53 as a uPAR mRNA binding protein that down-regulates uPAR expression, destabilizes uPAR mRNA, and thereby contributes to the viability of human airway epithelial or lung carcinoma cells.
	1185.	Regulation of miRNA expression into the transcriptional network regulated by p53.
	1186.	New gain of function of the common p53 cancer mutants in inducing genetic instability.
	1187.	Bloom symdrome-independent role for p53 in etoposide-induced, topoisomerase II-mediated DNA damage in human cells.
	1188.	p53 plays an essential role in the autophagic pathway downstream of the DNA mismatch repair system.
	1189.	These results demonstrate that, in the cells investigated, the level of NS is regulated by p14(ARF) and the control of the G1/S transition by NS operates in a p53-dependent manner.
	1190.	In the Italian population there is no association between codon 72-p53 gene polymorphism and the occurrence of rheumatoid arthritis.
	1191.	Results describe four novel single nucleotide polymorphisms within the promoter region of the p53 gene and their associations with uterine leiomyoma.
	1192.	There is strong evidence that low grade dysplasia is a neoplastic lesion and that p53 point mutation is deeply involved in esophageal carcinogenesis.
	1193.	Results suggest that intrinsic DNA binding affinity and p53 protein levels are important contributors to p53-induced differential transactivation.
	1194.	Immunohistochemical expression of this protein in squamous cell carcinomas from immunosuppressed renal transplant recipients and immunocompetent individuals
	1195.	v-Fos-stimulated invasion is independent of the pRb/p16(INK4a) and p53 tumor suppressor pathways and telomerase
	1196.	This study focused on the expression levels of Bcl-2 family regulators (anti-apoptotic Bcl-2 and Bcl-XL, pro-apoptotic Bcl-Xs and Bax), p53, and PCNA as a marker of proliferation, together with the evaluation of the level of apoptosis in human embryos.
	1197.	data suggest that p53pSer15 plays a dual role in the functional interactions with early complexes of Rad51-dependent recombination and with BLM-associated surveillance and signalling complexes within distinct nuclear subcompartments
	1198.	Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
	1199.	New mutations of p53 identified by SSCP in acute myeloid leukemia cell lines. Loss of p53 is not the decisive event causing tumor cells to proliferate in vitro without externally added growth factors.
	1200.	insulin inhibits TNF-alpha-dependent cell killing, induction of p53, p21 and apoptosis in a human cervical carcinoma cell line
	1201.	higher expression in atrophic oral lichen planus and patients with areca quid chewing
	1202.	initiation of DNA replication is regulated by p53 through Cdc6 protein stability
	1203.	findings suggest that overexpression of EGFR in glioblastomas in Chinese patients may be associated closely with the patients age but not with the tumors' pathological pathway
	1204.	In summary, the p53/p21 pathway is mainly responsible for GC-induced apoptosis, but the coordinated activation of the p53/p21 and p16 pathway is responsible for GC-induced endothelial cell senescence through a Rb-dependent mechanism.
	1205.	Results suggests that analysis of p53 codon 72 polymorphism may provide a simple predictive marker for selecting the right breast cancer patients to anthracycline-based neoadjuvant chemotherapy in clinical setting.
	1206.	Beta-interferon-induced senescence was more efficient in cells expressing either, p53, or constitutive allele of ERK2 or RasV12.
	1207.	The TP53 R337H mutation dramatically increases predisposition to childhood adrenocortical carcinoma (ACT) but not to other cancers, and explains the increased frequency of ACT observed in this geographic region.
	1208.	inactivation of p53 in osteosarcomas directly by mutation versus indirectly by HDM2 amplification may have different cellular consequences with respect to the stability of the genome
	1209.	aberrent expresion correlates with VEGF and IL-8 mRNA expression and neoangiogenesis in non-small-cell lung cancer
	1210.	Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.
	1211.	role in regulating growth-promoting gene IEX-1
	1212.	A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients
	1213.	mutation analysis of this gene in a case of familial endometriosis
	1214.	study showed that polymorphism at codon 72 of TP53 gene is not associated with an increased susceptibility to cervical disease and/or HPV infection in the Argentine women population
	1215.	PTEN inhibits MDM2 and protects p53 through both p13k/Akt-dependent and -independent pathways in ALL.
	1216.	Crucial role of p53 C-terminal phosphorylation in the regulation of its DNA-binding activity.
	1217.	survivin can reduce the cell growth inhibition and apoptosis, and p53 elevates the p21 level, which may attenuate the cell death in the quercetin-treated human lung carcinoma cells
	1218.	PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation
	1219.	low-dose radiation hypersensitivity is associated with p53-dependent apoptosis.
	1220.	possible interplay between p53 C-terminal phosphorylation and acetylation, and they provide an additional mechanism for the control of the activity of p53 by Checkpoint kinase 1 and Checkpoint kinase 2
	1221.	The human gene in transgenic mice behaves like its murine ortholog in mouse hepatocarcinogenesis.
	1222.	ING1 expression is frequently associated with Adenocarcinoma of the esophagogastric junction tumorigenesis, further supporting its role as a tumor suppressor gene, and ING1 expression is independent of p53 status
	1223.	VHL-mediated p53 upregulation may contribute to pVHL's tumor suppressive functions in renal cell carcinoma
	1224.	identification of defect in response pathway induced by de novo purine synthesis inhibition
	1225.	analysis of TP53 mutation pattern in radiation-induced sarcomas
	1226.	presence of p53 in a transcription complex of NPM and Sp1 or NF-kappaB at the promoter of the MnSOD gene was verified. p53 interacts with Sp1 to suppress expression of the MnSOD gene.
	1227.	p53 directly regulatescarboxylesterase 2expression in a colonic cancer cell line.
	1228.	Hdmx is an important determinant of the outcome of P53 activation
	1229.	analysis of the human p53 tetramerization domain
	1230.	p53-dependent staurosporine-induced caspase-3 activation is affected by the C-terminal products of cellular prion protein processing, C1 and C2
	1231.	Taurolidine induces apoptosis and necrosis, activates p53 and sensitizes cells to cisplatin, whereas PVP-I inhibits cell growth via necrosis.
	1232.	LSD1 has a pro-oncogenic function by modulating pro-survival gene expression and p53 transcriptional activity
	1233.	nuclear IKK-alpha-mediated accumulation of p73alpha is one of the novel molecular mechanisms to induce apoptotic cell death in response to CDDP, which may be particularly important in killing tumor cells with p53 mutation
	1234.	nutlin-3A stabilized p53 by preventing MDM2-mediated p53 degradation in and Reed-Sternberg (HRS) cells of Hodgkin's lymphoma (HL)
	1235.	SNP309 of HDM2 is a frequent event in bladder cancer, related to earlier onset of superficial disease and TP53 mutation status
	1236.	Our results suggest that phosphorylation of CBP by IKKalpha regulates the CBP-mediated crosstalk between NF-kappaB and p53 and thus may be a critical factor in the promotion of cell proliferation and tumor growth.
	1237.	effect of phosphorylation on structure and fold of transactivation domain
	1238.	persistence of induced levels of ROS in normal diploid human cells for 1 month after X-ray exposure and the role of TP53 in this oxidant response
	1239.	central and carboxy-terminal regions are essential for interaction and complex formation with PARP-1
	1240.	colocalization of a nonshuttling p53 with MDM2 either in the nucleus or in the cytoplasm is sufficient for MDM2-induced p53 polyubiquitination but not degradation.
	1241.	Epigallocatechin-3-gallate-induced stabilization of p53 caused an upregulation in its transcriptional activity, thereby resulting in activation of its downstream targets p21/WAF1 and Bax.
	1242.	A cytoplasmic accumulation of wild-type p53 in human primary glioblastomas correlates with GFAP and vimentin expression. Cytoplasmic p53 is inactive in growth suppression.
	1243.	p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
	1244.	low incidence for actinic damage, basal cell and squamous cell carcinoma as documented in vitiligo could well reside in a protective function of up-regulated wild-type p53.
	1245.	molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to the genome stabilizing function
	1246.	The 3' UTR of p53 was found to be a target of the RNA-binding protein HuR in a UVC-dependent manner in vitro and in vivo.
	1247.	Inhibition of p53 causes ubiquitination and down-regulation, through increased degradation, of the IGF-1R in human malignant melanoma cells. By sequestering Mdm2 in the cell nuclei, the level of p53 may indirectly influence the expression of IGF-1R.
	1248.	Zinc deficiency caused an increase in p53 protein expression.
	1249.	trp53 has a role in activation of the Fas/CD95 pathway
	1250.	p53 mutations are common among oral cavity cancers in the Brazilian population
	1251.	Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation
	1252.	p53 disruption has a dramatic effect on how glioblastoma cells process topoisomerase I inhibitor-mediated DNA damage.
	1253.	Decreased level of the phosphorylation is associated with basal cell carcinomas of skin
	1254.	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.
	1255.	Data show that human papillomavirus E6 oncoprotein does not prevent p53 or p300 recruitment to the chromatin but inhibits p300-mediated acetylation on p53 and nucleosomal core histones.
	1256.	Analysis of expression levels of p21(waf1), as well as the activity of caspase-3 and caspase-8, allowed us to characterize some aspects of the arrest of PC-3 cells in G2 and the apoptotic response to oxidative stress in the absence of functional p53
	1257.	Rb and p53 have roles in progression of primary non-small cell lung carcinoma
	1258.	WR1065 specifically modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observation that this agent elicits essentially p53-dependent, cell cycle arrest responses.
	1259.	the p14ARF-p53-MDM2 pathway has a role in development of oral squamous cell carcinoma
	1260.	in nasopharyngeal carcinoma cells, SarCNU-induced apoptosis is p53-dependent while SarCNU-induced G2/M arrest is mediated by the cyclin B1-cdc-2 complex
	1261.	Germline mutations of this protein exist in a cohort with childhood sarcoma: sex differences in cancer risk.
	1262.	review on mutations in brain neoplasms
	1263.	Immunostaining of p53 accumulation in families with multiple glioma pts showed that p53 alterations are as common in familial as in sporadic gliomas.Germline p53 mutations in exons 4-10 were not found.
	1264.	TP53INP1s and HIPK2 could be partners in regulating p53 activity.
	1265.	WRN and TP53 perform different functions in a shared DNA damage response pathway.
	1266.	RB18A plays a central role to control p53wt and p53mut protein content and functions in cells through a loop of regulation, which involves MDM2
	1267.	TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism
	1268.	These data indicate a novel p53-dependent mechanism in which cell stress mobilizes nucleolin for transient replication inhibition and DNA repair.
	1269.	The sequential accumulation of mutations in p53 drives the transition from normal epithelium through increasing adenomatous dysplasia to colorectal cancer.
	1270.	loss of nuclear p53 signal may have a role in cisplatin resistance in head and neck squamous cell carcinoma
	1271.	the p53 and MDM2 promoter polymorphisms do not appear to play a role on age of colorectal cancer onset in Lynch syndrome
	1272.	Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 contribute to the risk of developing lung cancer.
	1273.	Functional p53 can promote the adenovirus (Ad) lytic cycle
	1274.	p53 as a sensor of transcriptional integrity
	1275.	Copper alters the conformation and transcriptional activity of TP53 in Hep G2 cells.
	1276.	Data suggest that dose-dependent UV stabilization of p53 in cultured human cells undergoing apoptosis is mediated by poly(ADP-ribosyl)ation.
	1277.	p53 plays a role in regulation of cullin 7 activity
	1278.	increased expression is not an indicator of the presence of p53 gene mutations at exons 4-8 in hepatocellular carcinoma
	1279.	IkappaBalpha x p53 complex plays an important role in responses involving growth regulation, apoptosis, and hypoxic stress
	1280.	p53 activates ATF3 in human tumor cells
	1281.	Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
	1282.	Bcl-2 constitutively suppresses aptoptosis dependent on this protein in colorectal cancer cells.
	1283.	Upregulation of p14ARF paralleled with MDM2 inhibition contributes to p53 accumulation in the nucleus in radiation-treated breast cancer cells.
	1284.	reacts with glycogen synthase kinase-3beta after DNA damage
	1285.	A complex between tetrameric p53 and p300 in which four domains of p300 wrap around the four transactivation domains of p53.
	1286.	Review outlines uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors.
	1287.	the N-terminal domain of PIAS1 interacts with DNA as well as p53
	1288.	The first direct demonstration of p53 mutations in pleuropulmonary blastomas (PPB)suggests p53 inactivation can occur as a nonrandom genetic change involving the pathogenesis and outcome of PPB.
	1289.	The relationships and interactions between p53, Rb and bcl-2 immunostaining, clinical parameters and response to cisplatin-based chemotherapy were evaluated in the present study.
	1290.	NLS domain of ING4 is essential for the binding of ING4 to p53 and the function of ING4 associated with p53
	1291.	Differentiating human keratinocytes are deficient in p53 but they preserve global nucleotide excision repair as well as expression of genes encoding key DNA damage recognition proteins
	1292.	p53 activation is not necessary for up-regulation of NOXA in melanoma cells
	1293.	recombinant p53 binds to BLM and WRN helicases and attenuates their ability to unwind synthetic Holliday junctions in vitro
	1294.	the greater severity of TP53-mutant B-CLLs compared with ATM-mutant B-CLLs is consistent with the additive effect of defective apoptotic and elevated survival responses after DNA damage in these tumors
	1295.	Results suggested that the loss of p53 expression in conjunction with the overexpression of p21(WAF1/CIP1) was a stronger predictor of survival benefit than either molecule alone in Japanese serous-type advanced ovarian cancer.
	1296.	BTG2 expression was found to be significantly reduced in a large proportion of human kidney and breast carcinomas, suggesting that BTG2 is a tumor suppressor that links p53 and Rb pathways in human tumorigenesis.
	1297.	p53 inhibits protein synthesis in human lung carcinoma cells;The mechanism involves dephosphorylation and accumulation of the translational inhibitor 4E-BP1, and increased association of 4E-BP1 with initiation factor eIF4E.
	1298.	Tumours with FGFR3+/p53- phenotype seem to have a distinctive pathway in bladder tumorigenesis.
	1299.	Protein phoaphatase-1 directly dephosphorylates p53. This has as important an impact on its functions as phosphorylation does. One way PP-1 promotes cell survival is to dephosphorylate p53, & thus negatively regulate the p53-dependent death pathway.
	1300.	A Small Ras-like GTPase protein Ray was indicated to modulate p53 transcriptional activity of PRPK.
	1301.	findings show that p53 modulates the balance between the utilization of respiratory and glycolytic pathways; identifed Synthesis of Cytochrome c Oxidase 2 (SCO2) as the downstream mediator of this effect
	1302.	The present paper aims to provide updated information on p53 regulation and function, with specific interest on its role in breast cancer.
	1303.	Increased GEF-H1 expression contributes to the tumor progression phenotype associated with the p53 mutation.
	1304.	ECT2 is negatively regulated by wild-type p53 but not tumor-derived mutant p53 or other p53 family members.
	1305.	As the amount of p53 protein increases, there is a downregulation of the VRK1 protein level independent of its promoter.
	1306.	Antisense ODN to p53 impairs secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.
	1307.	The results obtained demonstrated that, at least in vitro, the p53 family members tested (TAp63alpha, TAp73alpha, DeltaNp63alpha, but not DeltaNp73alpha) were able to drive transcription from the PKCdelta promoter.
	1308.	BCCIP in maintaining the transactivation activity of wild type p53; down-regulation of BCCIP as a novel mechanism to impair the p53 function in cells harboring wild type p53
	1309.	Cancer-associated missense mutations targeting MDM2's central zinc finger disrupt the interaction of MDM2 with L5 and L11.
	1310.	We showed that renal cell carcinoma with rhabdoid features is a very aggressive neoplasm with a poor prognosis. We observed an overexpression of p53 in the rhabdoid component that may be implicated in the tumor dedifferentiation.
	1311.	These findings indicate that DYRK2 regulates p53 to induce apoptosis in response to DNA damage.
	1312.	immunoreactivity of p53, MDM2, WAF1, and BCL-2 were measured in soft tissue sarcomas cases consisting of 54 low-grade, 40 intermediate-grade, and 58 high-grade sarcomas
	1313.	p53 and p73alpha have roles in cell migration
	1314.	p53 is regulated by hGTSE-1 during apoptosis control after DNA damage in S and G2 phases
	1315.	Histone deacetylase inhibitors can induce Gadd45 through its promoter without the need for functional p53, and Oct-1 and NF-Y concertedly participate in Trichostatin A-induced activation of the gadd45 promoter.
	1316.	Study indicate that the coexistence of p53 protein accumulation and HER2 overexpression is a strong prognostic molecular marker in breast cancer.
	1317.	The p21 upregulation followed the p53 phosphorylation process in irradiated MOLT-4 ce
	1318.	O(6)MeG-triggered apoptosis in proliferating lymphocytes was preceded by a wave of double stranded breaks, which coincided with p53 and Fas receptor upregulation
	1319.	TP53 mutations could be a useful prognostic indicator in precancerous oral lesions.
	1320.	results suggest that microsatellite instability and p53 mutations are involved in tumor progression of dermatofibrosarcoma protuberans to fibrosarcoma as early and late events, respectively
	1321.	YY1 regulates the transcriptional activity, acetylation, ubiquitination, and stability of p53 by inhibiting its interaction with the coactivator p300 and by enhancing its interaction with the negative regulator Mdm2.
	1322.	The ability of p53 to bind and inactivate JNK, together with the activation of the p53 target genes related to cell cycle arrest and DNA damage repair, is responsible for its protection of cells against UV-induced apoptosis.
	1323.	COX-2-positive prostate cancer cells can have impaired p53 function even in the presence of wild-type p53 and that p53 activity can be restored in these cells via inhibition of COX-2 activity.
	1324.	Homozygosity for Pro of p53 Arg72Pro is potentially one of the genetic risk factors for hepatocarcinoma in a Chinese population.
	1325.	expression of p21/CDKN1A is necessary and sufficient for the negative regulation of gene expression by p53
	1326.	DeltaNp73alpha not only acts as an inhibitor of p53/TAp73 functions in neuroblastoma tumors, but also cooperates with wt-p53 in playing a physiological role through the activation of BTG2TIS21/PC3 gene expression
	1327.	Haplotype analysis also showed a significant association between TP53 and schizophrenia. These results provide further evidence that TP53 may play a role in the pathogenesis of schizophrenia.
	1328.	besides P53 alterations, mouse double minute 2 gene deregulation seems to be an important event in hepatocarcinogenesis
	1329.	Logistic regression analysis showed p53 and COX-2 as dependent predictors in pancreatic carcinogenesis, and a reciprocal relationship to neoplastic progression between p53 and COX-2.
	1330.	Results show that the TP53 R337H germline mutation predisposes to a larger spectrum of tumours.
	1331.	Caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol; these translocate to mitochondria and induce membrane depolarization.
	1332.	While ATL patients carrying a wild-type p53 enter remission following treatment with AZT, those with a mutated p53 did not respond, and patients' disease relapse was associated with the selection of a tumor clone carrying mutated inactive p53.
	1333.	p53 Arg72Pro may play a role in the early stages of colorectal neoplasia and possibly in progression to invasive disease, depending on site and sex
	1334.	The alterations of the p53 gene evaluated by DNA sequence analysis is relatively accurate. Expression of P53 protein could not act as an independent index to estimate the prognosis of cholangiocarcinoma.
	1335.	Data suggest that the TP53 and CHEK2 mutations can substitute each other in at least 25% (21/84) of prostate cancers and that DNA damage-signaling pathway plays an important role in prostate cancer tumorigenesis.
	1336.	Results show that the p53beta isoform is the only p53 species to be endogenously expressed in the neuroblastoma (NB)cell line SK-N-AS, suggesting that the C-terminus truncated p53 isoforms may play an important role in NB tumor development.
	1337.	p53 mutation is not an important mechanism for beta-catenin activation in primary cutaneous T-cell lymphoma; p53 codon 72 polymorphism may influence negative feedback control involving beta-catenin and p53.
	1338.	Bcl-2 inhibition might therefore improve the efficacy of existing acute myeloid leukemia therapies by inactivating this suppression of wild-type p53 activity
	1339.	Notch signaling downregulated p53-dependent apoptosis induced by ultraviolet irradiation.
	1340.	somatic alterations in p53 and EGFR have roles in progression of primary lung cancer
	1341.	These data demonstrate the importance of Noxa induction in determining the apoptotic response to fenretinide and emphasise the role of Noxa in p53-independent apoptosis.
	1342.	nuclear mutant p53 protein is expressed in early precancerous stages suggesting this is an early change in NSCLC tumorigenesis; may be a potential marker for development of NSCLC
	1343.	cytoplasmic sequestration of p53 by the E1B 55-kDa protein plays an important role in restricting p53 activities in human osteosarcoma cells
	1344.	p53 status is an important modulator of nitric oxide-induced mutagenesis and apoptosis, and suggest that level of the Apaf-1 ans XIAP proteins are regulated by p53
	1345.	Data describe the correlation between inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 activities and p53 gene status in head and neck squamous cell carcinomas in vivo and in vitro.
	1346.	identification of one known and five new modulators of p53-dependent proliferation arrest, using an RNA interference library
	1347.	l structure of the p53 binding domain of USP7 alone and bound to an EBNA1 peptide
	1348.	germline mutations in the TP53 gene in five index cases of German and Swiss origin with cancers typical of Li-Fraumeni syndrome
	1349.	p53 has a differential role in effecting G(2) arrest in response to topoisomerase II inhibitors, depending upon the mechanisms of action of the inhibitors tested.
	1350.	These results suggest that Chk2 regulates the transcription-independent mechanism of p53-mediated apoptosis by inducing stabilization of p53 in response to IR.
	1351.	TP53 abnormalities are early and frequent events in the pathogenesis of gallbladder carcinoma, starting from chronic cholecystitis.
	1352.	differentiation status of the tumor was found for the p53 aberration but not for CD95 expression.
	1353.	These findings indicate that PKCdelta regulates p53 to induce apoptotic cell death in the cellular response to DNA damage.
	1354.	TP53 mutation is common in early stage ovarian carcinomas of serous histology, with a mutation frequency comparable to that reported for advanced-stage ovarian tumors.
	1355.	The poor prognosis associated with p53-null mutation is independent of the mutation mechanism in ovarian cancer survival.
	1356.	p53 acts upstream of Bax to promote antineoplastics mediated cell death in a proline-rich domain-dependent manner through both transcription-dependent and -independent mechanisms in human colon cancer HCT116 cells.
	1357.	TP53 deletion significantly associated with malignant transformation of breast papilloma, pointing to p53 role as a progression factor
	1358.	Down-regulation of Cdc7 by small interfering RNA in a variety of tumor cell lines causes an abortive S phase, leading to cell death by either p53-independent apoptosis or aberrant mitosis.
	1359.	p53 not only can provide proapoptotic signals but also regulates a survival pathway influencing Mcl-1 and Bcl-x(L) levels
	1360.	These findings suggest that impairment of transcriptionally active p53 in response to replication blockade is not a general phenomenon.
	1361.	results establish a direct functional link between p53 and human Rad51, and reveal that one of p53's functions in genome stabilization may be to prevent detrimental genome rearrangements promoted by Rad51
	1362.	Individuals carrying Arg allele compared to those with Pro allele have an increased risk for esophageal squamous cell carcinoma.
	1363.	role in regulating survivin 2B
	1364.	p53 is an effective repressor of snRNA gene transcription by RNA polymerases II and III.
	1365.	an aberrant p53 status was related to IL-8 expression in patients with non-small cell lung carcinoma
	1366.	Results illustrate a novel mechanism of the alteration of p53 function that is mediated by a cutaneous HPV type and support the role of HPV38 and deltaNp73 in human carcinogenesis.
	1367.	We suggest that p53 has a role in RAD51 clearance post DSB repair and that nucleoli might be sites of RAD51 protein degradation.
	1368.	p90Rsk-mediated modulation of Hdm2 nuclear is linked to cytoplasmic shuttling with the diminished ability of p53 to regulate cell cycle checkpoints that ultimately leads to transformation
	1369.	The data implicate cyclin A1 as a downstream player in p53-dependent apoptosis and G2 arrest.
	1370.	Polymorphism in the p53 gene at codon 72 revealed no significant association with the development of CAD or diabetes in Kuwait.
	1371.	p53 mediates the suppression of TR3 on MDM2 at both transcriptional and post-transcriptional level and suggest TR3 as a potential target to develop new anticancer agents that restrict MDM2-induced tumor progression.
	1372.	expression of hTERT reduces the number of foci and the level of active p53, thereby decreasing sensitivity to growth factor depletion
	1373.	H pylori-associated chronic gastritis expressed the mutant-type p53, which was significantly associated with more severe atrophic and metaplastic changes.
	1374.	Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome
	1375.	a correlation between focal p53 immunostaining in primary primary prostate cancers and cancer recurrence after radical prostatectomy
	1376.	Results identify a novel mechanism of p53-dependent apoptosis in which p53-mediated up-regulation of MnSOD and GPx, but not CAT, produces an imbalance in antioxidant enzymes and oxidative stress.
	1377.	A selective growth advantage for cells carrying a type of TP53 mutation seen in breast carcinomas when the mutation resides on Arg72 allele. These are not seen in colorectal neoplasms.
	1378.	We propose that a major mechanism by which p53 maintains genome stability is the prevention of DSB accumulation at long-lived ssDNA regions in stalled-replication forks.
	1379.	Data suggest that certain p53 mutations may have prognostic value in superficial bladder transitional cell carcinoma, even though they were not associated with other classic recurrence and tumor progression parameters.
	1380.	Expression or this protein does not predict outcome in colorectal cancer patients.
	1381.	Expression of p53 is associated with NIH risk category, various pathological features, and clinical outcome, and may be independently prognostic for gastrointestinal stromal tumours.
	1382.	Atypical meningioma showed TP53 mutations and a 22q loss of heterozygosity (LOH), while glioblastoma showed epidermal growth factor receptor (EGFR) amplification and TP53 mutations.
	1383.	MUC1 regulates p53-responsive genes and thereby cell fate in the genotoxic stress response
	1384.	TP53 pathway is invslved in the carcinogenesis ofHepatic undifferentiated (embryonal) sarcoma.
	1385.	Phosphorylation of p53 plays a crucial role in detection and interaction with sites of DNA damage and unusual DNA structures.
	1386.	Many p53-defective tumors retain activity of the apoptosome, which is therefore a potential target for cancer chemotherapy. Inhibition of ACS may be a novel strategy to induce the death of p53-defective tumor cells
	1387.	inhibition in HTLV-1-transformed cells is regulated by activated AKT
	1388.	p53-induced apoptosis may be important for efficient cell lysis and viral spread and that E1B-19K may neutralize the apoptotic activity of p53 at multiple levels
	1389.	TP53 gene mutations alone are not likely to represent a widely useful prognostic marker of the risk of progression to malignancy, at least not in Barrett's esophagus without dysplasia.
	1390.	Results describe the opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.
	1391.	transglutaminase 2 (TG2) modification of p53 could be an additional mechanism whereby TG2 could facilitate apoptosis
	1392.	Myc overexpression causes DNA damage in vivo and the ATM-dependent response to this damage is critical for p53 activation, apoptosis, and the suppression of tumor development
	1393.	the VEGF system is integrated into the p53 transcriptional network by an SNP in the flt-1 promoter
	1394.	identification of a second binding site helps stabilize the interaction between HDM2 and p53 during p53 degradation
	1395.	Hghly modular role for the L1 loop in the recognition of specific DNA sequences, target transactivation, and apoptotic signaling by p53.
	1396.	p53 as a determinant of the response to oncogene inhibition
	1397.	p53 and c-erbB-2 may have independent role in carcinogenesis of gall bladder cancer
	1398.	the TP53 codon 72 polymorphism could be associated with susceptibility for adrenocortical cancer
	1399.	data indicate that a mutant p53 can contribute to the suppression of apoptosis in a human breast cancer cell line and suggest a rationale for the selection of p53 mutations early in tumorigenesis to suppress apoptosis in an emerging tumor
	1400.	The DU145 cell line harbors a TS mutant of p53 and, in addition to being a widely used model of human prostate carcinoma, may also reveal new insights into p53 function due to the unique transcriptional properties of its TS phenotype.
	1401.	Epigenetic alteration of XAF1 is frequent in human urogenital cancers and may contribute to the malignant progression of tumors by rendering tumor cells a survival advantage partially through the attenuated p53 response.
	1402.	Our results provide evidence of how poliovirus counteracts p53 antiviral activity by regulating PML and NBs, thus leading to p53 degradation.
	1403.	p53 family proteins are potent therapeutic agents for human papilomavirus-associated uterine cervical cancers.
	1404.	high level of p53 protein in cPNETs measured by immunostaining intensity associated with poor patient survival
	1405.	p53 mutational pathway may favor selection for ErbB2 gene amplification during tumor progression in breast cancer
	1406.	MDMX-mediated regulation of p53 activity during development.
	1407.	Mutations in exons 4-10 of the p53 gene in acute myeloid leukemia patients screened in an epidemiologic study in Brazil were found to correlate with poor prognosis and to occur at frequencies similar to those reported for Northern America and Europe.
	1408.	description of a novel MDM2 binding interface in p53 that plays a regulatory role in MDM2-dependent ubiquitination of p53
	1409.	These results indicate that p53 and BLM functionally interact during resolution of stalled DNA replication forks and provide insight into the mechanism of genomic fidelity maintenance by these nuclear proteins.
	1410.	p53 mutations were found in 70% of pancreatic adenocarcinoma cell lines and 33% of primary tumors. p53 missense mutations correlated with more frequenct metastases to all sites.
	1411.	sequestration of replication protein A by p53 at the sites of recombination is one means by which p53 can inhibit homologous recombination processes
	1412.	We investigated three common sequence variants in TP53 and p21 for possible associations with the risk of breast cancer and with various phenotypic features of this disease
	1413.	Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
	1414.	The presence of E-cadherin mutations can significantly alter the accumulation of the apoptosis-regulating p53 protein, whereas no correlation with the p53 mutation status or with Ki-67 staining was observed.
	1415.	DeltaN-p63-alpha mediates the silencing of its own promoter thereby altering the pattern of p53-target gene expression.
	1416.	a productive human herpesvirus 6B infection suppresses T-cell proliferation concomitant with the phosphorylation and accumulation of p53
	1417.	Nitric oxide depletion reduces the presence of p53-DNA complexes after cisplatin treatment.
	1418.	Constitutive dephosphorylation at Ser 376 correlated with the nuclear accumulation of p53, but not with the transcriptional activity of the protein in glioma.
	1419.	Colorectal cancers not expressing hMLH1 or hMSH2 may have distinct features from those expressing these mismatch repair proteins. p53 expression appears to be implicated in a compensatory pathway with mismatch repair proteins.
	1420.	UV-induced DNA damage in epidermal KCs triggers p53 activation and apoptosis. Lack of activation in aging KCs and psoriatic Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes
	1421.	RNA polymerase III transcription can be derepressed by mutations that compromise p53 function in tumours and Li-Fraumeni syndrome. Substitution R175H, the most common mutation in cancers, converts p53 from a pol III repressor to an activator.
	1422.	Refolding and structural characterization of the human p53 tumor suppressor protein.
	1423.	Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
	1424.	HSU94788 may not be the wild-type p53 sequence. AF136270 and AF135120 may be the correct wild-type intron 7 sequences.
	1425.	We show a novel alternative pathway of apoptosis in human primary cells that is mediated by transcriptionally dependent decreases in p53 and c-Myc and decreases in p21.
	1426.	p53 protein transport in hepatoma cells with VP22
	1427.	P53 mediates ceramide-induced apoptosis in SKN-SH cells
	1428.	The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China.
	1429.	Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species.
	1430.	p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling
	1431.	ING1 has a subtle antiproliferative effect even in the absence of p53, and ING1b enhances the DNA damage responses through p53-dependent and -independent mechanisms.
	1432.	hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53
	1433.	High p53 protein level is associated with advanced TNM stage and positive nodal status of squamous cell carcinoma of hypopharyngeal cancer
	1434.	SCN3B mediates a p53-dependent apoptotic pathway and may be a candidate for gene therapy combined with anticancer drugs.
	1435.	p53 gene mutation may be an early event in esophageal carcinogenesis
	1436.	TP53 mutation has only a limited role in the transformation of lymphoma to diffuse large B-cell lymphoma, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent.
	1437.	indicate a novel translational control of p53 gene expression and activity
	1438.	These data provide evidence that in addition to the COOH-terminal residues, p53 may also be ubiquitinated at sites in the DNA-binding domain.
	1439.	some isoforms of p63 serve as a pro-survival factor by up-regulating GPX2 to reduce the p53-dependent oxidative stress-induced apoptotic response
	1440.	E6AP is extensively involved in the ubiquitin-mediated degradation of p53 (an HPV E6-dependent substrate) as a cellular E3 ubiquitin-protein ligase.
	1441.	Alleles and smoking play a significant role in modified prostate cancer risk in this study population.
	1442.	serum p53 protein may have a role in hepatocellular carcinoma
	1443.	We demonstrated that p53 wild-type protein nuclei accumulation is associated with GEP protein expression in human HCC specimens, and GEP modulates p53 wild-type protein levels in vitro.
	1444.	Somatic chromosomal mutations, especially in exon 6 of Tp53 gene, among esophageal cancer patients of an ethnically homogenous population of Kashmir valley are closely related to continued exposure to various common dietary risk factors.
	1445.	hHR23B thus plays a critical role in the activation and function of p53 after specific genotoxic exposures.
	1446.	In transfected cells and KSHV-infected B lymphoma cells, KSHV-encoded latency-associated nuclear antigen (LANA) expression stimulates degradation of tumor suppressors von Hippel-Lindau and p53.
	1447.	study found associations of risk haplotypes and protective haplotypes in p53 for glioblastoma and in ATM for meningioma; study provides new data that could add to our understanding of brain tumour susceptibility
	1448.	Our results imply that HERV-I LTR, while under negative control by its LTR cis-elements and by wild type p53, may become active upon p53 mutation
	1449.	p53 expression in gastric cancer was associated with poorer survival and was an independent predictor of tumor behavior and patient response to therapy.
	1450.	Mutations of p53 were associated with lymph node metastases and III/IV stage of tumors that are signs of unfavorable prognosis in colorectal cancer.
	1451.	Bub1 compromise triggers p53-dependent senescence, which limits the production of aneuploid and potentially cancerous cells.
	1452.	Efficient repair of bulky anti-BPDE DNA adducts from non-transcribed DNA strand requires functional p53 but not p21(waf1/cip1) and pRb.
	1453.	Identification of a novel mouse gene, mRTVP-1, as a p53 target gene. The mRTVP-1 protein has 255 amino acids and differs from the human RTVP-1 protein by two short in-frame deletions of two and nine amino acids. (mRTVP-1)
	1454.	These results demonstrate direct activation of the human DDB2 gene by p53. The corresponding region in the mouse DDB2 gene shared significant sequence identity with the human gene but was deficient for p53 binding and transcriptional activation.
	1455.	SAK repression by p53 is likely mediated through the recruitment of HDAC repressors, and SAK repression contributes to p53-induced apoptosis
	1456.	NPM inhibits ionizing irradiation-induced p53 transactivation, and interacts with p53 in hematopoietic cells.
	1457.	the p53-HDM2 interaction can be inhibited by a newly isolated hexylitaconic acid from the marine-derived fungus, Arthrinium
	1458.	Both kinetics and free energy landscape analyses indicate that bound MDM2 unfolds in the order of p53 unbinding, tertiary unfolding, and finally secondary structure unfolding.
	1459.	the expression of p53 is very probably involved in the regulation of leukemic hematopoiesis and that the inhibition of p53 expression could modulate the proliferation of leukemic cells.
	1460.	p53 and c-fos are significantly overexpressed in thyroid cancer patients, indicating their role in the genetic mechanisms leading to thyroid tumorigenesis
	1461.	Mutation of human thioredoxin reductase 1 promotes p53-dependent gene expression
	1462.	MDMX, when exceedingly overexpressed, inhibits MDM2-mediated p53 degradation by competing with MDM2 for p53 binding
	1463.	bcl-2/Jh lymphomas show molecular heterogeneity and that bcl-6 and p53 mutations may be acquired during the evolution of such lymphomas
	1464.	Thus, the accumulation of mutant p53 in tumor cells may contribute to tumorigenesis by inhibiting stress-inducible kinase pathways.
	1465.	p53-induced transcription is inhibited by SINK-homologous serine-threonine kinase
	1466.	p53 gene mutations might be a main causal factor for carcinogenesis for gynecological neoplasms.
	1467.	p53 must be dephosphorylated on serine residues during N-alpha-tosyl-L-phenylalanyl chloromethyl ketone-induced apoptosis
	1468.	expression of iNOS, P53 and Bax in the gallbladder wall
	1469.	when p53 protein levels increase, it contributes to its own demise by up-regulating the transcription of S100B protein as part of a negative feedback loop
	1470.	association between genetic polymorphisms of GSTT1, p53 codon 72 and bladder cancer in southern Taiwan
	1471.	Data show that Topors enhances the conjugation of the small ubiquitin-like modifier 1 (SUMO-1) to p53 in vivo and in a reconstituted in vitro system.
	1472.	observations identify hMutL proteins as regulators of p53 response and demonstrate for the first time a function of hMLH1-hPMS1 complex in controlling the DNA damage response
	1473.	age dependent phosphorylation of p53 protein and deregulation of p53 gene has a role in the development of human vestibular schwannomas
	1474.	Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study
	1475.	expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma
	1476.	Evaluation of relationship between chromosome 22 and p53 gene alterations and the subtype of meningiomas by the interphase-FISH technique.
	1477.	identified a global suppressor motif involving codons 235, 239, and 240
	1478.	p53 is associated with the telomeric complex in alternative lengthening of telomeres (ALT) cells; inhibition of DNA synthesis in ALT cells by p53 requires intact specific DNA binding and suppression of recombination functions.
	1479.	p53 plays an important role in PP2C alpha-directed cell cycle arrest and apoptosis
	1480.	investigated whether Tat might alter p53 acetylation and p53-responsive transcription; results allude to mechanism where the HIV-1 trans-activator might impair tumor suppressor functions favoring establishment of neoplasia in AIDS
	1481.	Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
	1482.	summarize the current understanding of post-translational modifications and their effect on conformation-based functional relationship between Mdm2 and p53
	1483.	CARF is co-regulated with ARF and cooperates with it in activating p53
	1484.	Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.
	1485.	Caffeine induces cell cycle arrest and apoptosis in association with activation of p53 by a novel pathway to phosphorylate the Ser-15 residue and induction of phosphorylation of cdc 2 in leukemic cells with normal p53.
	1486.	activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner
	1487.	p53-induced apoptosis inhibited by activated Notch1
	1488.	inactivation of p53 is a protective mechanism utilized by cells to adapt to ER stress.
	1489.	Hsp90 is required to maintain the folded, active state of p53 by a reversible interaction
	1490.	Hsp90 chaperone activity is important for the transcriptional activity of genotypically wild-type p53
	1491.	mutations in rheumatoid arthritis synovium
	1492.	p53 is acetylated by tumor necrosis factor alpha, then p53 attenuates its trans-activation by depleting CREB binding protein in rheumatoid synoviocytes
	1493.	this gene regulates the matastasis suppressor gene Nm23 in cultured tumor cells.
	1494.	Integrin alphav controls melanoma cell survival in 3D-collagen through a pathway involving p53 regulation of MEK1 signaling.
	1495.	p53 antagonizes c-Myb by recruiting mSin3A to down-regulate specific Myb target genes
	1496.	Activation domain 2 of p53 is required for induction of the proapoptotic target gene insulin-like growth factor binding protein 3 (IGFBP3) and p53 basic domain inhibits induction of this gene.
	1497.	Data suggest that securin is a p53 target gene and may play a role in p53-mediated cellular response to DNA damage.
	1498.	Codon 249 mutation in exon 7 of this gene in plasma DNA may be a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.
	1499.	p53 expression may have a role in progression of inflammatory breast cancer
	1500.	TP53 does not have a role in the histologic response to chemotherapy in patients with osteosarcoma, but its mutation may be associated with disease progression
	1501.	decreased cell-surface expression of Fas and resistance to Fas-mediated apoptosis may occur independently of loss of wt p53 expression in esophageal adenocarcinoma
	1502.	an apoptosis-deficient Pro allele of the p53 gene may be related to psoriasis resistance to UV-based therapy
	1503.	Study reports the first unequivocal case of a ganglioglioma harboring aberrant TP53 product that was expressed predominantly in the neuronal component.
	1504.	We propose that induction of NQO2 may relate to the observed increased expression of p53 that, in turn, contributes to the observed suppression of cell growth in both melanoma cell lines.
	1505.	A proteasome inhibitor, lactacystin, enhances TNFalpha cytotoxicity in p53-positive and -negative cells.
	1506.	4-oxo-2-nonenal, a lipid peroxidation product is a potential trigger of the p53 pathway
	1507.	an independent prognostic marker in stage III colrectal carcinoma
	1508.	Expressions of p53 proteins should be useful for determining the tumor properties, including prognosis, in patients with esophageal squamous cell carcinoma.
	1509.	HIPK2 cooperates with p53 in Gal-3 repression and that this cooperation requires HIPK2 kinase activity.
	1510.	The p53-46F mutant with enchanced ability to induce p53-dependent apoptosis was reported.
	1511.	p53 is functional in the absence of p14(ARF) in malignant pleural mesothelioma
	1512.	Klotho normally regulates cellular senescence by repressing the p53/cyclin-dependent kinase inhibitor 1A pathway
	1513.	transcriptional activation of the IGF-IR gene by Cav-1 requires an intact p53 signaling pathway
	1514.	1,25 dihydroxyvitamin D3 photoprotection is associated with an increase in p53 and a decrease in nitric oxide products
	1515.	the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin' destroys p53
	1516.	a genetic instability of the 17p13 region, occurring early in adrenocortical cancer development, involves various genes located in this region, including TP53
	1517.	modified LDL results in an increased transfer of mitochondria-derived superoxide anion to p53, which stimulates a conformational change in Bax favoring its translocation to the mitochondria with resultant apoptosis of progenitor cells
	1518.	Cancer-associated mutant p53 can augment the induction of nuclear factor kappaB (NFkappaB) transcriptional activity in response to the cytokine tumor necrosis factor alpha (TNFalpha).
	1519.	this study reveals protein targets of p53 and highlights the role of transcription-independent effects for the p53-induced biological response
	1520.	The ability of mutant p53 to prevent arrest induced by replicational stress per se is primarily dependent on preventing p21CIP1 up-regulation.
	1521.	p53 represses TauT and is involved in renal development and apoptosis.
	1522.	potential improvement of the International Prognostic Scoring System by the addition of molecular analysis to the system, with particular reference to the configuration of the TP53 gene
	1523.	Comprehensive site-directed mutagenesis technique & a yeast-based functional assay were used to construct, express, & evaluate 2,314 p53 mutants representing all possible AA substitutions caused by a point mutation throughout the protein.
	1524.	the expression of DAP kinase, p19ARF, p53, and p21WAF1 was significantly down-regulated in the chronically HIV-1SF2-infected HUT78 T cells
	1525.	Loss of p21 and/or p53 might not predict for prognosis in oropharnyggeal squamous cell carcinoma.
	1526.	deacetylated p53 can transactivate the p21Waf1 gene
	1527.	Abnormality of the p53 pathway was detected in cervix cancer and in CINs.
	1528.	use of p53MH algorithm in detection of p53-responsive genes
	1529.	the inhibitory protein c-FLIP(L) is involved in resistance to CD95-mediated apoptosis in ovarian carcinoma cells with wild-type p53
	1530.	Cyclin D1, p53, and p21Waf1/Cip1 have roles in progression of serous epithelial ovarian cancer
	1531.	Data show that squamous cell carcinoma cells escape suspension-induced, p53-mediated anoikis by forming multicellular aggregates that use fibronectin survival signals mediated by integrin alpha(v) and focal adhesion kinase.
	1532.	mtCLIC/CLIC4, an organellular chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53.
	1533.	Data show that aspirin decreases endothelial cell proliferation through cell cycle arrest mediated by enhanced p53 expression.
	1534.	p53 participates in a feedback mechanism with JNK to regulate the apoptotic process and is oppositely regulated by JNK1 and JNK2.
	1535.	Mutations in proline 82 of p53 impair its activation by PIN1 and CHK2 in response to DNA damage.
	1536.	ATM directly activates p53 while activating a safe-lock mechanism to inactivate the negative regulators of p53, Mdm2, and Mdmx [review]
	1537.	p53 undergoes ubiquitin-independent degradation by the 20S proteasomes and that this process is regulated by NAD(P)H quinone oxidoreductase 1 (NQO1) together with NADH [review]
	1538.	Our results indicate that the TP53 P allele is associated with a worse prognosis (P=0.011) while P21 polymorphism genotypes did not reveal any statistically significant result (P>0.05).
	1539.	The low-molecular-weight compound PRIMA-1 restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells.
	1540.	PolH has a novel role in the DNA damage checkpoint, and a p53 target can modulate the DNA damage response and subsequently regulate p53 activation.
	1541.	Data suggest a model in which p53 directly recruits a TRRAP/acetyltransferase complex to the mdm2 gene to activate transcription. In addition, this study defines a novel mechanism utilized by the p53 tumor suppressor to regulate gene expression.
	1542.	The results indicate that overexpressed ER-beta may induce LoVo cell apoptosis and anti-proliferation by increasing p53 signaling in a ligand-dependent manner, and without hTNF-alpha involvement.
	1543.	In this study, the p53 protein immunoreactivity was not a marker of malignant transformation of chronic actinic cheilitis to squamous cell carcinoma.
	1544.	presence of a codon 72 of p53 germline variant genotype increased the risk for HHV6 infection more than five times after kidney transplant
	1545.	Caspase 7 promoter was found to have p53-binding sites and prohibitin activated this promoter through p53.
	1546.	whereas exogenous p73 exhibits similar transcriptional activity to p53 in H1299 cells, the endogenous p73 that accumulates upon DNA damage in HCT116 cells is unable to compensate for p53 function
	1547.	role in regulating expression of 67-kDa laminin receptor precursor 37LRP
	1548.	Expression of c-erbB-2 and p53 has no prognostic value in patients with early-stage breast cancer in which axillary lymph node metastasis is absent.
	1549.	hypoxia may decrease tumor cell radiosensitivity through the suppression of p53 activity in some tumor cell lines
	1550.	p53 is not required for LKB1-induced apoptosis in pancreatic neoplasms
	1551.	p53 induced by ionizing radiation requires IFI16
	1552.	To determine whether genotoxic stress regulates DNA binding by p53 in vivo, we have performed quantitative chromatin immunoprecipitation (ChIP) assays on tumor and normal cell lines containing wild-type p53
	1553.	Induction of gene amplification is a gain-of-function phenotype of mutant p53 proteins.
	1554.	TP53 has a role in aortal endothelial cell aging
	1555.	role in enhancing MUC2 mRNA expression
	1556.	two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53
	1557.	Perturbations of chromosome 17 in general and the p53 locus in particular occur frequently in severe/late stage endometriosis.
	1558.	Mutation of p53 gene endows gliomas with an angiogenic phenotype by reducing thrombospondin-1 production as well as enhancing the angiogenesis inducers in the early phase of malignant progression.
	1559.	p53-dependent apoptosis triggered by fast neutrons in lymphoid cells requires caspase 8-mediated BID cleavage
	1560.	modulation of level by cyclin G via a negative feedback reglation
	1561.	mutations induce loss of DNA methylation and amplification of the TROP1 gene
	1562.	P-53 over-expression can occur in initial stages of HCV-related liver disease.
	1563.	half-life (t(1/2)) of the unfolding of highly destabilized mutants
	1564.	p53 is inactivated by leukemic protein MLL-ELL
	1565.	tp53 has a role in recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage
	1566.	The frequency of p53-positive patients is relatively low in T-ALL (29%) and B-CLL (16%). B-ALL, AML and CML patients revealed higher frequency of p53 protein.
	1567.	The levels of p53 protein elevated in keloid, hypertrophic scar and white and hard hypertrophic scar
	1568.	p53 inactivation caused by HPV infection may play a role in the pathogenesis of colon cancer
	1569.	The presence of wild-type p53 increased survival of prostate carcinoma cells after fractionated exposure to radiation.
	1570.	Tumor cells with wild-type p53 activity exhibited up-regulation of surface CD95 after ionizing irradiation.
	1571.	p53 is an important mediators of chemoresistance in ovarian cancer cells.
	1572.	p53-dependent apoptosis requires BOK and NOXA
	1573.	MNNG induces apoptosis in lymphoblastoid cells by activating the p53-dependent Fas receptor-driven pathway.
	1574.	Regulation of cyclin E expression plays a role underlying numeral homeostasis of centrosomes in human bladder cancer cells and that deregulation of cyclin E expression, together with inactivation of p53, results in centrosome amplification.
	1575.	Results demonstrated a novel function of Ser(392) phosphorylation in regulating the oncogenic function of mutant p53.
	1576.	Tumorigenesis pathway independent of p53 dysfunction appears to exist in association with ulcerative colitis.
	1577.	HHV-6 has a mechanism for retaining p53 within the cytoplasm and protects the infected cells from apoptosis.
	1578.	eIF5A may be a regulator of p53, and syntenin might regulate p53 by balancing the regulation of eIF5A signaling to p53 for apoptosis
	1579.	p53 gen mutation analysis may be useful in the follow-up of at-risk patients, and introduces new possibilities to analyse molecular markers before malignant lesions are clinically apparent.
	1580.	TP53 function closely influences the decision between apoptosis and growth arrest following Fatty acid synthase blockade
	1581.	mechanism of p53 regulation originating through alternative splicing of the human p53 gene resulting in the expression of a novel p53 mRNA
	1582.	Serine 392 exerts important effects upon p53 stability via the inhibition of its nuclear export mechanism.
	1583.	MDR functional phenotype could be associated with p53 mutation in the advanced stage of leukemias
	1584.	herpesvirus saimiri (HVS) ORF73 binds both p53 and pRb in vitro and in vivo, colocalizes with p53 in T cells infected with HVS, and in cells overexpressing both ORF73 and p53, and adversely influences pRB/E2F and p53 transcriptional regulation
	1585.	in tumor cells lacking functional p53 and/or p21, p14(ARF) impaired mitotic entry and enforced a primarily cytoplasmic localization of p34(cdc2) that was associated with a decrease in p34(cdc2) kinase activity and reduced p34(cdc2) protein expression
	1586.	Excision of nucleoside analogs from DNA by p53 protein suggests a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase
	1587.	Nuclear genetic polymorphisms related to oxidative stress or apoptosis may modify the age at onset of Leber's hereditary optic neuropathy (LHON).
	1588.	GSK3-dependent phosphorylation of Mdm2 regulates p53 abundance
	1589.	The Aberrant expression of p53 Genes were determined in bone marrow samples of children with de novo B-lineage (n=170) and T-lineage (n=25) acute lymphoblastic leukemia (ALL).
	1590.	P53 is probably involved in the development of conjunctival and eyelid tumors due to its high rate of presence in both benign and malignant neoplasms of these organs.
	1591.	the presence or absence of wild-type p53, may be an important determinant of response to antiangiogenic therapy
	1592.	These results demonstrate that overexpression of Activating transcription factor 3 (ATF3) suppresses tumor necrosis factor-alpha-induced cell death of HUVECs, at least in part, through down-regulating the transcription of p53 gene.
	1593.	This protein is required for the Nuclear localization of Y-box factor YB1.
	1594.	p53 accumulation and loss of bax expression influence the acquisition of a malignant phenotype but seem to have no further impact on tumor progression.
	1595.	This additivism, where doxorubicin acts via p53 expression and vinorelbine through p38 MAP KINASE activation, may contribute to the high clinical response rate when the two drugs are used together in the treatment of breast cancer.
	1596.	p53 mutations reflected histological progression in Barrett's patients with p53 mutations found in 30% of metaplasia patients (P=0.4) and low-grade dysplasia patients (P=0.33).
	1597.	The detection of mutant p53 protein in hepatocellular cancer is corellated with clinicopathologic parameters and incidence of the liver neoplasms in Turkey.
	1598.	L11 functions as a negative regulator of HDM2 and there might exist in vivo an L11-HDM2-p53 pathway for monitoring ribosomal integrity
	1599.	proline-directed acetylation of p53 is a post-DNA binding event
	1600.	there may be a p53-dependent regulatory pathway of the maspin protein in human cancer
	1601.	p53-dependent cell fate is determined by E1A-binding p300 nucleoprotein
	1602.	in sensitive organs mitochondrial p53 accumulation in vivo occurs soon after a death stimulus
	1603.	Plk3 is a RelA-NF-kappaB-regulated gene that induces apoptosis in both p53-dependent and -independent signaling pathways
	1604.	The HIF-1alpha ODD domain binds weakly to the isolated p53 core domain but tightly to full-length p53 to give a complex of one HIF-1alpha ODD domain with a p53 dimer.
	1605.	mutant p53 is reactivated and apoptosis is induced by maleimide analogs in human tumor cells
	1606.	Expression of p53 in renal carcinoma cells is independent of VHL.
	1607.	p53 isoforms can regulate p53 transcriptional activity.
	1608.	Tumor suppressor molecule p53 maintains mitochondrial genetic stability through its ability to translocate to mitochondria and interact with mtDNA polymerase gamma (pol gamma) in response to mtDNA damage.
	1609.	analysis of the role of HTLV I Tax in p53 inhibition in leukemia [review]
	1610.	induction of transcription is mediated by HIC1 p53-responsive element
	1611.	DNA hypermethylation of p53 was detected in a quarter of the low-grade, low-stage transitional cell carcinomas(TCC) and undifferentiated small cell carcinomas, but only sporadically in squamous cell carcinomas, and was absent in high-grade, high-stage TCC
	1612.	expression of p53 is essential for cytotoxic effect of cisplatin in human malignant glioblastoma cells, A172 and T98G, and introduction of apoptotic signal molecules, such as p53, will be beneficial to achieve chemosensitivity in malignant glioma
	1613.	p53 overexpression in esophageal cancer tissue is positively associated with the presence of the Arg allele of the p53 codon 72 polymorphism
	1614.	Our results indicate that chromatin alteration in interstitial chromosomal regions is the most likely cause of continuous activation of p53, which results in the induction of SLGA by ionizing radiation.
	1615.	The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a mutational hotspot in hepatocellular carcinoma. 4-HNE may cause human cancers with mutations at codon 249 of p53 gene.
	1616.	Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck
	1617.	Mutations of p53 gene were present in 24% (5 of 21) of the evaluable cases, all of them overexpressing p53 in the majority of tumor cells.
	1618.	TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene
	1619.	The detected pattern of the p53/ bcl-2 ratio in hypertrophic actinic keratosis suggests important role for another gene: the proapoptotic gene bax.
	1620.	p53 mutation [p53(R273H)], is frequently found in human cancers.
	1621.	The homeodomain of Msx1 functions as a protein-protein interacting motif rather than a DNA-binding domain and is essential for stabilization, nuclear accumulation, and apoptotic function of wild-type p53.
	1622.	mutants of p53 may induce loss of drug sensitivity is via the NF-kappaB2 pathway
	1623.	The data was obtained that establishes the contribution of the transcription-independent mitochondrial p53 pathway to apoptosis of primary cells in response to deregulated oncogenes.
	1624.	p33ING1b prominently enhances etoposide-induced apoptosis through p53-dependent pathways in human osteosarcoma cells.
	1625.	pathogenesis of nasopharyngeal carcinoma in children may involve EBV infection leading to LMP-1 expression and p53 overexpression
	1626.	Akt enhances Mdm2-mediated ubiquitination and degradation of p53.
	1627.	role in inducing CD95 gene expression in endothelial cells exposed to doxorubicin
	1628.	acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases
	1629.	Purification, crystallization and preliminary X-ray analysis of the BRCT domains of human 53BP1 bound to the p53 tumour suppressor
	1630.	p53 gene mutation is an independent predictor of poor prognosis in colorectal cancers
	1631.	Fibrillar aggregates of the p53 core domain contribute to the loss of function of p53 and seed the accumulation of conformationally altered protein in some cancerous cells.
	1632.	role of pathway in regulating G1-S transition and apoptosis along with RFT
	1633.	Emerging evidence in this review discusses a key survival/death checkpoint in both peripheral and central neurons that involves the p53 tumor suppressor and its newly discovered family members, p73 and p63.
	1634.	analyses of statistical interactions between polymorphisms (p73 G4A, p53 Arg72Pro and p21 Ser31Arg polymorphisms) revealed the marginally significant risk of non-Hodgkin's lymphoma for interaction between p53 Arg72Pro and p73 G4A polymorphisms
	1635.	inverse relationship seen between HPV infection and p53 positivity suggests loss of p53 function in cervical cancer, either by binding to E6 oncoprotein of HPV or by mutation in p53
	1636.	minor role of exon 5-9 among Sudanese breast cancer patients
	1637.	enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics
	1638.	Mutations for basal cell carcinoma (BCC), were screened in 15 cases of sporadic BCCs that developed in sun-exposed skin region in a Korean population
	1639.	p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation.
	1640.	Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
	1641.	Many genes are affected by TP53 gene dosage for their expression. We report several candidate genes as potential downstream targets of p53 in nonstressed cells. Among them, CSPG2 is validated as being directly transactivated by p53.
	1642.	Results identify a 22-mer peptide derived from the p53 core domain (peptide 14), which inhibits p53-specific DNA binding, and may prevent inappropriately-triggered apoptosis in normal tissues.
	1643.	Ras appears to attenuate p53 in SW480 cells by two independent regulatory mechanisms, the one leading to increased Mdm2-dependent p53 degradation and the other leading to a decrease in p53 transcription.
	1644.	activation of the DNA DSB checkpoint provides the selective pressure for the high frequency of p53 inactivation in human cancer [review]
	1645.	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.
	1646.	Syncytia from cells expressing the HIV-1 Env gene fused with cells expressing CD4/CXCR4 undergo apoptosis after nuclear translocation of mTOR, mTOR-mediated p53 phosphorylation, p53-dependent Bax upregulation & mitochondrial death pathway activation.
	1647.	expressed in biopsies from children with Langerhans cell histiocytosis
	1648.	Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
	1649.	both HPV infection and p53 gene abnormalities may contribute to Bilharzial bladder carcinogenesis in an independent way
	1650.	Aberrant HPLC chromatographies were found in tumor tissues, while their normal-adjacent counterparts running in parallel showed a normal shape.
	1651.	results suggest that SAP contributes to the execution of some p53 functions
	1652.	describes that lactoferrin specifically transactivates the p53 tumor suppressor gene through the activation of nuclear factor-kappaB and consequently regulates p53-responsive oncogenes
	1653.	The p53 codon 72 gene polymorphism is not associated with the susceptibility of leiomyomas.
	1654.	The results suggest that I3C represses cell proliferation through up-regulation of NAG-1 and that ATF3 may play a pivotal role in DIM-induced NAG-1 expression in human colorectal cancer cells.
	1655.	Two cases of lymphomatoid palulosis with mutated p53 gene in biopsy showed no progression of disease in 5 yr follow up. May not play any significant role in the pathogenesis, progression or transformation of cutaneous CD30(+) lymphoproliferative diseases.
	1656.	P53-negative AsPC-1 cells are resistant to p53-mediated apoptosis.
	1657.	expression has an independent effect on prediction of survival, progression, and development of metastasis in transitional cell bladder carcinoma
	1658.	NO induces the accumulation of transcriptionally active p53 in a variety of cell types and NO signaling to p53 does not require ataxia telangiectasia-mutated (ATM), poly(ADP-ribose) polymerase 1, or the ARF tumor suppressor protein
	1659.	Interacts with WT1 in insulin-like growth factor-I receptor gene regulation
	1660.	p53 protein was estimated by immunohistochemistry of beta-catenin and p53 proteins in colorecta mucinous carcinoma.
	1661.	Phosphorylation of p53 on N-terminal serine residues is not required for increased transcription of most p53-responsive genes. Induction of p53 by p14ARF, with little phosphorylation, leads to substantial repression of genes with roles in proliferation.
	1662.	p53 interacts with RNA via its C-terminal domain; oligomerization of p53 is significantly enhanced by disrupting this. Binding of RNA to p53 is involved in the mechanism of p53 latency.
	1663.	NDRG1 is necessary but not sufficient for p53-mediated caspase activation and apoptosis
	1664.	p53 is an essential effector of PKCdelta in human colon cancer cells
	1665.	The p53 Pro allele is associated with an increased frequency of p53 mutations in non-small cell lung cancer.
	1666.	Data show that the status of codon 72 polymorphism and p53 mutations can be used as a means for prediction of treatment response, although variables for each cancer type requires detailed evaluation.
	1667.	p53 represses myelocytomatosis oncogene c-myc transcription through a mechanism that involves histone deacetylation
	1668.	Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index.
	1669.	DNA-PK and p53 may form a sensor complex that detects the disruption of DNA replication caused by nucleoside analogue incorporation and may subsequently signal for apoptosis.
	1670.	different genotype combinations of p53 and GSTM1 increase the risk of developing specific histological subtypes of NSCLC.
	1671.	Nucleophosmin (NPM) interacts directly with p53, regulates the increase in stability and transcriptional activation of p53 after different types of stress, and induces p53-dependent premature senescence on overexpression in diploid fibroblasts
	1672.	p53 controls global nucleotide excision repair of low levels of structurally diverse benzo(g)chrysene-DNA adducts in human fibroblasts.
	1673.	p53 activity is regulated by 14-3-3 sigma
	1674.	Association association between lack of response to 5-fluorouracil and mitomycin and mutations affecting the L2/L3 domains of the p53 protein.
	1675.	BRCA1-BARD1 complexes act as an adaptor to mediate phosphorylation of p53, influencing G(1)/S cell cycle progression after DNA damage.
	1676.	activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 are induced during tumor cell differentiation by beta-catenin
	1677.	We thus identified ik3-2 as a proapoptotic factor involved in both p53-mediated and p53-independent apoptotic pathways.
	1678.	binding and activation of PIG3 promotoer via a pentanucleotide microsatellite sequence
	1679.	The restoration of wild-type p53 expression and function in human autologous lung carcinoma IGR-Heu cells results in a significant potentiation of target cell susceptibility to cytotoxic T cell-mediated lysis.
	1680.	cloned and characterized a p53 consensus element located within the first intron of the TRAIL-R3 gene
	1681.	Daxx significantly augmented p53-mediated transcription and the Adenovirus E1B 55-kDa protein eliminated this effect.
	1682.	small airway epithelial cells expressing a p53 mutant alleles were able to inhibit endogenous p53 activity; only one allele, 248W demonstrated a markedly increased ability to facilitate E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) replication
	1683.	combined expression of p53 and metallothionein did not improve the predictive value for recurrence compared to MT alone
	1684.	Downregulation of p16(INK4a) and loss of wild-type p53 expression occurs after escape from cell immortalization.
	1685.	mutations in TP53 do not have a role in formation of human cerebral vascular malformations
	1686.	Protein tyrosine phosphatase 1-B levels increased with introduction of wt p53 and may be involved in the dephosphorylation of Janus kinase 2
	1687.	estimation of the sensitive positions to mutations in human p53 protein
	1688.	R273H removes an arginine involved in DNA binding, H168R and R249S induce substantial structural perturbation around the site
	1689.	p53 might play a similar role in certain tissue stem cells and suppress the development of cancer stem cells [review]
	1690.	p14ARF induces p53-dependent cell cycle arrest but not apoptosis
	1691.	Transactivation-dependent apoptosis does not always play a major role in p53-dependent apoptosis, indirectly supporting the importance role of the transactivation-independent mechanism.
	1692.	that wt-tumor protein p53 gene transfer inhibits interleukin 8 production and NF-kappaB transcription activity in cancer cells
	1693.	p53-specific serum antibodies are not associated with a history of skin carcinoma in renal transplant recipients and immunocompetent individuals.
	1694.	p53 is induced by urokinase in lung epithelial cells
	1695.	Transcriptionally active p53 is required for nuclear localization of Y-box-binding protein (YB1).
	1696.	p53 codon 72 genotypes are associated with the age of onset of colorectal carcinoma in a mismatch repair deficient background in a dose dependent manner
	1697.	IFN-alpha plus IFN-gamma triggers apoptosis independent of p53 in HaCaT cells, and also demonstrate an unexpected survival role for p53 in human KCs as regards apoptotic responsiveness to cytokines
	1698.	P53 interferes with the TAD-truncated p73alpha-mediated activation of NFkappaB.
	1699.	Mutations do not confer a growth advantage to somatic heterozygous clusters or maintenance turnover units.
	1700.	p53 gene alterations may be involved in Balkan endemic nephropathy genetic pathways.
	1701.	Findings suggest TP53 allele combinations other than Arg/Arg may contribute to the risk of development of papillary thyroid cancer in individuals exposed to radiation during their late childhood, adolescence or in young adulthood.
	1702.	Findings support the hypothesis that p53 mutations are homogeneous throughout a tumor and may thus be a more useful diagnostic and prognostic indicator.
	1703.	Data suggest that detection of mutated p53 could be a useful serological marker for diagnostic purposes.
	1704.	results indicate that KSHV vIRF1 comprehensively compromises an ATM/p53-mediated DNA damage response checkpoint by targeting both upstream ATM kinase and downstream p53 tumor suppressor
	1705.	caspase-6 and its cleavage of lamin A are critical in apoptotic signaling triggered by resveratrol in the colon carcinoma cells, which can be activated in the absence of Bax or p53
	1706.	Our data indicated that in MTX M cells, p53 is sequestered in the cytoplasm by a novel mechanism that abrogates p53 residual function.
	1707.	findings of the present study indicate that p53 codon 72 arginine homozygous genotype may represent a genetic predisposing factor for colon cancer development
	1708.	Variations in TP53 and BAX alleles are unrelated to the development of pemphigus foliaceus.
	1709.	angiostatins K1-3, K1-4 and K1-4.5 mediate anti-angiogenesis in a process involvingp53, FasL, AKT and mRNA deregulation
	1710.	CD154 can sensitize leukemia cells to apoptosis via the c-Abl-dependent activation of p73 and mitigate the resistance of p53-deficient CLL cells to anticancer drug therapy.
	1711.	NS3 plays an important role in the hepatocarcinogenesis of Hepatitis C virus by interacting differentially with p53 in an NS3 sequence-dependent manner.
	1712.	PGE(2)-stimulated phosphoserine p53 abrogated DNA binding of c/EBPbeta dimers and c/EBPbeta/NF-kappaB p65 heterodimers.
	1713.	p53 not only plays a key role in the regulation of the topoisomerase I response to UV-C irradiation but also to treatment with colcemid
	1714.	analysis of novel mechanisms for apoptosis induction by silibinin involving p53-caspase 2 activation and caspase-mediated cleavage of Cip1/p21
	1715.	alteration of both p53 and PTCH genes is likely to play a role in radiation-induced basal cell carcinogenesis
	1716.	Metabolic activation of hormones can generate endogenous mutagens, and we demonstrate that estrone-quinone attenuates p53 function in human breast cancer cells.
	1717.	genomic instability is an early event that occurs at precancerous stages prior to changes in tumor suppressor genes (p53 and adenomatosis polyposis coli) in Barrett's esophagus-associated tumorigenesis in patients
	1718.	p53-induced cell cycle arrest is a function of not only the transactivation of cell cycle inhibitors but also the repression of targets that regulate proliferation at several distinct phases of the cell cycle
	1719.	The Bcl-2 protein expression has a close correlation with p27 and p53 protein expressions and the proliferation activity determined by MIB-1 counts in invasive ductal carcinoma of the breast.
	1720.	identification of polymorphisms in lung carcinoma of never smokers
	1721.	Tumour protein p53 plays a role in facilitating histone H2AX phosphorylation, an important step in the mobilization of the DNA repair machinery at the site of DNA double-strand breaks.
	1722.	these findings identify the first instance of a ubiquitin ligase that causes stabilization of p53 while inactivating its transcriptional activities.
	1723.	Interval between the onset of rheumatoid arthritis and lymphoproliferative disorders development was significantly longer in patiets with p53 gene mutations and had more advanced diseases and an unfavorable prognosis
	1724.	Phosphorylation of specific serine and/or threonine residues reduces the affinity of the S100B-p53 interaction.
	1725.	The functional consequences of the identified PIDD/nucleolin interaction remain to be elucidated, but may be related to a recently discovered new role for PIDD in the activation of NF-kappaB upon genotoxic stress.
	1726.	Although pterygium has limited local invasion and ainability to metastasize, concomitant presence of altered p53 in 8-OHdG-immunoreactive cells could provide evidence of apparent genetic instability, which is in contrast to its benign clinical course.
	1727.	ZNF415 isoforms in COS-7 cells inhibits the transcriptional activities of AP-1 and p53, suggesting that the ZNF415 protein may be involved in AP-1- and p53-mediated transcriptional activity.
	1728.	Inhibition of KSP induces apoptosis independently of p53 and that p53 is dispensable for spindle checkpoint function. Thus, KSP inhibitors should be active in p53-deficient tumors.
	1729.	Chromatin immunoprecipitation analyses show that LKB1 is recruited directly to the p21/WAF1 promoter, as well as to other p53 activated promoters, in a p53-dependent fashion.
	1730.	The differential ability of p53 and p73 to inhibit glucocorticoid receptor transcription activity is due, in part, to differences in their N-terminal and C-terminal sequences.
	1731.	Moreover, these M6P/IGF2R 3'UTR mutations and the TP53 mutations detected previously were mutually exclusive in most of the tumors, suggesting two independent pathways to HCC development.
	1732.	In an analysis of breast cancer-specific survival up to 5 years, high Ki-67, high p53, and negative ER as well as aneuploidy of the tumour were significant prognostic factors.
	1733.	p53 to NF-kappaB signaling has a role in chemotherapy responsiveness of neuroblastoma
	1734.	While the DNA replication checkpoint is unlikely to regulate the assembly of a p21 promoter initiation complex, it signals to one or more factors involved in the process of transcriptional elongation.
	1735.	the gene encoding Ku86 (XRCC5) is an essential gene in human somatic cells, and its absence cannot be suppressed by the loss of p53 function
	1736.	individual variations in radiosensitivity and in the level of induction of TP53 (and consequently CDKN1A) are congruent, irrespective of the genetic background of the nontransformed fibroblasts
	1737.	There are different immunohistochemical expression patterns of p16INK4A and p53 between intraductal papillary-mucinous neoplasm and pancreatic intraepithelial neoplasm
	1738.	Cytoplasmic relocalization of HIPK2 induced by HMGA1 overexpression is a mechanism of inactivation of p53 apoptotic function.
	1739.	Review of ongoing work on biological functions of p53 tumor suppressor in different cell types and under various physiological conditions will help to unravel the complexity of molecular circuits that orchestrate the biological response to p53 activation.
	1740.	p53 binds to and positively regulates BLIMP1.
	1741.	result combined with our two previous analyses indicates that the p53 Y220C mutation was expressed in 6/50 HLA-A2+ squamous cell carcinomas of the head and neck tumors tested
	1742.	Overexpression of p53 is associated with pancreatic cancer
	1743.	human Ada3 has an essential role in p53 acetylation
	1744.	Most non-small cell lung cancers (NSCLCs) have mutations of p53.[Review]
	1745.	Nutlin-3a shows antitumor activity in vivo in a mouse xenograft model, exploiting new options for exploiting reactivation of p53 as treatment for virally-induced lymphoma.
	1746.	These findings establish HIPK2 as an MDM2 target and support a model in which, upon nonsevere DNA damage, p53 represses its own phosphorylation at Ser46 due to HIPK2 degradation.
	1747.	the binding of nuclear p53 to the specific sites within the PUMA promoter is essential for its ability to induce apoptosis and is likely to be required for its tumor suppressive capacity
	1748.	high and low P-glycoprotein, glutathione S-transferase pi expression, excision repair cross-complementing 1 alterations, and tumor suppressor p53 mutation were candidates for future clinical trials of chemosensitivity tests in lung cancer patients.
	1749.	p53 upregulates restin transcription through an indirect mechanism rather than by direct interaction with the cis-activating element of the restin promoter.
	1750.	The Arg72Pro polymorphism of p53 alters the transcription of p53 target genes and modifies the apoptotic potential of cells but there are inconclusive results with respect to breast cancer risk
	1751.	The delay in traversing S phase was reduced by the presence of p53 in HCT 116 cells exposed to cytotoxic drugs.
	1752.	p53 modulates DNA DSB repair by, in part, inducing hnRNP G
	1753.	stress-induced premature senescence (SIPS) from hydrogen peroxide is associated with a transient increase in DNA-binding activity of p53 and an increased expression of p21(WAF-1) in human hTERT fibroblasts
	1754.	CARF may exert a vital control on p53-HDM2-p21(WAF1) pathway that is central to the cell cycle control, senescence, and DNA damage response of human cells
	1755.	A microtubule-facilitated nuclear import pathway for p53 is described.
	1756.	theaflavins induce apoptosis in human prostate cancer cells through induction of p53, down-regulation of NF-kappa B and mitogen-activated protein kinases pathways
	1757.	shielding of reactive cysteines contributes to a negative regulation for human p53 and imply that such an inactivation of the transcription factor may represent an acute defensive response with significant consequences for oncogenesis.
	1758.	correlation between p53 gene deletion and mammary gland carcinoma
	1759.	analysis of the p53-Mdm2 feedback loop using protein lysate microarrays
	1760.	p53 protein appears only in sporadic cases (6.6%) of severe colonic dysplasia
	1761.	interactions with DNA in solution using time lapse atomic force microscopy
	1762.	the lack of correlation between p73 or p63 and p53 expression in head and neck squamous carcinoma suggests an independent and/or compensatory functional role
	1763.	MDMX post-translational processing may be regulated by p53
	1764.	p53 was detected more frequently in CIN I compared with CIN II/III and invasive carcinoma
	1765.	A loss of wild-type p53 gene function and consequent p53 overexpression in gastric carcinomas may be involved in early stages of tumor progression.
	1766.	regulation of function by Pin1 during DNA damage
	1767.	The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein.
	1768.	basal expression of p53 plays a functional role in a glucocorticoid receptor-mediated response regulating the expression of p21(Waf1/Cip1) via a mechanism that is suppressed by PP5 and associated with the phosphorylation of p53 at Ser-15
	1769.	a transcriptional switch from P(0)-/P(2)- to P(1)-initiated p53 mRNA could be an important mechanism by which cells regulate p53 expression
	1770.	Patients with tumors who also showed overexpression of p53 had a significantly inferior response to chemotherapy compared with the patients with p53-negative tumors
	1771.	TP53-mediated transcription is induced by prohibitin in human tumor cells through enhanced recruitment to promoters
	1772.	tp53 has a role in apoptosis along with noxa protein in human tumor cells
	1773.	Expression of apoptosis-inductive genes were increased by X-ray irradiation in squamous cell carcinoma cells(SAS) with wild-type p53, but not in SAS cells expressing mutated p53. Radiation sensitivity may come from expression of apoptosis-related genes.
	1774.	This protein interacts with TFAM and helps regulate DNA damage.
	1775.	Radiation induced increased expression of p53. Ionizing radiation induces p53-dependent cell apoptosis in bladder cancer cells with wt- p53 but not in those with mutated p53.
	1776.	The p53 tumor suppressor pathway is disrupted in most oral squamous cell carcinomas at the cellular levels, due to either an abnormality in p53 itself or loss of expression of p53 regulatory factors.
	1777.	p53 alteration is an independent and significant indicator to predict unfavorable prognosis in patients with unresectable non-small cell lung cancer.
	1778.	P53 mutation predicts the failure of intravesical adriamycin instillation in transitional cell carcinoma of the bladder.
	1779.	A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.
	1780.	Ligase dead mutants of Mdm2 did not act in a dominant negative manner to reactivate p53 and they are not oncogenes in human mammary epithelial cells.
	1781.	The immunodetection of both p53 and bcl-2 proteins in squamous cell carcinoma of the uterine cervix can be used as an independent diagnostic marker for cervical cancer associated with HPV infection.
	1782.	The ability to form unique amphipathic structures in both an aqueous cytosolic-like and a mixed organic membrane-mimetic solution environment may allow a p53 peptide from the mdm-2 binding domain to selectively and rapidly disrupt cancer cell membranes.
	1783.	Acetylation of p53 in vivo may contribute, at least in part, to its transcriptional activation functions.
	1784.	adenovirus 2 E1B-55K protein blocks p53 as a transcriptional repressor protein of the survivin and the MAP4 promoters
	1785.	p53 mutants showed increased binding to NQO1, which can explain their resistance to dicoumarol-induced degradation, as NQO1 has an important role in stabilizing hot-spot p53 mutant proteins in cancer
	1786.	p53 might be involved in homologous recombination and/or checkpoint function by directly binding to DMC1 protein to repress genomic instability in meiotic germ cells
	1787.	Adenovirus-p53 induces the expression of a variety of proapoptotic genes and that lack of induction in one of these genes does not block Ad/p53-mediated cell killing in human lung cancer cells.
	1788.	Results suggest that p53 degradation and inhibition of p14(ARF) signaling are independent functions of HPV16 E6, and that long-term proliferation of mammary epithelial cells requires inactivation of the p14(ARF)-p53 pathway.
	1789.	TP53 mutations develop in non-neoplastic epithelial lesions of the vulva, lichen sclerosus and squamous hyperplasia and are intrinsic to the clonal evolution that leads to squamous cell carcinoma of the vulva.
	1790.	Binding to the p53 binding sites of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
	1791.	p53 protein overexpression was noted in 59% of T-cell ltymphoblastic lymphoma cases and was correlaed with higher rate of relapse
	1792.	Wild-type p53 protein conformation is stabilized upon CP-31398 exposure.
	1793.	In response to irradiation, the amount of p53 protein synthesized in patients with AT and NBS was significantly lower than that in normal cells.
	1794.	p53 activation is inhibited by MDMX, which is transported to the cell nucleus with or without p53 upon DNA damage
	1795.	Hepatitis B virus X protein in liver cells down-regulates the expression of PTEN and activates AKT and affects p53-mediated transcription of PTEN.
	1796.	Here we showed that 361 out of 1501 p53 responsive genes contained p53 consensus DNA-binding sequence(s) in their regulatory region, approximately 80% of which were repressed by p53
	1797.	Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters
	1798.	generation of the polyubiquitinated forms of p53 that are targeted for proteasome degradation requires the intrinsic ubiquitin ligase activities of MDM2 and p300
	1799.	Data show that growth arrested keratinocytes may resist ultraviolet-light induced apoptosis by inactivating the pro-apoptotic function of p53.
	1800.	the p53 gene polymorphism may associate with NPC susceptibility in Thai population, particularly the Pro/Pro genotype carriers with age of >40 years.
	1801.	examination of expression of p53, p21, and phosphorylated p42/44 mitogen-activated protein kinase in human pulmonary arterial smooth muscle cells
	1802.	TIAF1 and p53 functionally interact in regulating apoptosis, and TIAF1 is likely to participate in the nuclear translocation of activated p53.
	1803.	p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1
	1804.	findings suggest that the tumor protein p53 codon 72 polymorphism is unlikely to be associated with endometriosis in Japanese women
	1805.	p16INK4A, p14ARF, p53, and PCNA have roles in the progression of cervical neoplasia
	1806.	Data show that the fundamental active unit of p53 appears to be the tetramer, which is induced by DNA binding.
	1807.	SN2 DNA-alkylating agent-induced phosphorylation of p53 increases its DNA-binding properties to cause an increased expression of p21 that may play a role in cell cycle arrest and/or apoptosis of human colon cancer cells HCT-116.
	1808.	inhibition by TP53 of G2 phase checkpoint abrogation and radiosensitization induced by PD0166285
	1809.	TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins.
	1810.	The temperature sensitive mutant p53-143ala extends in vitro life span, promotes errors in DNA replication and impairs DNA repair in normal human oral keratinocytes.
	1811.	An identical single nucleotide deletion within the C/EBP-like site of the promoter in 2 OF 18 Li-Fraumeni families. This site is not utilized in the wild type TP53 promoter and mutation of this site in LFS/LFL does not have a functional effect.
	1812.	polymorphism in codon 72 and risk of head and neck neoplasms
	1813.	Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53.
	1814.	role of binding to mdm2 protein in p53 regulation
	1815.	pivotal role of NO in the induction of cellular stress and the activation of a p53 response pathway during chronic inflammation
	1816.	description of the role of ionic interactions in the stability of the p53 tetramer and of heterotetramers of the protein scaffold
	1817.	types of mutations in sinonasal NK/T cell lymphoma in northeast district of China
	1818.	new roles for several DNA damage response factors by demonstrating that they also participate in the oncogenic stress signaling pathway between E2F1 and p53
	1819.	Loss of p53, directly or indirectly, perturbs the normal regulation of phosphorylation of serine 10 in histone H3.
	1820.	UV-induced activation of p53R2 transcription and binding of p53R2 to hRRM1 to form RR holoenzyme are impaired in the p53-mutant cell line PC3.
	1821.	Activation of p53 reduces binding and relieves transcriptional repression of the Dnmt1gene, whereas loss of p53, a frequent, early event in tumorigenesis, may significantly contribute to aberrant genomic methylation.
	1822.	There was no correlation between human papillomavirus status and p53 overexpression in human oropharyngeal squamous cell carcinoma.
	1823.	Review focuses on potency of p53 as an inducer of apoptosis and reasons for extraordinarily high frequency of p53 inactivation in tumors, and mechanisms of tumor cell sensitization to p53-induced apoptosis.
	1824.	TP53 is ubiquitinated by topors
	1825.	A significant association between p53 gene Bam HI RFLP polymorphism and the infarction volume was found in patients with carotid atherothrombotic stroke from Moscow population.
	1826.	were not able to confirm that the TP53 polymorphism at exon 4 increases the susceptibility to be infected by HPV or to develop high-grade intra-epithelial lesion of the cervix
	1827.	biogenesis in vitro to determine how wild type and mutant forms form hetero-oligomers
	1828.	A new germline p53 mutation was found associated with a choroid plexus papilloma. The 7-BP insertion in exon 5 causes a frameshift from 161-182 and affected transactivation but not apoptosis induction.
	1829.	Ubiquitination and degradation of p53 are largely controlled by Mdm2, an oncogenic E3 ligase.
	1830.	role in mediating cell cycle arrest in Rb(-/-) Saos2 cells
	1831.	findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population; the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade
	1832.	the net deubiquitination of the various targets of HAUSP determines the steady-state level of p53
	1833.	complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis
	1834.	No association between p53 status and overall survival in human glioma.
	1835.	phosphorylation of p53 at Ser-215 by Aurora-A is a major mechanism to inactivate p53
	1836.	blockade of pol II-mediated transcription induces p53 accumulation in mitochondria and is the critical factor for eliciting p53-dependent but transcription-independent apoptosis
	1837.	Proliferative inhibition of breast cancer cells by Velcade is associated with stabilization of p53.
	1838.	expression of p53, MDM2, and p21Waf1 suggests a role for these oncoproteins in the regulation of endometrioma cell growth, but not in adenomyosis
	1839.	review of the evidence for p53 as a participant in the responses of multiple CNS cell types to the presence of HIV and propose the hypothesis that HIV induced alterations in the CNS extracellular milieu converge at neuronal p53 activation
	1840.	role of p53 as a major pro-apoptotic factor in the pathogenesis of AIDS [review]
	1841.	review of current knowledge about association of aneuploidy and p53
	1842.	Data show that latent infection with Kaposi sarcoma-associated herpesvirus in B lymphocytes can be terminated by glycyrrhizic acid.
	1843.	CHIP-induced degradation was observed for mutant and wild-type p53, which transiently associate with molecular chaperones Hsc70 and Hsp90 and can be diverted onto a degradation pathway through this association
	1844.	Ser15 phosphorylation is important in regulating the oncogenic function of mutant p53 apoptosis induction in the context of the NF-kappaB/IkappaB signaling pathway
	1845.	p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1
	1846.	Transient transfection of hepatitis B virus into the SMMU-7721 cell line can enhance p53 expression and its effects on development of hepatocarcinoma
	1847.	The current data collectively indicate that BaP induces apoptosis of Hepa1c1c7 cells via activation of p53-related signaling, which was, in part, regulated by p38 kinase.
	1848.	overexpression of c-myc (p=0.038) related to poor survival whereas increased positivity for p53 predicted better survival (p=0.013).
	1849.	p53 expression in HBV or HCV cirrhotic liver are a rather late event in carcinogenesis and related to hepatocellular carcinoma grade
	1850.	p53 may act as a DNA topology-modulating factor
	1851.	TP53 expression may be a useful biomarker for assessing the risk of developing esophageal cancer.
	1852.	Results demonstrate that p53 base mutations in combination with allelic imbalance do not predict survival or progression of colorectal cancer.
	1853.	Both p53 and c-erbB-2 proteins appear to be involved at an early stage of malignization of pleomorphic adenoma
	1854.	Loss of p53 function can lead to decreased hOgg1 repair activity.
	1855.	Although SIRT1 deacetylates p53, this does not play a role in cell survival following DNA damage in certain cell lines and primary human mammary epithelial cells.
	1856.	molecular analysis of p53 haplo-insufficiency
	1857.	TP53 G-->T transversions associated with tobacco smoke carcinogens were most frequent (50%) in the intermediate location.
	1858.	Cyclin dependent kinase 9, whose well-known substrate is RNA polymerase II, can also phosphorylate p53.
	1859.	This study defines a new role for residues 53 and 54 of p53 in regulating transrepression and demonstrates that 25-26 and 53-54 work in the same pathway to induce apoptosis through gene repression.
	1860.	Fatty acid synthase (FAS) gene, encoding for a key enzyme involved in the biogenesis of membrane lipids in rapidly proliferating cells, is a conserved target of the p53 family throughout the evolution.
	1861.	Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis [review]
	1862.	binding of p53 serves to modify simian virus 40 large T antigen (SV40 LT) by targeting CREB binding protein and p300 binding to direct the acetylation of SV40 LT
	1863.	p53 codon 72 polymorphisms do not serve as a susceptibility factor affecting the chances of miscarriage in an unselected population.
	1864.	NKX3.1 engages cell cycle and cell death machinery via association with HDAC1, leading to increased p53 acetylation and half-life through MDM2-dependent mechanisms.
	1865.	distribution of methylation sites and repetitive elements in silent and nonsense p53 mutations in cancers
	1866.	NF-kappaB-dependency of the platelet-activating factor -induced increase in VEGF expression is due to decreased p53 activity, which is reciprocally regulated by increased NF-kappaB activity.
	1867.	Moreover, in the absence of overt apoptotic signals, the constitutive induction of AIF by p53 may underpin a cytoprotective maintenance role, based on the role of AIF in ensuring proper mitochondrial function.
	1868.	p53 binding to the central domain of Mdm2 is regulated by phosphorylation
	1869.	These results suggest that DFNA5 plays a role in the p53-regulated cellular response to genotoxic stress probably by cooperating with p53.
	1870.	high frequency of somatic TP53 gene mutations implicates TP53 as a predominant factor for breast carcinogenesis in moderate risk ethnic Kashmiri population
	1871.	results show that p53 transcriptionally activates the alpha(II) collagen prolyl-4-hydroxylase [alpha(II)PH] gene, resulting in the extracellular release of antiangiogenic fragments of collagen type 4 and 18
	1872.	Alkyl resorcinol exerts its cytotoxic effect in both hepatocellular cell lines through apoptotic cell death. For Hep3B, cells with mutated p53 and Fas, apoptosis would proceed by p53- or Fas-independent pathways.
	1873.	The Pro/Pro genotype of the p53 codon 72 polymorphism carries a higher risk for gastric cancer in general and is also associated with a much higher risk for early gastric cancer than advanced gastric cancer.
	1874.	p53 and pRB can be sumoylated by SUMO-2/3 in vivo, and such modification of p53 and pRB may play roles in premature senescence and stress response
	1875.	Although p53 is a main regulator of apoptosis in mammalian cells, the Tfpt induced apoptosis appears p53-independent.
	1876.	Negative control by p53 on Nrf2 transactivation appears to be aimed to prevent the generation of a strong anti-oxidant intracellular environment that could hinder the induction of apoptosis.
	1877.	Stimulation of macrophage inhibitory cytokine 1-dependent S phase arrest in normal gut epithelial cells might help to revitalize the clinical use of N-phosphonacetyl-l-aspartate, which has been limited by gut toxicity
	1878.	RNPC1a is required to maintain the stability of p21 transcript induced by p53.
	1879.	Our findings show that p53 is a transcriptional regulator of ECK in mediating apoptosis.The discovery of the novel p53-binding motif in the promoter may lead to the identification of a new class of p53 target genes.
	1880.	Study demonstrates that the p53-mediated induction of RhoE in response to DNA damage favors cell survival partly through inhibition of ROCK I-mediated apoptosis.
	1881.	no specific pattern for p53 mutations was observed in HCV genotype 4-associated hepatocellular carcinoma and no significant relation between p53 mutations, HCV-NS3 expressions or any HCV sub-genotype-4 sequence in Egyptian patients
	1882.	study reveals that the TP53 Arg allele, active smoking and human papillomavirus infection infection are the important risk factors in lung cancer development in the north part of Iran, Mazandaran province
	1883.	Mutant p53 may contribute to its 'gain of function' effects which accelerate the oncogenesis and promotion of lung adenocarcinoma.
	1884.	No siatistically significant value in assocation with survival or event-free survival in head and neck squamous cell carcinoma.
	1885.	Critical role of subcellular localization in the dominant-negative action of p53.
	1886.	common polymorphisms in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are not shown to increase breast cancer risk
	1887.	This study strengthens the rationale for targeting p53 deubiquitylation by drugs like Nutlin as a promising new strategy in Neuroblastoma therapy.
	1888.	results suggest that some cells from head and neck cancer may contain the oncogenic mutation of the p53 gene, and the oncogenic p53 protein prevents cancer cells from undergoing apoptosis after DNA damage
	1889.	xeroderma pigmentosum group C protein polymorphism might affect p53 alteration and the molecular pathway defined by the p53 alteration in the development of muscle-invasive bladder cancer
	1890.	Our finding that two different p53 haplotypes are associated with colorectal adenoma and cancer, respectively, suggests that each of these haplotypes may independently impact on p53 function within different genetic pathways of colorectal carcinogenesis.
	1891.	The negative role played by the WTH3 gene in MDR development is through its proapoptotic potential that is regulated by multiple mechanisms at the transcription level, and one of these mechanisms is linked to the p53 gene.
	1892.	The central domain of the p53 protein targeted by 80% of p53 mutations is associated with the DNA-binding activity of the p53 protein;it is the binding site for proteins that play a key role in p53 regulation such as ASPP proteins or BclxL.
	1893.	findings point to the calpain pathway as a key player to maintain steady state levels of p53 in resting cells without affecting its activity.
	1894.	alteration and/or a modulation of the p53-p21 pathway in response to UV could be determinant for human papillomavirus 16-infected keratinocyte survival and HPV-associated carcinogenic process
	1895.	p53 is required for sensitization to TRAIL
	1896.	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling
	1897.	Human tumor suppressor ARF impedes S-phase progression independent of p53.
	1898.	Targeted inactivation of p53 in human cells does not result in aneuploidy.
	1899.	findings suggest a novel mechanism of MLH1 in the induction p53 and apoptosis by inhibiting RNA polymerase II-dependent transcription on damaged DNA templates
	1900.	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. The most common combination of mutations was p53 and APC (27.1%), whereas mutations in both p53 and K-ras were extremely rare.
	1901.	Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding.
	1902.	This protein and p73 interact with CTF2 and regulate HMG1 gene expression.
	1903.	results demonstrated significant positive staining of p53 in the salivary tumorigenic tissue but not in the surrounding non-tumorigenic tissue, pointing to a biological role in the tumorigenic process
	1904.	tp53 may negatively control the MAKP pathway via MKP1
	1905.	During apoptosis, p53 activates transcription of PAC1 by binding to a palindromic site in the PAC1 promoter
	1906.	P53 protein expression in quiescent vascular smooth muscle cells [VSMCs] is paradoxically increased by application of a growth stimulus. Through mediation of p21WAF1/CIP1 and Bax, induced p53 protein negatively regulates the growth of dividing VSMCs
	1907.	Results showed that mutations in the p53 gene were frequently detected in in recurrent hepatocellular carcinoma.
	1908.	Mutations in PTEN/MMAC1 gene correlated inversely with an altered p53 status.
	1909.	role of p53 gene in the biophysics and biology in murine erythroleukemia cell line with the goal of understanding the influence of this tumor suppressor gene on the deformability and metastasis of tumor cells
	1910.	role of glycogen synthase kinase-3beta in binding and promoting action of p53
	1911.	p53 induced apoptosis is inhibited by Bcl-xL in head and neck neoplasms
	1912.	Data reveal that controlled MDM2 degradation is an important new step in p53 regulation.
	1913.	Correlation between p53 accumulation and survival in bilharziasis associated bladder squamous cell carcinoma.
	1914.	Probably no association between TP53 polymorphism at codon 72, HPV infection and the etiology of cervical cancer in this population sample.
	1915.	ATR-p53 pathway is suppressed in noncycling lymphocytes via ATR downregulation.
	1916.	The expression of p21 protein depends on p53 protein largely in normal gastric mucosa and dysplasia, but not in gastric carcinoma.
	1917.	p53 codon 72 polymorphism may contribute to gastric cancer susceptibility
	1918.	suppression of p53-C277Y by RNAi reduced pig3 promoter activity, RNA, and protein expression
	1919.	Cyclin A1 methylation was inversely related to p53 mutational status in primary tumors, and forced expression of cyclin A1 resulted in robust induction of wild-type p53 in HNSCC cell lines.
	1920.	examined the binding of DNA in solution to a series of unmodified p53 constructs that lack various domains, and identified the residues of the C terminus that interact with the non-specific DNA
	1921.	Results link p53 status with POLkappa expression and suggest that loss of p53 function may in part contribute to the observed POLkappa upregulation in human lung cancers.
	1922.	Relation between expression, DNA ploidy and human papillomavirus infection in cervical carcinoma.
	1923.	Glioma cells with functional p53 were relatively resistant to gamma-radiation, and ceramide may play an important role in caspase activation during gamma-radiation-induced apoptosis of glioma cells lacking functional p53.
	1924.	Disruption of p53-p21/WAF1 cell cycle pathways contributes to tumor progression and worse clinical outcome of hepataocellular hepatoma.
	1925.	mutant p53s are likely to be distinct in terms of the extent to which each mechanism contributes to their gain-of-function phenotypes
	1926.	role of Cul4A in the MDM2-mediated proteolysis of p53
	1927.	We conclude that overexpression of PKCdelta in human colon cancer cells induces multiple antineoplastic effects that depend on the activities of p21(Waf1/Cip1) and p53.
	1928.	The finding of different p53 gene mutations among multiple esophageal carcinoma lesions suggest further evidence of multicentric or field carcinogenesis of the human esophagus
	1929.	Radiation treatment in the presence of p53 C-terminal peptides is more effective for inducing p53 -mediated apoptosis than radiation treatment alone or p53 C-terminal peptide treatment alone in cancer cells.
	1930.	interaction of Ubc9 with p53 was regulated by phosphorylation of p53
	1931.	Results describe the role of Daxx in modulating the apoptotic threshold and identify it as a possible integrating factor that coordinates the response of p53 family members.
	1932.	proximal 5'-flanking region of the IKKalpha gene contains a functional promoter reciprocally regulated by p53 and ETS-1
	1933.	an over-representation of the Pro allele of the p53 gene in women with idiopathic recurrent miscarriage gives support to the theory that p53 has a potential role during pregnancy.
	1934.	p53-dependent loss of Fbxw7 leads to genetic instability by mechanisms that might involve the activation of Aurora-A, providing a rationale for the early occurrence of these mutations in human cancers
	1935.	P53 is induced by Aluminum in neuron-like cells suggesting that the p53-dependent intrinsic pathway may be responsible for Aluminum-induced apoptosis.
	1936.	Data suggest that MTBP differentially regulates the activity of MDM2 towards two of its most critical targets (itself and p53) and in doing so significantly contributes to MDM2-dependent p53 homeostasis in unstressed cells.
	1937.	We conclude that (1) clinically achievable doses of ionizing radiation can trigger CDKN1A-dependent accelerated senescence in some human tumor cell lines that express wild-type TP53.
	1938.	A spontaneous increase of wild-type p53 occurring in ageing normal human MRC-5 fibroblasts is associated with irreversible reduction of proliferative potential.
	1939.	P73 may replace p53 in triggering not only apoptosis but also cell cycle arrest or DNA repair effectors in breast cancer cells.
	1940.	analysis of gain of function from a Li-Fraumeni TP53 mutation
	1941.	overproduction of Mdm2, resulting from a naturally occurring SNP, inhibits chromatin-bound p53 from activating the transcription of its target genes.
	1942.	Among women with p53 alterations, adjuvant radiotherapy substantially increased survival
	1943.	following stress-induced phosphorylation, p53 needs to form a complex with Pin1 and to undergo a conformational change to fulfil its biological roles
	1944.	The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response
	1945.	Results indicate that full-length p53 is a modular protein consisting of defined structured and unstructured regions, which may allow the physiological interaction of p53 with a multitude of partner proteins and the regulation of its turnover.
	1946.	Affects relative biological effectiveness of light ions in human tumoural cell lines.
	1947.	Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
	1948.	Results showed significant differences in the expression patterns among p53-null. wild-type p53, and p53 mutants A138T, C141Y, R158L, G245C, and R248Q samples. We also report here the first found p53 mutant-triggered alternative splicing.
	1949.	The capability of p53 to activate transcription was used to develope a new assay that permits rapid determination of the status of p53 in cancer cell lines of different origin.
	1950.	These data suggest that nucleophosmin is an early responder to DNA damage that prevents premature activation of p53.
	1951.	Clinical course of B-CLL in group of patient with trisomy 12, trisomy 12 and TP53 deletion simultaneously is more aggressive compared to the course of disease of patients with no cytogenetic aberrations.
	1952.	The frequent presence of TP53 deletion detected in 48% of patients is surprising. It is generally thought that the aberration is found in 10-15% of clinical cases.
	1953.	p53 might play a protective role against cell damage induced by generation of intracellular ROS, through transcriptional activation of ALDH4
	1954.	STAG1, a novel transcriptional target for p53, mediates p53-dependent apoptosis, and might be a good candidate for next-generation gene therapy in cancer.
	1955.	The activation of the p53 pathway appears to be an effective approach in inhibiting tumor development.
	1956.	T-oligos transcriptionally down-regulate COX-2 expression in human skin via activation and up-regulation of p53, at least in part by inhibiting NFkappaB transcriptional activation
	1957.	ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function
	1958.	p53 and p21 act in series in mediating cell cycle arrest. However, the two risk factors, p53 proline homozygosity and p21 arginine allele, although part of a common causal pathway, appear to act in a mutually exclusive manner.
	1959.	The p53 codon 72 Arg/Pro polymorphism is not associated with age of onset or severity of glaucoma.
	1960.	mutant p53 suppresses the expression of the MSP (MST-1/HGFL) gene, encoding the ligand of the receptor tyrosine kinase RON, implicated in a variety of cellular responses
	1961.	p53 protein can regulate huntingtin expression at transcriptional level
	1962.	The results showed that retroviral vector-mediated RNAi can substantially downregulate the expression of human p53 in 293-T cells.
	1963.	The degree of acetylation regulates p53 nucleus-cytoplasm trafficking by neutralizing a lysine-dependent charge patch, which in turn, controls oligomerization-dependent p53 nuclear export.
	1964.	Mutation rate of p53 is not particularly high, but there is a significant risk that cancer cells will resist p53 retroviral gene therapy as a result of retroviral replication errors.
	1965.	specific amino acid substitutions in hepatitis C virus NS3 impair p53 interaction and anti-apoptotic activity of NS3
	1966.	UbcH5B/C are E2s for Mdm2, which contribute to the maintenance of low levels of p53 and Mdm2 in unstressed cells; inhibition of p53 ubiquitination and degradation by targeting UbcH5B/C is not sufficient to up-regulate p53 transcriptional activity.
	1967.	p53 binds telomeric single strand overhangs and t-loop junctions in vitro
	1968.	mutations in epithelial ovarian cancer
	1969.	UVB-mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53.
	1970.	These results suggest that p53 is vulnerable to free radical-mediated oxidation at cysteine residues.
	1971.	Two peptide epitopes on Mdm2 oncoprotein affect this protein's degradation.
	1972.	Human wild-type p53 inhibits homologous recombination between substrates for conservative HR & for gene deletions. Non-homologus end-joining was downregulated after p53 expression. p53 mutations at codon 281, 273, 248, 175, or 143 disrupted DSB repair.
	1973.	beta-catenin, p53 and PCNA may play important roles in the carcinogenesis of colorectal adenoma.
	1974.	Mutations of p53 gene are associated features of aggressive phenotype of transitional cell carcinomas but do not seem to offer additional prognostic information.
	1975.	p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop.
	1976.	p53 has different modes of high affinity DNA binding which are related to its tumor suppressor functions
	1977.	Results suggest that apoptosis-associated speck-like protein (ASC) can function as an adaptor molecule for Bax and regulate a p53-Bax mitochondrial pathway of apoptosis.
	1978.	results show that low levels of Mdm2 activity induce monoubiquitination and nuclear export of p53, whereas high levels promote p53's polyubiquitination and nuclear degradation
	1979.	increase in intracellular reactive oxygen species (ROS) associated with the magnitude of p53 protein expression correlated with the induction of either senescence or apoptosis in both normal and cancer cells
	1980.	The positive expression rates of p21 and p53 proteins were 75.0% and 57.3% respectively in pancreatic carcinoma, which were significantly different from those in the normal tissue (P<0.05). p21 and p53 proteins were positively correlated (P<0.05).
	1981.	Upregulation of p53 protein is associated with breast disease
	1982.	Human papillomavirus infection and/or changes in p53 protein coexist in oral cavity papillomas.
	1983.	TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNA-damage.
	1984.	DNA-damaging stresses showed a strong p53-dependent element in their responses, no discernible p53-dependent responses were triggered by the non-DNA-damaging stresses.
	1985.	there is a decrease in p53 apoptotic rate associated with the No Ins-72Pro haplotype in BRCA2 mutation carriers
	1986.	The expression of bcl-2 and p53 represent biological characteristics of colorectal carcinomas.
	1987.	VEGF and p53 are highly expressed in esophageal carcinomas
	1988.	Hypophosphorylation of Mdm2 augments p53 stability.
	1989.	TP53 arginine/arginine genotype could represent a potential risk factor for the development of squamous cell carcinoma in renal transplant recipients
	1990.	p53 mutations are a later event in vulvar carcinoma
	1991.	hepatitis C virus core protein induces p53-dependent gene expression of TAP1 protein and MHC class I upregulation in liver cells and thus impairs NK cell cytotoxicity
	1992.	P53 transcriptional activity is inhibited by MDM-2 overexpression, which blocks UV-induced cell cycle arrest and apoptosis
	1993.	p53 activity and PIG3 gene function are uncoupled by UV-dependent alternative splicing through rapid proteolytic degradation
	1994.	Co-mutation of p53 and K-ras gene has neither synergic carcinogenesis-promoting effect, nor prognostic effect on rectal cancer.
	1995.	Stress-induced activation of p53 in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species
	1996.	findings show that p53 plays a central role in the response of ARPE-19 cells to DNA damaging agents that act via different mechanisms. ARPE-19 cells with reduced p53 expression behave similar to tumor cell lines with mutated or non-functional p53.
	1997.	Inactivating TP53 mutations were found in 55% of lethal metastatic pancreatic neoplasms.
	1998.	redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells requires thioredoxin
	1999.	p53-mdm2 binding is subtler than previously thought and involves global contacts such as multiple "non-contiguous" minimally structured motifs instead of being localized to one small helix mini-domain in p53 TAD
	2000.	P53 protein accumulation may be responsible for gastric carcinogenesis and tumor aggressiveness of gastric cancer in northern China.
	2001.	p53 and c-Myc expression may have a role in regulation of telomerase activity in ovarian tumours
	2002.	effect of HCV core, NS3, NS5A and NS5B on cell proliferation is independent of p53 expression, and only HCV core protein induces the expression of both c-myc and p53
	2003.	C-terminus of p53 is required for G(2) arrest.
	2004.	overexpression may be marker of radioresistance in head and neck cancer
	2005.	binding sites of 53BP1
	2006.	role of tyrosine phosphorylation of Mdm2 by c-abl in p53 regulation
	2007.	studies define a novel p53-survivin signaling pathway activated by DNA damage that results in down-regulation of survivin, cell cycle arrest, and apoptosis
	2008.	Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
	2009.	Delayed activation of p53 occurrs in the progeny of irradiated cells.
	2010.	p53 is recruited into the PML nuclear bodies by PML along with chk2
	2011.	results suggest that VEGF expression is involved in the promotion of angiogenesis in cervical neoplasia and that p53 is likely to be involved in the regulation of VEGF expression
	2012.	p53 and/or p21(WAF1/CIP1) genotype may influence the progression during gastric tumorigenesis.
	2013.	Review. the role of p53 post-translational modifications in carcinogenesis and cancer prevention
	2014.	IRF-1-p300 interface as an allosteric modifier of DNA-dependent acetylation of p53 at the p21 promoter
	2015.	In human osteosarcomas, hypermethylation of HIC1 is frequent only in tumors with p53 mutation
	2016.	cell lines that contain human tumor-derived temperature-sensitive p53 mutants show that Hsp90 is required for both stabilization and reactivation of mutated p53 at the permissive temperature
	2017.	Tip60 plays a double role in the p53 pathway: under normal growth conditions, Tip60 contributes to maintain a basal pool of p53 by interfering with its degradation; following DNA damage, Tip60 functions as p53 co-activator
	2018.	Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53
	2019.	Mutation pattern included base substitution (point mutation, G-->T, T-->G) and frame-shift mutation (base insertion and base loss).
	2020.	A case-control study showed that polymorphism in codon 72 of the p53 gene was not a cervico-uterine cancer risk factor in Mexico.
	2021.	hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites in an ATM-independent manner, which is different from other forms of oxidative stress such as H2O2 or UV light.
	2022.	E4orf6 uniquely utilizes two BC-box motifs for degradation of p53 and another target, Mre11
	2023.	Structural analysis shows that the high stability of the Ser116Met modeled mutant is due to the preservation of the p53 core domain loop L1 conformation and the reduction of mobility in that region.
	2024.	Regulation of the nuclear export of hdm2 mRNA provides a mechanism whereby mitogen-stimulated cells avoid p53-dependent cell cycle arrest or apoptosis by maintaining the dynamic equilibrium of the Hdm2-p53 feedback loop
	2025.	the increased malignancy of canc

Table Of Contents

Links

Entrez Gene Info

General info

Related sites

Feedback

Subscriptions

Recent activity

1: TP53 tumor protein p53 [ Homo sapiens ]

[Top][Help]Summary

[Top][Help]Genomic regions, transcripts, and products

[Top][Help]Bibliography

Related Articles in PubMed

GeneRIFs: Gene References Into Function What's a GeneRIF?